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1 Introduction
1.1 The Immune System
The immune system protects the body from infection and death. It comprises a set of
cells and molecular products as well as a specialized infrastructure, the lymphoid
organs. Most cells of the immune system patrol the body for activation signals.
Recognition of pathogens by individual immune cells activates the immune system
which leads to eradication of the pathogen during the ensuing immune response and
eventually the return to the inactive state.
Cells of the innate immune system (granulocytes, macrophages, mast cells, NK cells
and dendritic cells) react rapidly to a number of stimuli common to a wide range of
pathogens or dangerous conditions, e.g. bacterial cell wall components, double-
stranded RNA (e.g. from viral replication), unmethylated CpG-containing DNA (e.g.
from lysed bacteria) or the loss of normally obligatory major histocompatibility
complex (MHC) class I molecules on somatic cells (indicating immune escape of
tumor or virus-infected cells). The elicited responses comprise phagocytosis and
intracellular killing of pathogens, secretion of cytotoxic and microbicidal metabolites
and proteins as well as production of messenger molecules, which are able to spread
the activation information to other cells, both inside and outside of the immune
system.
While the innate immune response does not have a “memory” of the previously
encountered pathogens, one of the hallmarks of adaptive immunity is its ability to
“remember” previous activation states and thus to react more rapidly and in a more
specific fashion during a secondary immune response to the same pathogen. The
immunological memory manifests itself in the somatic mutations found in previously
activated, clonally selected memory B and T lymphocytes.
In contrast to B lymphocytes, which recognize their cognate antigen directly via a
transmembrane version of the antibody they are clonal for, the T cell receptor is only
able to identify short peptides bound to a cleft on self-MHC molecules on the surface
of antigen presenting cells (APCs).
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Subsets of T lymphocytes have been found to fulfill different functions: MHC class I-
restricted CD8+ T cells mediate cytotoxic responses, thereby inhibiting the replication
of intracellular pathogens or tumor growth by killing infected or degenerated cells.
Upon activation, MHC class II-restricted CD4+ helper T (TH ) lymphocytes produce
cytokines and important cell surface molecules. These supply the survival signals for
recently activated naïve B and cytotoxic T cells, rescuing them from apoptotic death
or paralysis (anergy), effectively validating the activation stimulus as non-self and
enabling a lymphocyte response to the pathogen (Sornasse et al., 1992; Ridge et al.,
1998).
1.2 Dendritic Cells: Antigen Presenting Cells Bridging Innate and
Adaptive Immunity
Dendritic cells (DCs) are a heterogeneous cell population characterized by dendritic
processes which generate a large interaction surface for efficient cell-cell contact.
Due to their appearance, in his first description of DCs in the epidermis, Langerhans
in 1864 erroneously identified DCs as nerve cells. Only much later, in 1973,
Steinman and Cohn (Steinman and Cohn, 1973) realized that DCs are antigen
presenting cells.
Until the emergence of DCs as essential APCs, activated B cells and macrophages
were believed to be the main APCs, positioning the adaptive branch of immunity as a
secluded entity of late evolutionary origin able to leverage the destructive capabilities
of innate immunity as additional effector mechanisms without being dependent on it
for antigen presentation.
With the discovery of DCs it became clear that this cell type is much better suited to
initiate immune responses due to its constitutively high antigen presenting capacity,
the broad distribution in almost all tissues and its migratory properties. Indeed, the
presence of DCs has been shown to be crucial for priming of naïve T lymphocytes
and the induction of primary immune responses (Ronchese and Hausmann, 1993).
1.2.1 Dendritic Cell Ontogeny
Like all leukocytes of the immune system, DCs are derived from common pluripotent
stem cell precursors in the bone marrow. These give rise to myeloid and lymphoid
progenitors which further differentiate and commit to the different myeloid and
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lymphoid lineages. Myeloid progenitors can give rise to erythrocytes,
megakaryocytes, granulocytes and monocytes/macrophages, the lymphoid
progenitors have been shown to be the common precursors of B and T lymphocytes
and NK cells.
Originally thought to be of myeloid origin, recent research suggested that both a
myeloid and a lymphoid subset of DCs exist (Liu et al., 2001). However, DC
development seems to be characterized by high plasticity, since (in mice) both
lymphoid-restricted and myeloid-restricted bone marrow precursors could be shown
to produce all known mature splenic and thymic DC subsets in vivo (Manz et al.,
2001; Wu et al., 2001). Consequently the final DC phenotype does not appear to be
predetermined at the early myeloid/lymphoid developmental junction. Nevertheless,
since mature DCs are non-proliferative, and in vivo BrdU-labeling in mice indicates
that the different DC subpopulations have different life spans (Kamath et al., 2000),
some degree of DC sublineage commitment downstream of the early hematopoietic
precursors can be assumed, probably at the level of monocytes and immature DCs
found in blood (Shortman and Liu, 2002).
As the labels "myeloid" and "lymphoid" suit well to describe the fundamental
differences between the DC subsets, they will be used throughout the rest of the text,
bearing in mind that also in humans they possibly might not describe the situation
adequately.
The myeloid DC set comprises interstitial DCs and epidermal Langerhans cells which
have been shown to develop from a CD34+CD11c+/CLA- or CLA+ (cutaneous
lymphocyte-associated antigen) blood precursor, respectively (Strunk et al., 1997).
Interstitial DCs share a common progenitor with monocytes and macrophages and
have been shown to spontaneously develop from a subset of inflammatory
monocytes upon a phagocytosis stimulus both in vitro (human) and in vivo in mice
(Randolph et al., 1998; Randolph et al., 1999). Langerhans cell development is
dependent on TGF-β, and they are absent from TGF-β-deficient mice (Borkowski et
al., 1996).
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Figure 1.1 Pathways of human DC development.
Schematic representation of the DC differentiation pathways as deduced from in vitro studies. It is not
yet clear whether the DCs generated from monocytes are equivalent to tissue DCs in vivo. Illustration
modified after Shortman and Liu (2002).
The lymphoid DC subset contains the plasmacytoid DCs. Their name stems from the
plasma cell-like morphology of their precursor cells which can be found in blood and
many lymphoid tissues. They require IL-3 for survival, are only weakly phagocytic
and secrete large amounts of type I interferons in response to viral stimulation
(Grouard et al., 1997). Plasmacytoid DCs acquire the dendritic morphology and
functional competence upon CD40 ligation, enabling them to induce TH2-biased T
cell responses (see 1.3.4). They also seem to play a role in CTL tolerance by
inducing CD8+ regulatory T cells (Gilliet and Liu, 2002) (see also 1.3.5).
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1.2.2 DC Model Systems
DC-like cells can be produced in vitro either from CD34+ hematopoietic precursor
cells from the bone marrow, peripheral blood or cord blood or from blood monocytes.
CD34+ cells acquire DC characteristics upon culture with GM-CSF and TNF (Caux et
al., 1992). Monocytes can be driven to a DC phenotype by IL-4 and GM-CSF (Peters
et al., 1993; Sallusto and Lanzavecchia, 1994; Zhou and Tedder, 1996).
The CD34+ cells give rise to a mixture of immature and mature DCs. DCs derived
from monocytes are immature with intermediate T cell activating capacity and mature
to fully competent antigen presenting cells in response to a number of inflammatory
stimuli such as TNF, LPS, CD40 ligation or necrotic cells (Sauter et al., 2000).
To date, there are no known human DC cell lines. However, the CD34+
myelomonocytic cell line KG1 has been shown to differentiate into dendritic-like cells
in response to GM-CSF plus TNF-alpha or PMA (St Louis et al., 1999) and a number
of myeloid cell lines have been reported to acquire a DC phenotype after treatment
with calcium ionophore (Koski et al., 1999).
1.3 Dendritic Cell Function
DCs originate from CD34+ hematopoietic precursors and are seeded to the tissues
via the bloodstream. An extensive network of interstitial DCs can be found in virtually
all tissues except the brain, parts of the eye and the testes (Hart , 1997) but most
prominently at sites of possible pathogen entry like epidermis and mucosal surfaces,
e.g. intestinal tract (Pavli et al., 1993) and respiratory tract (Schon-Hegrad et al.,
1991). In non-lymphoid tissues, DCs are present at an “immature” stage of
development, where they perform sentinel functions, continuously sampling the
environment for antigen (Sallusto et al., 1995). In the absence of inflammation, i.e.
under homeostatic conditions, low level turnover of immature DCs can be observed,
which probably take up inhaled or ingested proteins and dying cells derived from
normal cell turnover and take them to the draining lymph nodes (Huang et al., 2000)
where they presumably play a role in maintaining tolerance to self antigens
(Steinman et al., 2000; Roncarolo et al., 2001). Encounters with “danger” signals
such as microbial products like lipopolysaccharide (LPS), cytokines such as TNF or
necrotic cells (Sauter et al., 2000) or T cell signals like CD40L and interferon γ (IFN-γ)
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initiate rapid DC maturation, accompanied by shutdown of endocytosis, loading of the
antigenic sample taken at the time of “danger” onto MHC molecules for presentation
on the cell surface (Steinman et al., 2000) and emigration to the draining lymph
nodes via the afferent lymphatic vessels, where DCs are recognized as “veiled” cells.
Maturation also upregulates the expression of costimulatory molecules which are
required for efficient interaction with T lymphocytes. In the lymph nodes, the matured
“interdigitating” DCs efficiently activate T lymphocytes specific for the peptides
presented on the MHC-peptide complexes. While the activated T lymphocytes
recirculate through the efferent lymph and home to sites of inflammation through the
bloodstream, DCs rapidly disappear after successful T cell clustering in vivo (Ingulli et
al., 1997) and very probably die in the lymph nodes, since they neither appear in the
efferent lymph nor accumulate in the lymph node (Steinman, 1991).
1.3.1 Antigen Uptake
Immature DCs avidly sample their environment using several endocytic mechanisms:
they take up small solid particles (< 0.5 µm) such as immune complexes and solutes
by receptor-mediated endocytosis and fluid-phase micropinocytosis, respectively,
both of which deliver antigen into clathrin-coated intracellular vesicles via triggering
clathrin-coated pit-associated membrane receptors and are independent of actin
polymerization (Aderem and Underhill, 1999).
Particles larger than ca. 0.5 µm such as bacteria and apoptotic cells are mostly
picked up by phagocytosis which is usually clathrin-independent and involves actin
polymerization-dependent extension of pseudopodia around the particle which then
becomes engulfed into a cytosolic phagosome. Table 1.1 lists the most important
receptors involved in antigen uptake and their ligands.
Table 1.1 Receptors involved in antigen uptake expressed on DCs
Receptor Ligand/Function
Fcα-, ε-, γ- receptors1,2 immune complexes
macrophage mannose receptor3 mannosylated antigens on bacteria
CD364 phosphatidylserine on apoptotic cells
αVβ5 integrin (CD51/β5 integrin)4 necessary for engulfment
1 (Geissmann et al., 2001), 2 (Sallusto and Lanzavecchia, 1994), 3 (Sallusto et
al., 1995), 4 (Albert et al., 1998a)
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DCs have been shown to constitutively sample large volumes of extracellular fluid by
macropinocytosis which is downregulated during DC maturation (Sallusto et al.,
1995). Macropinocytosis is related to phagocytosis in that it is also actin-dependent
and clathrin-independent and proceeds by forming large fluid-filled vesicles through
closure of plasma membrane lamellipodia generated primarily at ruffling, cholesterol-
rich membrane domains (Nichols and Lippincott-Schwartz, 2001).
While macropinocytosis provides a mechanism for antigen-agnostic surveillance of
the surroundings by DCs, receptor-triggered uptake mechanisms can induce further
DC responses, including activation (Rodriguez et al., 1999; Singh-Jasuja et al., 2000)
and facilitation of CTL induction (Schuurhuis et al., 2002) or tolerogenization (Urban
et al., 2001).
1.3.2 Antigen Processing and Presentation
Antigen presentation on MHC molecules requires proteolytic degradation of proteins
into short peptides of 9-11 residues (MHC class I) or 10-30 residues (MHC class II)
which are small enough to bind to the clefts of the MHC molecules. The intracellular
processing of antigen and the loading of class I versus class II molecules is strictly
compartmentalized in most cells, resulting in MHC class I molecules which carry
peptides derived from endogenously produced, cytosolic proteins and MHC class II
molecules presenting peptides derived from endocytosed proteins.
Subsequent to its internalization, exogenous antigen is proteolytically degraded to
short peptides in acidic endosomes/lysosomes. Fusion of the lysosomes with MHC
class II-containing compartments enables the formation of peptide-MHC complexes
which are then transported to the cell surface. In mature DCs, this process takes
place very efficiently and together with the prolonged MHC surface retention time
contributes to their antigen presentation proficiency (Cella et al., 1997). In contrast,
the relatively poor immunogenicity of immature DCs is caused by impaired vesicle
fusion, impaired antigen processing, inefficient degradation of the invariant chain
peptide that protects the cleft of MHC class II molecules from being loaded with
endogenously produced peptides in the ER and the rapid re-endocytosis and
degradation of peptide-loaded MHC class II (Steinman et al., 2000; Pierre and
Mellman, 1998; Villadangos et al., 2001).
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Cytosolic cellular proteins are degraded by the proteasome, a multi-subunit
proteolytic complex. The ensuing peptides are then translocated into the ER where
they are loaded onto MHC class I molecules and presented on the cell surface of all
nucleated cells. In DCs, proteosomal degradation of ubiquitinated cytosolic proteins
is characterized by immunoproteasomes which have been shown to produce
peptides with proper motifs for efficient MHC binding. They account for half of the
proteasomes in immature DCs and constitute all of the proteasomes in mature DCs,
while in macrophages and several other cell types, the respective
immunoproteasomal subunits are only produced after cellular activation by
inflammatory mediators such as IFN-γ (Van den Eynde and Morel, 2001).
One outstanding feature of DCs is their ability to efficiently "cross-present" antigen,
i.e. to present endocytosed antigen via the cytosolic pathway on MHC class I
molecules to cytotoxic CD8+ T lymphocytes (Kurts et al., 2001). Apparently DCs
possess an efficient way to transport small molecules (< 50 kDa) to the cytosol where
they can gain access to the MHC class I presentation pathway (Rodriguez et al.,
1999). Cross-presentation plays a role in acquiring immunity to tumor antigens and to
viruses, which do not replicate in DCs, as well as in tolerance induction.
In addition to presenting proteinaceous antigens, the DCs are able to present
glycolipid antigens to NK T cells via CD1d molecules which are structurally highly
related to MHC molecules (Kitamura et al., 1999).
1.3.3 Costimulation
Initiation of productive immune responses by T cells requires a second signal in
addition to TCR triggering, which is provided by membrane-bound costimulatory
molecules on the APC. Compared to macrophages and B lymphocytes, DCs are
distinguished by their constitutive expression of low levels of costimulatory molecules
and their ability to rapidly upregulate their expression upon activation/maturation
signals. The chief costimulatory molecules on DCs are the members of the B7 family
of proteins, most notably B7.1 (CD80) and B7.2 (CD86) which interact with CD28 on
T cells and lead to expression of CD40 ligand (CD40L), a member of the TNF family,
on the activated T cells. CD40L in turn activates APCs through interaction with CD40
on their surface which is the most potent stimulus for upregulating B7 expression.
Activation through CD40 ligation is necessary to confer to APCs the ability to prime
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CTLs (Bennett et al., 1998; Ridge et al., 1998; Schoenberger et al., 1998) and forms
the basis of the feedback loop that validates an antigen as being non-self. Cell-cell
contact is initiated and stabilized by interaction of adhesion molecules on the
surfaces of both cell types, most importantly the members of the ICAM family on DCs
which are ligands for LFA-1 (CD11a) on T cells.
Upon activation, DCs are able to secrete very high levels of soluble mediators,
including various cytokines and chemokines. Most prominently, activated myeloid
DCs produce large amounts of the T and B cell coactivator IL-12. Plasmacytoid DCs
are only weak producers of IL-12 but rapidly synthesize large amounts of type I IFNs
when activated, which has identified them as the natural type I IFN-producing cells in
blood (Siegal et al., 1999; Cella et al., 1999).
1.3.4 Helper T cell polarization
Activation of CD4+ helper T cells by DCs does not only lead to T cell proliferation.
DCs also influence and perhaps dictate the subsequent development of the dividing
T cells and thus the characteristics of the ensuing immune response.
Two subsets of activated helper T cells can be distinguished based on their cytokine
expression profiles. The TH1 subset produces large amounts of IFN-γ, TH2 cells
secrete IL-4, IL-5, IL-9, IL-10 and IL-13. The ensuing TH1- and TH2-type immune
responses both include humoral and cell-mediated components, but the effector cells
and antibody isotypes involved are distinct. TH1 cells are responsible for the
activation of macrophages to a microbicidal state, the induction of IgG antibodies that
mediate opsonization and phagocytosis and the support of CD8+ cytolytic T cells. By
contrast, Th2 cells stimulate the growth and differentiation of mast cells and
eosinophils, as well as the production of antibody isotypes, including IgE, which can
mediate the activation of these cells.
Polarization of helper T cell depends on cytokines: IL-12 (Trinchieri, 1995) as well as
IL-18 (Micallef et al., 1996) and type I IFNs (Sareneva et al., 1998) favour TH1
differentiation while IL-4, OX40-ligation (Ohshima et al., 1998) as well as other, not
yet defined stimuli generate the TH2 phenotype.
Due to their high level IL-12 expression upon activation, myeloid DCs were initially
thought to induce TH1 differentiation (Macatonia et al., 1995) while lymphoid
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(plasmacytoid) DCs did not express IL-12 and seemed to generate mainly TH2 cells
(Rissoan et al., 1999), which led to the designation as DC1 and DC2, respectively.
However, recent reports indicate that, depending on the DC activation stimulus, both
myeloid and lymphoid DCs can be instructed to prime either TH1 or TH2 responses
(Liu et al., 2001; Guermonprez et al., 2002). This concurs with the finding that the
polarization of helper T cell responses ex vivo induced by DCs isolated from different
tissues depends on the originating tissue, irrespective of the ratio of myeloid to
lymphoid DCs, suggesting tissue-specific DC polarization and a high degree of DC
functional plasticity.
1.3.5 Tolerance Induction
In addition to their stimulatory properties, DCs can modulate immune responses by
inhibiting or modulating T cell activity. Immature DCs have been shown to anergize T
cells in an antigen-specific fashion (Dhodapkar et al., 2001). In vivo, constitutive
trafficking of apoptotic cell-bearing immature DCs from non-inflamed tissues to the
draining lymph nodes has been observed in rats (Huang et al., 2000). This constant
low level turnover has been suggested to play a role in maintaining peripheral
tolerance to self antigens in the absence of danger signals (Steinman et al., 2000).
Additionally, DCs treated with inhibitory stimuli are able to generate suppressive T
cell populations. IL-10-treated myeloid and CD40L-activated lymphoid DCs have
been reported to induce regulatory CD4+CD25+ (Jonuleit et al., 2001) and CD8+ non-
cytotoxic T cells (Gilliet and Liu, 2002), respectively, which inhibit bystander T cell
activation and expansion by secretion of IL-10.
1.3.6 Interactions with other Cells of the Immune System
DCs interact with a number of cells other than T lymphocytes, including B
lymphocytes, NK T cells and NK cells.
DCs can induce and influence B cell proliferation and differentiation through secretion
of IL-12 and IL-6R α-chain (Dubois et al., 1997; Dubois et al., 1998). They also play a
role in heavy chain isotype switching to IgG (Gerloni et al., 1998; Wykes et al., 1998)
and IgA (Fayette et al., 1997). Due to their expression of T- and B cell-specific
chemokines such DC-CK1 (Lindhout et al., 2001) and BLC (Vissers et al., 2001) and
due to the fact that DCs are able to capture and retain unprocessed antigen for
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transfer to naïve B cells (Wykes et al., 1998), DCs probably serve to integrate
encounters of the cells of adaptive immunity with one another and antigen.
Like DCs, NK cells belong to the innate arm of immunity and an intense cross-talk
exists between both cell types, DCs inducing expansion and activation of NK cells
and vice versa, NK cells activating or inhibiting DC activity (Guermonprez et al.,
2002). Upon activation, DCs rapidly produce NK cell-activating cytokines such as IL-
12 or type I IFNs and recently myeloid DCs have been reported to secrete IL-2
immediately after receiving a maturation stimulus which could potentially stimulate
NK cell proliferation in the periphery (Granucci et al., 2001). In response to the DC-
secreted cytokines, NK cells produce large amounts of IFN-γ well ahead of the
appearance of TH1 cells and are able to lyse aberrantly MHC class I molecule-
expressing, potentially virus-infected or tumor cells.
Conversely, the ability of activated NK cells to mature and activate DCs would
enhance the sensory repertoire of the latter for danger signals.
DCs have also been shown to interact with NK T cells through presentation of
glycolipid antigens via CD1 molecules (Kitamura et al., 1999). This in turn leads to
IFN-γ as well as IL-4 production by adult NK T cells, irrespective of the activating DC
population, with myeloid DCs acting through CD1d and plasmacytoid DC using a
CD1d-independent pathway to activate the NK T cells (Kadowaki et al., 2001).
1.4 DC Morphology and Function at the Different Stages of
Differentiation
During in vitro differentiation of monocytes to DCs by IL-4 and GM-CSF, the initially
round cells first undergo a macrophage-like adherent stage during which the cells
enlarge and have a typical “fried-egg”-shaped appearance. After one to two days of
culture most cells detach from the surface of the culture vessel in clusters which
separate to give a single cell suspension around day three to four of culture. At this
point, the generated DCs display an immature phenotype which is characterized
morphologically by moderate amounts of dendritic processes that serve to greatly
enhance the surface area of the cells as illustrated in Figure 1.2B.
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In vivo, immature DCs form a network of interstitial cells in non-lymphoid tissues,
possessing characteristic dendritic processes and constitutively expressing MHC
class II molecules on their cell surface (see Figure 1.2A).
Figure 1.2 Dendritic cell morphology.
A, A network of dendritic cells in vivo. Fluorescence microscopical image of mouse Langerhans cells
in an epidermal sheet prepared from murine ear skin, stained with an antibody against MHC class II.
Image by courtesy of Dr. T. Jakob, Klinik und Poliklinik für Dermatologie und Allergologie, Technische
Universität München. B, Morphology of a dendritic cell derived from human monocytes in vitro. Image
by courtesy of Prof. Dr. Andreas Mackensen, Abteilung für Hämatologie und Onkologie, Regensburg.
Maturation of DCs by LPS or other danger signals leads to further ramification of the
dendritic processes. In vivo, the maturing DCs migrate into the lymphatics and
appear as veiled cells in the afferent lymph. Eventually the mature DCs arrive in the
lymph nodes where they engage in cell-cell interactions with naïve lymphocytes and
are recognized as interdigitating DCs.
Functionally, differentiation of monocytes to immature DCs increases the
phagocytic/endocytic activity (Sallusto et al., 1995) and the expression levels of
antigen presenting, costimulatory and adhesion molecules, which result in improved
antigen presentation capabilities compared to monocytes.
Danger signals such as microbial products (including LPS, dsRNA, CpG-DNA) and
inflammatory cytokines (TNF, IFN-γ) lead to DC maturation, which is accompanied by
a marked reduction of phagocytosis/endocytosis caused by diminished expression of
Fc- and other antigen receptors and a lowered antigen processing activity. At the
same time, the amounts of membrane molecules involved in antigen presentation
B
A
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increase, most importantly MHC class II and the costimulatory molecules CD80 and
CD86 as well as adhesion molecules such as CD54 (ICAM-1) and CD58 (LFA-3).
The concomitant changes in chemokine receptor repertoire lets them emigrate
towards the afferent lymphatics and eventually the regional lymph nodes in response
to chemokines, e.g. SLC produced by lymphatic endothelium (Saeki et al., 1999). DC
maturation induces expression of the NK and lymphocyte co-activator IL-12 as well
as a switch in chemokine expression which further enhances their efficacy in
interacting with other immune cells. Upregulation of CD40 makes the maturing DCs
more susceptible to activation by T cell-expressed CD40 ligand.
Ligation of CD40 activates the mature DCs and further upregulates expression of
costimulatory molecules, maximizing DC antigen presentation capacity.
Figure 1.3 Schematic representation of the functional and morphological changes occurring
during DC differentiation from monocytes in vitro.
1.4.1 Characteristic Molecules
Although the constitutive presence of MHC class II molecules on DCs has been
widely used as a DC marker in non-lymphoid tissues in the absence of inflammation,
MHC class II molecules as well as the other markers listed the first half of Table 1.2
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are also expressed by other cells in secondary lymphoid tissues and during
inflammation, mostly activated B cells and macrophages. Since DCs surpass the
latter in antigen presentation, during the past decade considerable effort has been
invested in finding molecules with specific expression in DCs that would account for
their superior ability to present antigen and could serve as unique markers of DCs.
The genes listed in the second half of Table 1.2 have been identified recently and
can serve as reliable markers of DCs and DC subsets in vivo. DC-LAMP is a member
of the lysosome-associated membrane glycoprotein family (LAMP), which is most
similar (29% aa identity) to the D-type scavenger receptor CD68 (macrosialin) and
may play a role in antigen processing. MADDAM (metalloprotease and disintegrin
dendritic antigen marker) or ADAM 19 is a member of the ADAM (a disintegrin and
metalloproteinase) family with unknown function. Langerin, DC-SIGN and BDCA-2,
as well as several other genes with relatively specific expression in DC not listed,
belong to the lectin family of carbohydrate-binding molecules and have been
implicated in antigen capture. DC-CK1 is a CC chemokine with specificity for naïve T
and B lymphocytes (Lindhout et al., 2001). B7-DC belongs to the B7 family of
proteins which also includes CD80 and CD86 (B7.1 and B7.2, respectively) and is a
strong costimulator of T cell activation.
Table 1.2 Genes with specific expression in DCs
Name Location Family Reference
S-100b cytosol S100/Ca-binding  Takahashi et al., 1981
CD1a (Langerhans) membrane MHC homolog/Ig-SF  Chu et al., 1982
CD83 membrane Ig-superfamily (Ig-SF)  Zhou et al., 1992
Fascin/p55 cytosol Fascins/actin bundling  Mosialos et al., 1996
DC-CK1 secreted β-chemokine  Adema et al., 1997
DC-LAMP (CD208) lysosomal D-type scavenger-R?  de Saint-Vis et al., 1998
Langerin (CD207)
(Langerhans)
membrane C-type lectin  Valladeau et al., 1999
MADDAM membrane ADAM family  Fritsche et al., 2000
DC-SIGN (CD209) membrane C-type lectin  Geijtenbeek et al., 2000
BDCA-2 (plasmacytoid) membrane C-type lectin  Dzionek et al., 2000
B7-DC membrane B7 family  Tseng et al., 2001
Research Objectives
15
2 Research Objectives
The aim of this work was to gain further insight into the differentiation pathways and
lineage-commitment steps of DCs vs. macrophages as well as to define new
molecular DC markers by identifying genes with specific expression in DCs during
differentiation from blood monocytes.
DC-specific mRNA transcripts were to be cloned by subtracting monocyte- and
macrophage-expressed mRNAs from DC-derived mRNA transcripts using a PCR-
based cDNA subtraction method, Representational Difference Analysis (RDA). The
products were to be analyzed for DC-specificity on the RNA and protein level and
their regulation was to be correlated with the DC differentiation status to allow for
further investigation of their possible function in DCs.
To elucidate mechanisms governing the expression of the identified genes in DCs,
the promoters of the most promising candidates were to be examined and analyzed
for elements possibly involved in conferring DC-specificity by molecular biological
techniques.
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3 Materials and Methods
3.1 Equipment and Materials
3.1.1 Equipment
Autoclave Technomara, Fernwald, Germany
Camera Polaroid, Cambridge, USA
CCD-video documentation system Intas, Göttingen, Germany
Centrifuges Heraeus, Hanau; Eppendorf, Hamburg, Germany
Densitometer Molecular Dynamics, Krefeld, Germany
Electrophoresis equipment Biometra, Göttingen; BioRad, Munich, Germany
Elutriator J6-MC Beckman, Munich, Germany
FACScan Becton-Dickenson, San Jose, USA
Heat sealer (Fermant 400) Josten & Kettenbaum, Bensberg, Germany
Incubators Heraeus, Hanau, Germany
Laminar air flow cabinet Heraeus, Hanau, Germany
Luminometer (Sirius) Berthold Detection Systems, Pforzheim, Germany
Microscopes Leitz, Heidelberg, Germany
PCR thermocyclers Perkin Elmer, Überlingen, Germany and MJ
Research, Hessisch Oldendorf, Germany
pH-Meter Knick, Berlin, Germany
Power supplies Biometra, Göttingen; Bachofer, Reutlingen,
Germany
Pump, Masterflex 70 1600 Cole-Parmer, Chicago, USA
Spectrophotometer Perkin Elmer, Überlingen, Germany
Stratalinker UV Crosslinker 1800 Stratagene, Heidelberg, Germany
Thermomixer Eppendorf, Hamburg, Germany
TopCount microplate scintillation counter Packard BioScience, Frankfurt, Germany
Ultracentrifuge Optima L-70 Beckman, Munich, Germany
Vacuum dot blot manifold Schleicher und Schuell, Dassel, Germany
Water purification system Millipore, Eschborn, Germany
3.1.2 Materials
Cell culture flasks Costar, Cambridge, USA
U-shaped well multiwell cell culture plates Greiner, Nürtingen, Germany
Pipettes Costar, Cambridge, USA
Polystyrene tubes for flow cytometry (4 ml) Falcon, Heidelberg, Germany
PCR, screw-top micro test tubes Sarstedt, Nümbrecht, Germany
Cryo tubes Nunc, Wiesbaden, Germany
Sterile micropore filters Millipore, Eschborn, Germany
Nylon transfer membrane MSI, Westboro, MA, USA
Nitrocellulose membrane (Protran) Schleicher & Schuell, Dassel, Germany
PVDF membrane (Immobilon-P) Millipore, Eschborn, Germany
KODAK X-OMAT AR autoradiography film Eastman Kodak, , Germany
Micro test tubes (0.5, 1.5, 2 ml) Eppendorf, Hamburg, Germany
Multiwell cell culture plates (6, 24, 96 well), cell
culture and Petri dishes
Falcon, Heidelberg, Germany
Centrifuge tubes (15, 50, 225 ml) Falcon, Heidelberg, Germany
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3.1.3 Chemicals
 Unless noted otherwise, chemicals where purchased either from Sigma Chemicals,
Deisenhofen, Germany or from Merck, Darmstadt, Germany. Ready-made buffers
and cell culture media were obtained from Biochrom, Berlin, Germany.
 Water was generally of Millipore-purified/distilled quality. When denoted, ultra-pure,
DEPC-treated H2OUSB, purchased from USB Corp. through Amersham,
Braunschweig, Germany, was used.
3.1.4 DNA Oligonucleotides
General Sequence
18S rRNA-specific oligo 5’-ACG GTA TCT GAT CGT CTT CGA ACC-3’
M13 (-20) forward 5'-TTG TAA AAC GAC GGC CAG TG-3'
M13 reverse 5'-GGA AAC AGC TAT GAC CAT GAT-3'
β-ActinS 5’-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3’
β-ActinAS 5’-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3’
RDA
R-Bgl-12 5'-GAT CTG CGG TGA-3'
R-Bgl-24 5'-AGC ACT CTC CAG CCT CTC ACC GCA-3'
J-Bgl-12 5'-GAT CTG TTC ATG-3'
J-Bgl-24 5'-ACC GAC GTC GAC TAT CCA TGA ACA-3'
N-Bgl-12 5'-GAT CTT CCC TCG-3'
N-Bgl-24 5'-AGG CAA CTG TGC TAT CCG AGG GAA-3'
pZeRO-2s 5’-GCA TCA AGC TTG GTA CCG-3’
pZeRO-2as 5’-GGC GGC CGT TAC TAG TG-3’
Primers for Nortern blot probe PCRs
MCP-4s 5'-GCA GCT TTC AAC CCC CAG-3'
MCP-4as 5'-CCC ACA GGC ATG CTC TCA A-3'
Hep27e3s 5'-GAG CAG CAC CGG GAT AGA C-3'
C1qc_s 5'-ATC CGA GGA CCC AAA GGG-3'
C1qc_as 5'-ACA GCC AGC CAC ACC TCC T-3'
15LOXs 5'-ACG CCT GGT TCT GCA ACT G-3'
15LOXas 5'-CCC GAT TTC AGT GAT CTC TCG-3'
FR-βs 5'-CCT CAA TGT CTG TAT GGA TGC C-3'
FR-βas 5'-GCA GCT GGA GTG GGG AAG T-3'
MCP-4
MCP-4RACE outer 5'-GCA GCA TCC CTT CAT GTC CAT GAC T-3'
MCP-4RACE inner 5'-ACA ACC CAC TGC CAG CAG CTC ATA G-3'
CpGsS 5'-TTG TTG TTA AAT AAA AGT TGA AAT TG-3'
CpGsAS 5'-ACA CAA AAA CAC TAC AAA AAC TTT C-3'
CpGs2S 5'-TTT GGT GAT AAA ATA TAA GTA GAT TAG –3'
CpGas2S 5'-AAT TTC ACA ATA TTT CTT TAC CTC-3'
CpGasS 5'-ACC AAC TTT CTC TTC TAA CTT TCC-3'
CpGasAS 5'-AGA TTT TTA TGT TGA AGG TTA AGA G-3'
CpGas2S 5'-TTC TCT TCT AAC TTT CCC TCT C-3'
CpGas2AS 5'-GGT TAA GAG TTG GAG ATT TTA TAA TG-3'
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CpGi1sS 5'-TTT TGT GTT TGT TGT TTA TGA TAG TAG-3'
CpGi1sAS 5'-TCT ACC TCC AAC ATA AAC TTC AAC-3'
CpGi1asS 5'-CTA CTC ATA ACA ACA ACT TTC AAC C-3'
CpGi1asAS 5'-GAG GAG TTT TAT TAT TTT GGT GG-3'
MCP-4pS 5'-GAA CAG CTA GCA CGT GAA CAG AGT CCT TAG CAC AG-3'
MCP-4pAS 5'-AGT CTC CAG ATC TTT GCC TCT CTG CTC CTC-3'
MCP-4pPGL3s 5'-GAA CAG CTA GCA CGT GAA CAG AGT CCT TAG CAC AG-3'
CpG1s (-80 bp) 5'-CAT CAT GAC TTG GTC AAC GCC CTG CTC A-3'
CpG1as (-80 bp) 5'-CCT GAG CAG GGC GTT GAC CAA GTC ATG A-3'
mCpG1s (-80 bp) 5'-CAT CAT GAC TTG GTC AAmC GCC CTG CTC A-3'
mCpG1as (-80 bp) 5'-CCT GAG CAG GGmC GTT GAC CAA GTC ATG A-3'
CpG1M1s (-80 bp) 5'-CAT CAT GAC TTG GTC AAG CCC CTG CTC A-3'
CpG1M1as (-80 bp) 5'-CCT GAG CAG GGG CTT GAC CAA GTC ATG A-3'
CpG1M2s (-80 bp) 5'-CAT CAT GAC TTG GTC AAG AGC CTG CTC A-3'
CpG1M2as (-80 bp) 5'-CCT GAG CAG GCT CTT GAC CAA GTC ATG A-3'
CpG2s (-20 bp) 5'-CTC CCT ATA AAA GGC CGG CGG AAC AGC CAG-3'
CpG2as (-20 bp) 5'-CTC TGG CTG TTC CGC CGG CCT TTT ATA GG-3'
mCpG2s (-20 bp) 5'-CTC CCT ATA AAA GGC mCGG mCGG AAC AGC CAG-3'
mCpG2as (-20 bp) 5'-CTC TGG CTG TTC mCGC mCGG CCT TTT ATA GG-3'
Hep27
RACE inner 5'-CTT CCT GTC TAT CCC GGT GCT G-3'
Hep27GWouter 5'-TGT CTG GAG TGC AGT TTG GC-3'
Hep27GWinner 5'-AGC TGA GTA TGA GGA TGT GAG TAA G-3'
1s 5'-CCA GAC AGA CAG GTG CAC AGC-3'
a2s 5'-CTG CTC ACT CGT TGG GTC CG-3'
2s 5'-AAG ACC ACG AAT GCA CCG AGA G-3'
5as 5'-GAC GCC CCC ACA GTG CTC C-3'
8as 5'-CAG TTT ACC CGG ATG TCC TTG G-3'
10as 5'-CAC GAT TCC TGC ACA GTC CT-3'
3.1.5 Antibodies
monoclonal
CD1a (BL6) Coulter, Krefeld, Germany
CD11c (LeuM5) Dianova, Hamburg, Germany
CD14 (My4) Coulter, Krefeld, Germany
CD40 (14G7) Sanbio, Beutelsbach, Germany
CD54 (CBL 450F) Immunotech, Marseille, France
CD80 (BB1) Pharmingen, Hamburg, Germany
CD83 (HB15a) Immunotech, Marseille, France
CD86 (Fun-1) Pharmingen, Hamburg, Germany
HLA-DR (B-F1) Diaclone, Besançon, France
polyclonal
rabbit anti-MCP-4 Pepro Tech EC, London, England
rabbit anti-mouse DAKO, Hamburg, Germany
goat anti-rabbit, alkaline phophatase-
conjugated
Dianova, Hamburg, Germany
3.1.6 Enzymes, Inhibitors and Kits
Restriction endonucleases, DNA polymerases and protease inhibitors were
purchased from Boehringer Mannheim, Germany unless noted otherwise.
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Enzymes, Inhibitors and Kits, continued
5'-end Labeling kit Amersham, Braunschweig, Germany
SMART RACE kit Clontech, Palo Alto, USA
GenomeWalker kit Clontech, Palo Alto, USA
Oligotex mRNA kit Qiagen, Hilden, Germany
RNeasy RNA extraction kit Qiagen, Hilden, Germany
Plasmid preparation kits Qiagen, Hilden, Germany
QIAEX II gel extraction kit Qiagen, Hilden, Germany
ZAP Express cDNA synthesis kit Stratagene, Heidelberg, Germany
MACS Blood DC isolation kit Miltenyi, Bergisch Gladbach, Germany
Luciferase Assay System Promega, Mannheim, Germany
3.1.7 Molecular Weight Standards
DNA molecular weight standards:
(all from Gibco, Eggenstein, Germany)
λ/HindIII digest
23130 9416 6557 4361 2322 2027 564 125 (bp)
(477) (194) (135) (89) (48) (42) (12)  (ng per band/µg DNA)
Φx174/HaeIII digest
1353 1078 872 603 310281/271 234 194 118 72 (bp)
(250) (200) (160) (110) (57) (52/50) (43) (36) (22) (13) (ng per band/µg DNA)
1 kB Plus DNA Ladder (synthetic)
12000-2000/1kb steps 1650 1000 850 650 500-100/100 bp steps (bp)
Protein molecular weight standards:
(BioRad, Munich, Germany)
Kaleidoscope Prestained Standard
202,000 133,000 71,000 41,800 30,600 17,800 6,900 (kDa)
Low Range Prestained Molecular Weight Standard (BioRad, Munich, Germany)
103,000 77,000 50,000 34,300 28,800 20,700 (kDa)
3.1.8 Primary Cells and Cell Lines
NHDFC were kindly provided by Dr. Ulf Müller-Ladner, Internal Medicine Department,
University Hospital, Regensburg
Buffy Coats were obtained from the Bavarian Red Cross
THP-1 human acute monocytic leukemia (DSM No ACC 16)
HL-60 human acute myeloid leukemia (DSM No ACC 3)
Hep G2 hepatocellular carcinoma (ATCC No HB-8065)
HeLa human cervix carcinoma (DSM No ACC 57)
CaCo-2 human colon adenocarcinoma (DSM No ACC 169)
HT-29 human colon adenocarcinoma (DSM No ACC 299)
3.1.9 Bacterial E.Coli Strains
TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74 recA1 deoR
araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG
TOP10F‘ F´ {lacIq Tn10 (TetR)} mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74
recA1 deoR araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG
DH10B F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74 recA1 deoR
araD139 ∆(ara-leu)7697 galU galK rpsL endA1 nupG
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3.1.10 Plasmid Vectors
pZeRO-2 Invitrogen, Karlsruhe, Germany
pCR II Invitrogen, Karlsruhe, Germany
pCR2.1 TOPO Invitrogen, Karlsruhe, Germany
pGL-3 Basic Promega, Mannheim, Germany
pGL-3 CMV Promega, Mannheim, Germany
3.2 Cell Isolation
3.2.1 Monocytes
Required buffers and chemicals:
Ficoll-Hypaque (Pharmacia, Freiburg, Germany)
PBS
6% H2O2/PBS
HBSS (Hank’s Balanced Salt Solution) supplemented with 6% autologous blood plasma
Peripheral blood mononuclear cells (MNCs) were separated by leukapheresis (Graw,
Jr. et al., 1971) of healthy donors, followed by density gradient centrifugation over
Ficoll/Hypaque (Johnson, Jr. et al., 1977). Monocytes were isolated from MNCs by
countercurrent centrifugal elutriation (Sanderson et al., 1977).
Elutriation was performed in a J6M-E centrifuge equipped with a JE 5.0 elutriation
rotor and a 50 ml flow chamber (Beckman, Munich, Germany). After sterilization of
the system with 6% H2O2/PBS for 20 min, the system was emptied of air bubbles and
washed with 500 ml PBS. Following calibration at 2500 rpm and 4°C with HBSS,
MNCs were loaded at a flow rate of 52 ml/min. Fractions were collected and the flow
rate was sequentially increased according to Table 3.1.
Table 3.1 Elutriation parameters and cell types.
Fraction Volume (ml) Flow rate (ml/min) Main cell type contained
Ia 1000 52 platelets
Ib 1000 57 small (B) lymphocytes
IIa 1000 64 large (T) lymphocytes
IIb 500 74
IIc 400 82
IId 400 92
III 800 111 monocytes
Representing the largest cells within the MNC input, monocytes were obtained in the
last fraction and routinely were >85% pure as determined by morphology and
expression of CD14 antigen. Monocytes were centrifuged (8 min, 300xg, 4°C),
resuspended in RPMI and counted. Monocyte yields were donor-dependent and
typically accounted for 10-30% of the MNC input.
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3.2.2 Blood Dendritic Cell Isolation by MACS
Required buffers and equipment:
MACS buffer 1000 ml RPMI1640 supplemented with 2% human pooled AB serum,
penicillin/streptomycin and L-glutamine degassed for 20-30 min
at RT in an ultrasonic water bath, then put on ice
10% FCS/RPMI
70% Ethanol
MACS blood DC isolation kit Miltenyi, Bergisch Gladbach, Germany
The principle of MACS sorting lies in the use of antibodies conjugated to magnetic
particles which allow depletion or enrichment of antigen-bearing cells on a
paramagnetic column mounted in a strong magnetic field. To isolate blood DCs, T
cells, NK cells and monocytes were magnetically depleted by antibodies to the cell
type-specific antigens CD3, CD56 and CD11b, respectively. In a positive selection
step, CD4+ blood DCs are collected by magnetically labeled anti-CD4 antibody.
Isolation of blood DCs was essentially performed as described in the manufacturer's
product manual with the following modifications: As input, 109 cells from the pooled
elutriation fractions IIc and IId, and, if necessary, IIb, were suspended in 1.5 ml
MACS buffer, giving a total volume of 3 ml. MACS buffer was used throughout the
procedure. After the second positive selection step, cells were eluted with 500 µl
10 % FCS/RPMI.
The purity of the blood DC preparation was assessed by 4-colour flow cytometry after
staining of input cells and blood DCs with FITC-conjugated Lineage Cocktail (CD3,
CD14, CD16, CD19, CD20, CD56) (lin 1, Becton Dickinson), CD123-PE, anti-HLA-
DR-PerCP and CD11c-APC. Blood DCs were identified as lineage- , CD11c+,
CD123+, HLA-DR+ cells and amounted to 92-96% of the sorted cells.
3.2.3 Isolation of Granulocytes from Buffy Coats
Required buffers:
0.2% NaCl (aq), ice-cold
1.6% NaCl (aq), ice-cold
PBS
Ficoll (Biochrom AG, Berlin, Germany)
Granulocytes were prepared from buffy coats by centrifugation through a Ficoll
cushion and subsequent hypotonic erythrocyte lysis. The buffy coat was diluted with
2 volumes of PBS and 2x 30 ml were layered onto 20 ml Ficoll each in 50 ml
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centrifuge tubes. After centrifugation (30 min, 700xg, 18°C) with the brake off, the
supernatant containing MNC in a white interphase was discarded and the pellet,
containing granulocytes and erythrocytes was washed once with 50 ml PBS (8 min,
300xg, 4°C). Red cells were lysed hypotonically by suspending the pellet in 20 ml ice-
cold hypotonic 0.2% NaCl solution for 45 s and restoring isotonicity with 20 ml ice-
cold 1.6% NaCl solution. After centrifugation, the lysis procedure was repeated once
and the remaining cells were centrifuged (8 min, 300xg, 4°C) and washed with 50 ml
PBS.
3.3 Cell Culture
3.3.1 Cell Culture Conditions and Passaging
If not noted otherwise, cells where cultured in RPMI 1640 supplemented with
L-glutamine (2 mM), sodium pyruvate (1 mM) , antibiotics (50 U/ml penicillin and
50 µg/ml streptomycin), 2 ml vitamins, non-essential amino acids and 50 µM
β-mercaptoethanol. Media supplements were purchased from Life Technologies,
Karlsruhe, Germany.
Cells were cultured at 37°C, 5% CO2 and 95% relative humidity in an incubator. FCS
was heat-inactivated for 30 min at 56°C before use.
3.3.2 Assessing Cell Vitality by Trypan Blue Exclusion
Required solutions and materials:
Trypan blue solution 0.2% (w/v) Trypan blue
in 0.9% NaCl solution
Neubauer haemocytometer slide with coverslip
The number of viable and dead cells was determined by Trypan blue exclusion. The
cell suspension was diluted with trypan blue solution and the cells counted in a
Neubauer haemocytometer. The concentration of viable cells was then calculated
using the equation:
Number of viable cells/ml C = N x D x 104
with N: average of unstained cells
per corner square(1 mm2
containing 16 sub-squares)
D: dilution factor
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3.3.3 Freezing and Thawing Cells
Freeze medium 50% RPMI 1640
40% FCS
10% DMSO
Cells were harvested and suspended in ice-cold RPMI 1640 at 1-10 Mio cells/ml
(following ATCC recommendations for cell lines), T lymphocytes at 25-50 Mio/ml, and
1 ml of cell suspension was added to 1 ml ice-cold freeze medium in cryo-vials which
where closed and inverted twice to mix. To allow gradual freezing at a rate of -
1°C/min, the vials were placed in Styrofoam containers or isopropanol-filled cryo-
containers (Nalgene) and frozen at –80°C for 24 h. For long-term storage, the
samples were then transferred to liquid nitrogen (-196°C).
To recover frozen cells, the cell suspension was thawed in a water bath at 37°C. To
dilute the toxic DMSO, the suspension was transferred to 10-25 ml serum-containing
medium as soon as thawed and the cells were spun down (8 min, 300xg, 4°C) and
resuspended in fresh medium.
3.3.4 Primary Cells
3.3.4.1 Dendritic Cells
Immature monocyte-derived dendritic cells (DCs) were generated by culturing
elutriated monocytes in 10% FCS/RPMI1640 supplemented with 500 U/ml each of
recombinant human IL-4 (Schering-Plough, New Jersey, USA or Promocell,
Heidelberg, Germany) and recombinant human GM-CSF (Essex, Munich, Germany)
as described earlier (Meierhoff et al., 1998). To generate mature DCs, immature
monocyte-derived DCs were activated after five days of culture with 100 ng/ml LPS
or 10 ng/ml recombinant human TNF (Knoll AG, Ludwigshafen, Germany) for two
additional days.
3.3.4.2 Macrophages
In order to generate macrophages in vitro, monocytes were cultured in RPMI1640 in
the presence of 2% human pooled AB-group serum. If the macrophages had to be
detached for further experiments, the cells were cultured in Teflon bags on teflon foils
(Biofolie 25; Heraeus, Hanau, Germany), from which they could be harvested after
cooling to 4°C for 45 min (Andreesen et al., 1983). Otherwise, cells were seeded into
petri dishes at a density of 1-2x105 cells/cm2.
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3.3.5 Cell Lines
The cell lines THP-1, HL-60, HepG2 and HeLa were maintained in 10%
FCS/RPMI1640 with the supplements detailed under 3.3.1.
NHDFC were cultured in Dulbecco's modified MEM (DMEM) supplemented with L-
glutamine, antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin and 1 µg/ml
amphotericin B), 10 mM HEPES and 10% FCS.
The colon carcinoma cell lines CaCo-2 and HT-29 were cultured in 10% FCS/DMEM
supplemented with L-glutamine (2 mM), sodium pyruvate (1 mM) , antibiotics (50
U/ml penicillin and 50 µg/ml streptomycin), 2 ml vitamins and 5 ml non-essential
amino acids.
Cells were split 1:3 to 1:8 into fresh medium every 2-4 days. Adherent cells were
passaged by washing once with PBS and incubation with 3 ml 0.05% Trypsin/0.02%
EDTA/PBS per 75 cm2 culture vessel area at 37°C for 5-10 min. The detached cells
were washed once with 5 ml medium containing FCS and resuspended and split 1:3
to 1:10 into 13 ml complete medium/75 cm2.
3.3.6  Mycoplasma Assay
Cells were frequently checked for mycoplasma contamination by ELISA with a
Mycoplasma Detection Kit (Boehringer Mannheim, Mannheim, Germany) according
to the manufacturer's instructions.
3.3.7 Mixed Leukocyte Culture
When cultured together, leukocytes from two unrelated individuals begin to
proliferate. Bain and colleagues  (Bain et al., 1964) coined the term "Mixed Leukocyte
Reaction" to describe this observation and suggested that this reaction might be
useful as an indicator of compatibility between siblings prior to organ transplantation
to assess the risk of rejection of the transplant. Indeed, later on it could be shown
that the observed proliferation of the T lymphocytes is a response to the "allogenicity"
of the two leukocyte populations and that an MLR is absent if the MLC is carried out
between syngeneic populations which express the same MHC alleles. In a syngeneic
MLC, the proliferative response depends on the presence of both non-self antigens
and antigen presenting cells in the leukocyte populations. In an allogeneic setting, the
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MHC incompatibility alone is sufficient to trigger T cell proliferation, the magnitude of
the reaction being solely dependent on the costimulatory capacity of the antigen
presenting cells.
To ascertain the superior antigen presenting capabilities of DCs compared to the
monocytes the were generated from, the magnitude of the MLR induced by co-
culture with allogeneic T lymphocytes was assessed as the amount of tritium-labeled
thymidine incorporated during DNA synthesis by the proliferating T lymphocytes.
Ascending numbers of stimulators were used to induce proliferation of a fixed number
of responder cells and the stimulatory capacity of the antigen presenting cells was
assessed in terms of the amount of 3H-thymidine incorporated by the proliferating T
lympocytes.
T lymphocyte-rich elutriation fractions (IIa1) frozen previously from a different donor
were used as responder cells. The cells were thawed as described under 3.3.3 and
resuspended in 10%FCS/RPMI at a concentration of 1x106 responder cells/ml. A
fixed number of 1x105 responders (100 µl) was seeded into sterile roundbottom 96-
well plates, leaving one row empty for the stimulator-only control. As stimulator cells,
either DCs prepared as described above (see 3.3.4.1) or their monocyte precursors
were used, which had been frozen as above (see 3.3.3). To prevent cells in the
stimulator population from proliferating, stimulators were irradiated with a single dose
of 30 Gy from a 137Cs source. Stimulators were washed with 10% FCS/RPMI and
resuspended at 3x105 cells/ml in 10% human pooled AB serum/RPMI and further
dilutions of 1x105, 3x104, 1x104, 3x103 and 1x103 cells/ml were prepared in the same
medium. MLCs were set up as depicted in Figure 3.1:
One hundred milliliters quadruplicates of each concentration were added to the wells
containing the responder cells, except one row for the responder-only control. The
wells for the stimulator proliferation control were filled with 100 µl of the 3x105 cells/ml
suspension. The volume in single cell population-containing wells was adjusted to
200 µl by adding 100 µl of 10% AB serum/RPMI or 10% FCS/RPMI to FCS or AB
serum-containing well, respectively and the microwell plates were centrifuged for 8
min at 300xg and RT.
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Stim. A Stim. B Stim. C Stimulators Responders
A OOOO OOOO OOOO 3x104 none
B OOOO OOOO OOOO 3x104 1x105
C OOOO OOOO OOOO 1x104 1x105
D OOOO OOOO OOOO 3x103 1x105
E OOOO OOOO OOOO 1x103 1x105
F OOOO OOOO OOOO 3x102 1x105
G OOOO OOOO OOOO 1x102 1x105
H OOOO OOOO OOOO none 1x105
Following 5 days of incubation at 37°C, 5% CO2 and 95% relative humidity, 1 µCi/well
[methyl-3H]thymidine was added (10 µl of 1 mCi/ml diluted 1:10 with RPMI 1640) and
the cells were incubated as before for an additional 18 h. MLCs were harvested with
onto H2O-prewetted 96-well fiber glass filter plates using a FilterMate 196 harvester
(Packard BioScience), washed three times with H2O and air-dried briefly. The bottom
of the glass filter plate was sealed, 50 µl scintillation cocktail were added to each
well, the top of the plate sealed as well with transparent adhesive foil and the activity
measured in a TopCount scintillation counter (Packard Bioscience).
3.4 DNA
3.4.1 Transient transfection of THP-1 cells with DEAE-Dextran
Required buffers and reagents:
STBS 3.029 g (25 mM) Tris/HCl, pH 7.5
8.01 g (137 mM) NaCl
0.373 g (5 mM) KCl
0.161 g (0.6 mM) Na2HPO4⋅7 H2O
0.103 g (0.7 mM) CaCl2⋅2H2O
0.102 g (0.5 mM) MgCl2⋅6H2O
add H2O to 1 l, autoclave
DEAE-Dextran 10 mg/ml in STBS
filter sterilize (0.2 µm) and store at RT
PBS
1x PLB (Passive Lysis Buffer), Luciferase Reporter Assay System (Promega, Mannheim,
Firefly Luciferase Substrate Germany)
The day before transfection, a sufficient number of THP-1 cells to allow duplicate
transfection for each reporter plasmid was seeded at 250000 cells/ml into tissue
culture flasks. On the following day, for each transfection 6 ml cell suspension were
centrifuged (8 min. 300xg, 4°C) the cell pellet washed twice with 5 ml STBS each,
and the supernatant was removed completely. For each transfection, 200 ng of
reporter plasmid in 70 µl STBS were combined with 70 µl DEAE-Dextran (800 ug/ml),
Figure 3.1 MLC pipetting pattern.
Schematic drawing of a 96-well plate.
The numbers indicate cell numbers per
well in 200 µl final volume. The grey-
underlaid wells are the stimulator-only
and responder-only controls.
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mixed and immediately added drop-wise directly onto the THP-1 cell pellets. The
cells were incubated at 37°C for 20 min, washed twice with 5 ml STBS each,
resuspended in 6 ml 10% FCS/RPMI and cultured in ∅ 60 mm tissue culture dishes.
Cells were harvested after 48h, the culture dishes washed once with 5 ml PBS at RT
and the cells were pelleted (10 min , 400xg, 4°C). Pellets were washed once with 10
ml PBS and the PBS removed completely by decanting and briefly inverting the
centrifuge tubes onto Kleenex paper towels. Cells were lysed in 1x PLB for 15 min at
RT. After spinning down cellular debris (3', 16000xg, RT), luciferase activity of 20 µl
lysate was assayed with 100 µl Luciferase substrate each (Promega) in a
luminometer. Lysates were frozen at –20°C. Firefly luciferase activity of individual
transfections was normalized for protein concentration as determined by a BCA
protein assay (see 3.7.2).
3.4.2 Agarose Gel Electrophoresis
Required buffers:
TAE (50x) 252.3 g (2 M) Tris
20.5 g (250 mM) NaOAc/HOAc, pH 7.8
18.5 g (50 mM) EDTA
add H2O to 1 l
EDTA (0.5 M) 18.6 g (0.5 M) EDTA/NaOH, pH 8.0
add H2O to 100 ml
DNA loading dye 500 µl (50 mM) Tris/HCl, pH 7.8
DNA-LD (5x) 500 µl (1%) SDS (20%)
1 ml (50 mM) EDTA (0.5 M), pH 8.0
4 ml (40%) Glycerol
10 mg (1%) Bromophenol blue
add H2O to 10 ml
Table 3.2 Agarose gel composition
1.0% Agarose
TAE (1x) 50 ml 150 ml
Agarose 0.5 g 1.5 g
Ethidium
bromide
2.5 µl 7.5 ml
Other concentrations accordingly.
Table 3.3 Agarose concentrations for different separation ranges.
Efficient range of separation (kb) % [w/v] agarose in gel (%)
0.1-2 2.0
0.2-3 1.5
0.4-6 1.2
0.5-7 0.9
0.8-10 0.7
Taken from Sambrook et al., 1989.
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The required amount of agarose as determined according to Table 3.2 andTable 3.3
was added to the corresponding amount of TAE (1x) and approximately 10 ml of H2O
were added to make up for later volume loss. The slurry was heated in a microwave
oven until the agarose was completely dissolved, and the ethidium bromide added
after cooling the solution to 50-60°C. The gel was cast and mounted in the
electrophoresis tank and covered with TAE (1x). DNA-containing samples were
diluted 4:1 with DNA-LD (5x), mixed and loaded into the slots of the submerged gel.
Depending on the size and the desired resolution, gels were run at 40-100 V for 30
min to 3 h.
3.4.3 Denaturing Alkaline Agarose Gels for Analysis of Single-Stranded
DNA
Required solutions:
NaOH (10 M) 2 g (10 M) NaOH
add H2O to 5 ml
Loading buffer (5x) 250 mM NaOH (10 M)
5 mM EDTA
18% Ficoll 400, Pharmacia
0.15% Bromocresol green
store at 4°C
Electrophoresis buffer 2 ml (50 mM) NaOH (10 M)
800 µl (1 mM) EDTA (0.5 M)
add H2O to 400 ml
TCA (10%) 20 g (10%) Trichloroacetic acid
in 180 ml H2O
500 mg agarose were dissolved in 50 ml H2O by boiling in a microwave oven, cooled
to 60°C, 250 µl (50 mM) 10 M NaOH and 100 µl 0.5 M EDTA were added and the gel
cast, mounted and overlaid with electrophoresis buffer. Samples were diluted 4:1 with
5x loading buffer, loaded into the gel slots and the gel was run in a precooled
electrophoresis tank (-20°C) and precooled electrophoresis buffer (4°C) (Hoefer HE
33 Mini Submarine, Pharmacia) for 4-5 h at 30-50 V until the bromocresol blue had
traversed half of the gel. As a molecular weight marker, 3000-14000 cpm of a
λ/HindIII DNA ladder radioactively end-labeled with PNK (see 3.5.6) were used.
After the run had completed, the gel was rinsed in water for 3 min, fixed for 10 min in
10% TCA and pressed dry between two layers of Whatman 3MM filter paper on each
side with a stack of cellulose wadding underneath (<1 cm) and on top (~4 cm),
weighted with a ~4 kg weight for 1 hour.
Materials and Methods
30
The flattened gel was covered with plastic wrapping film and autoradiographed
overnight with an intensifying screen at –80°C.
3.4.4 Purification of DNA Fragments by Gel Extraction
DNA fragments were purified by running on an ethidium bromide-containing agarose
gel (3.4.2), excising the band containing the fragment under UV illumination and
subsequent gel extraction using the QIAEX II Gel Extraction Kit (Qiagen) following
the manufacturer's instructions. The amount of recovered DNA was estimated by
running an aliquot on an agarose gel in parallel with a DNA ladder of known DNA
band concentrations, such as λ/HindIII or Φ174/HaeIII.
3.4.5 Representation Difference Analysis
Required buffers, reagents and enzymes:
5x PCR buffer (335 mM) Tris/HCl, pH8.8@25°C
(20 mM) MgCl2
(80 mM) NH2SO4
(166 µg/ml) BSA
3x EE buffer (30 mM) EPPS, pH8.0@20°C
(3 mM) EDTA
dNTP dATP/dCTP/dGTP/dTTP (10 mM each)
TE 1 ml (10 mM) Tris/HCl (1 M), pH8.0
0.2 ml (1 mM) EDTA (0.5 M), pH8.0
add H2O to 100 ml
Phenol/Chloroform/ Buffered Phenol:Chloroform:Isoamyl Alcohol 25:24:1,
IAA saturated with 10 mM Tris, pH 8.0, 1 mM EDTA (Sigma)
CHCl3/IAA Chloroform:Isoamyl Alcohol 49:1, see 3.5.1
Ammonium acetate 7.71 g (10 M) NH4OAc
add H2O to 10 ml
3 M Acetate see 3.5.2
DpnII 10 U/µl New England Biolabs, Frankfurt, Germany
Mung Bean nuclease (MBN) (New England Biolabs)
DpnII (New England Biolabs)
Taq polymerase (5 U/µl) (Gibco)
T4 DNA ligase (400 U/µl, corresponding to 18 Weiss units)(New England Biolabs)
RDA of cDNA was performed as described by Hubank and Schatz (Hubank and
Schatz, 1994).
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3.4.5.1 cDNA-Synthesis
Synthesis of cDNA from mRNA by reverse transcription and nick translation was
carried out using the ZAP express cDNA synthesis kit by Stratagene, Heidelberg,
Germany according to the manufacturer's instructions.
Synthesis of cDNA was performed with 5 µg of poly A-selected mRNA prepared from
macrophages and DCs as described under 3.5.3. To control for successful 1st and 2nd
strand synthesis, one tenth of the reaction mixture and all of the 2nd strand reaction
were labeled with radioactive [α-32P]-dCTP and 0.75 µl of the radioactive 1st strand
reaction and 3 µl of the second strand reaction were run on a denaturing alkaline
agarose gel (see 3.4.3).
The 2nd strand reaction products (200 µl) were isolated by vortexing for 10 s with 200
µl buffered phenol/chloroform/IAA, centrifuging (2 min, 16000xg, RT) and extracting
the supernatant with 200 µl chloroform. After overnight precipitation at –20C from the
supernatant with 20 µl 3 M sodium acetate, pH5.2 and 400 µl 100% EtOH,
centrifuging for 1 h at 16000xg and 4°C, the cDNA was washed twice with 500 µl
each of ice-cold 70% EtOH, air-dried at RT for 15 min and dissolved in 20 µl H2O.
3.4.5.2 Generation of Representations
For each representation, approximately 2 µg cDNA, prepared from 5 µg polyA+
mRNA from monocytes/macrophages or DCs (see 3.5.3) (4/5th of the total amount)
were digested with 15 U DpnII (New England Biolabs) in 100 µl volume for 3½ h at
37°C and phenol-extracted with an equal volume (100 µl) of phenol/CHCl3/IAA by
vortexing for 10 s. After centrifugation (5 min, 16000xg, RT) and extraction of the
supernatant with one volume (100 µl) CHCl3/IAA, 2 µg glycogen were added to the
supernatant as a carrier and the cut cDNA was ethanol-precipitated overnight at
-20°C with 50 µl 10 M ammonium acetate and 200 µl 100% EtOH. The cDNA was
pelleted (30 min, 16000xg, 4°C), washed once with ice-cold 75% EtOH (5 min,
16000xg, 4°C), dried and resuspended in 20 µl TE.
Approximately 1.2 µg (12 µl) cut cDNA was then ligated to the R-Bgl-12/24 adapter in
a 60 µl reaction containing 4 µl desalted R-Bgl-24 oligo (2 mg/ml), 4 µl desalted R-
Bgl-12 oligo (1 mg/ml), 6 µl 10x ligase buffer (New England Biolabs) and 31 µl H2O.
Oligonucleotides were annealed to each other and to the cDNA in a PCR cycler by
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heating the ligation reaction to 50°C and then cooling to 10°C over a period of 1 h.
Ligation was carried out by adding 3 µl (1200 U) T4 DNA ligase (corresponding to 18
Weiss units)(New England Biolabs) and incubating for 18 h at 14°C.
Ligations were diluted to 6 ng/µl by adding 140 µl TE and 25 parallel PCR reactions
were set up to generate the initial representations. Each 200 µl reaction contained 2
µl diluted ligation and (final concentrations) 66 mM Tris/HCl, pH 8.8@25°C, 4 mM
MgCl2, 16 mM (NH4)2SO4, 33 µg/ml BSA, 0.34 mM each dNTP and 2 µg R-Bgl-24
primer overlaid with two drops of mineral oil (Sigma) in 0.5 ml PCR tubes. After
melting away the 12-mer for 3 min at 72°C, 1 µl (5 U) Taq polymerase (Gibco) was
added, the 3' ends were filled in for 5 min at 72°C and 20 cycles of amplification (1
min, 95°C; 3 min, 72°C) and 10 min extension at 72°C were performed on a Perkin
Elmer thermocycler 480. Four PCR products each were combined and extracted
twice with 750 µl phenol/CHCl3/IAA, once with 750 µl CHCl3/IAA, precipitated for 30
min at –20°C with 75 µl 3 M acetate and 800 µl 100 % isopropanol, washed once
with 70% EtOH, dried and resuspended in 30 µl H2OUSB. The samples were pooled,
DNA concentration was determined by measuring OD260 (OD260 of 1 corresponds to
50 µg/ml DNA) and adjusted to 0.5 mg/ml with H2OUSB.
To remove the R-adapters, 300 µg (600 µl) of each amplification product were
digested with 750 U DpnII in 1.4 ml reactions for 4 h at 37°C. The digests were
divided into two portions of 700 µl each and purified by extracting twice with
phenol/CHCl3/IAA and once with CHCl3/IAA. After precipitation with 0.1 volumes (70
µl) 3M Acetate and 700 µl isopropanol for 30 min at –20°C, the driver representation
was pelleted (30 min, 16000xg, 4°), washed twice with 1 ml ice-cold 70% EtOH each,
dried and dissolved at a concentration of 0.5 mg/ml as determined on a
spectrophotometer.
To generate the tester representation, 20 µg (40 µl) phenol-extracted DC-derived
DNA digest were diluted with 40 µl TE and 20 µl 5x DNA loading dye and gel-purified
from the R-adapters on a 1.2% TAE/agarose gel using QIAEX II resin (Qiagen)
according to the manufacturer's instructions. Two micrograms of the gel extract were
ligated to J-Bgl-12/24 adapter in a 60 µl reaction as described above for R-Bgl
adapter and the mixture diluted with 120 µl TE to give a final concentration of ~10
ng/ml DNA.
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3.4.5.3 Difference Analysis
For the first round of hybridization and subtractive amplification, a 100-fold excess of
driver (40 µg in 80 µl) were mixed with 0.4 µg (40 µl) tester representation in a 0.5 ml
PCR tube, the mixture extracted once with phenol and once with CHCl3, precipitated
with 30 µl 10 M ammonium acetate and 380 µl 100% EtOH for 10 min at –80°C,
centrifuged (15 min, 16000xg, 4°C), washed twice with 70% EtOH and air-dried. The
pellet was thoroughly resuspended in 4 µl 3x EE buffer, incubated for 5 min at 37°C,
vortexed, spun down, overlaid with 35 µl of mineral oil (Sigma) and the DNA
denatured in a PCR cycler for 5 min at 100°C. The mixture was cooled to 67°C, 1 µl 5
M NaCl was added to the solution and hybridization was performed at 67°C for 21½
h. After complete removal of the mineral oil, the DNA was diluted and mixed with 8 µl
TE containing 5 µg/µl yeast tRNA, followed by 25 µl and 362 µl TE.
The first selective PCR amplification was performed in four parallel 200 µl reactions
as above containing 20 µl diluted hybridization mix but initially omitting primers and
Taq DNA polymerase. After melting away the J-Bgl-12 oligonucleotides for 3 min at
72°C, 5 U (1 µl), Taq DNA polymerase (Gibco) was added to fill in ends for 5 min at
72°C, 2 µg J-Bgl-24 primer were added and ten cycles (1 min, 95°C; 3 min, 70°C) of
amplification and a final extension for 10 min at 72°C were performed. The four
reactions were combined, extracted twice with an equal volume phenol/CHCl3/IAA,
once with an equal volume CHCl3/IAA, precipitated for 30 min at -20°C together with
2 µg glycogen carrier by adding 75 µl 3 M acetate and 800 µl isopropanol, the pellet
washed twice with 1 ml 70% EtOH, air-dried and resuspended in 40 µl 0.2xTE.
To remove DNA single strands, half of the PCR product was digested with 20 U
Mung Bean nuclease (MBN) (New England Biolabs) for 35 min at 30°C in 40 µl
volume. The reaction was stopped by adding 160 µl 50 mM Tris/HCl pH 8.9 and
heating to 98°C for 5 min.
The first difference product was prepared by performing a second subtractive PCR
using 20 µl of the MBN-treated DNA each as a template in four 200 µl reactions set
up as above, this time including 2 µg (2 µl) J-Bgl-24 primer from the beginning, and
hot-started by adding 1 µl (5 U) Taq DNA polymerase (Gibco) each after melting the
DNA for 1 min at 95°C and cooling to 80°C. Following 18 cycles of amplification (1
min, 95°C; 3 min, 70°C) and 10 min extension at 72°C, the reactions were cooled to
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4°C, pooled, DNA extracted twice with phenol/CHCl3/IAA, once with CHCl3/IAA,
isopropanol-precipitated, washed and dried as described for the first subtractive PCR
and dissolved in 500 µl TE (at 0.5 µg/µl as determined by measuring OD260) to give
the first difference product (DP1).
To change the adapters from J-Bgl to N-Bgl, the difference product was digested with
150 U DpnII (New England Biolabs) for 3 h at 37°C in 300 µl reaction volume, twice
phenol- and once CHCl3-extracted as above, and ethanol-precipitated with 0.1
volume 3 M Acetate and 2.5 volumes (800 µl) 100% EtOH for 30 min at –20°C. The
DNA was pelleted, washed and dried as above, and dissolved in 30 µl TE. The
concentration was determined as OD260, 200 ng DpnII-digested DP1 were ligated to
N-Bgl-12/24 adapters as described before and the DNA was diluted to 1.25ng/µl by
adding 100 µl TE.
The second round of hybridization and subtractive amplification was carried out with
an 800-fold excess of driver representation (40 µg in 80 µl) over N-Bgl-ligated DP1
(50 ng in 40 µl) using N-Bgl-24 primers for the subtractive PCRs as described above.
In the final cut and ligation step, the N-adapters on the DP2 were changed back to J-
adapters and the J-ligated DP2 was diluted to 1 ng/µl by adding 160 µl TE to the
ligation reaction. 10 µl diluted ligation were diluted 1:100 with 990 µl TE containing 30
µg yeast tRNA carrier to give 10 pg/µl J-ligated DP2.
For generation of the third difference product a 400000-fold excess of driver (40 µg)
was subtracted from 100 pg J-ligated DP2 (10 µl) by hybridization and two rounds of
PCR with intermittent MBN digestion as described above, the second subtractive
PCR being carried out for 22 cycles instead of 20 cycles.
To clone the final difference product , the adapters were removed from 25 µg DP3 by
digesting with 75 U DpnII in a 100 µl reaction for 4 h at 37°C and gel extraction after
separation on a 2% agarose/TAE gel using QIAEX II resin (see 3.4.4).
DP3 was "shotgun"-cloned by ligating 3-fold molar excess (50 ng) of DpnII-cut, gel-
extracted DP3 with 14 ng BamHI-restricted pZeRO-2 vector using 120 U (0.3 µl) T4
DNA ligase for 1½ h at 16°C in 10 µl volume and transforming chemically competent
TOP10F' E.Coli (Invitrogen) with 2 µl ligation reaction.
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3.4.6 Reverse Dot Blot
Required reagents and materials:
SSPE (20x) 2.76g (0.2 M) NaHPO4/NaOH, pH 7.4
0.74 g (20 mM) EDTA
17.5 g (3 M) NaCl
add H20 to 100 ml, autoclave
Prehybridisation buffer15 ml (50%) formamide
7.5 ml (5x) SSPE (20x)
150 µl (0.1%) SDS (20%)
600 µl (0.5 mg/ml) tRNA (25 mg/ml)
300 µl (0.1 mg/ml) Herring sperm DNA (10 mg/ml)
add H2O to 30 ml
Hybridisation solution 15 ml (50%) Formamide
7.5 ml (5x) SSPE (20x)
150 µl (0.1%) SDS (20%)
6 ml (5%) PEG 8000 (25%)
600 µl (0.5 mg/ml) tRNA (25 mg/ml)
300 µl (0.1 mg/ml) Herring sperm DNA (10 mg/ml)
add H2O to 30 ml
Wash solution A 50 ml (2x) SSC (20x)
2.5 ml (0.1%) SDS (20%)
add H2O to 500 ml
Wash solution B 12.5 ml (0.5x) SSC (20x)
2.5 ml (0.1%) SDS (20%)
add H2O to 500 ml
Wash solution C 2.5 ml (0.1x) SSC (20x)
2.5 ml (0.1%) SDS (20%)
add H2O to 500 ml
Wash solution D 2.5 ml (0.1x) SSC (20x)
25 ml (1%) SDS (20%)
add H2O to 500 ml
3 M NaOH
Nylon transfer membrane Magna NT, 0.22 µm; MSI, Westborough, MA, USA
Blot paper Whatman GB003; Whatman, Göttingen, Germany
Vacuum dot blot manifold Schleicher und Schuell, Dassel, Germany
To check for specificity of the difference product, cloned inserts of 85 randomly
picked clones were PCR-amplified, blotted in duplicates onto two nylon transfer
membranes and hybridized with radioactively labeled driver or tester cDNA. Utilizing
pZeRO-2 vector-specific primers (pZeRO-2s/as), inserts were amplified by PCR from
single bacterial colonies.
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PCR mixture (100 µl)
10 µl (1x) PCR buffer (10x)
8 µl (0.2 mM) dNTP (2.5mM each)
0.8 µl (0.8 µM) pZeRO sense primer (100 µM)
0.8 µl (0.8 µM) pZeRO antisense primer (100 µM)
0.8 µl (4 U) Taq DNA polymerase (5 U/µl)
79.6 µl H20USB
PCRs were on a Perkin Elmer 9600 PCR cycler equipped with a hot bonnet under
the following conditions:
95°C, 2 min; 35x(93°C, 1 min; 60°C, 1 min; 72°C, 1 min); 72°C, 5 min; 4°C.
The PCR products were denatured with 10 µl of 3 M NaOH (0.3 M final) for 30 min at
room temperature. Two dot blots with identical layout were prepared. For each blot, a
transfer membrane was rinsed in distilled water, equilibrated for 1 min with 20x SSC,
mounted on top of one layer blot paper soaked with 20x SSC and washed once by
filling all wells with 500 µl of 20x SSC each and applying vacuum to the manifold.
Wells were filled a second time with 500 µl 20x SSC each, half of each denatured
PCR mix was directly added to the SSC in successive wells and blotted by applying
vacuum. Wells were washed with 200 µl 20x SSC each, the membrane removed
from the manifold, dried for 5 min on Whatman 3M paper and UV-crosslinked with
120 mJ/cm2 at 254 nm wavelength.
After UV-crosslinking, membranes were washed for 30 min at 65°C in wash buffer D
and prehybridized for 2 h at 52°C in 10 ml prehybridization buffer. Blots were
hybridized overnight to radioactively labeled driver, i.e. monocyte/macrophage cDNA
representation, or tester, i.e. dendritic cell cDNA representation, respectively, in 5 ml
hybridization solution each at 52°C. The following day, blots were washed for 5 min in
wash buffer A, and for 20 min each in wash buffers B and C at RT, followed by a final
wash for 30 min at 50 °C in wash buffer D. Blots were heat-sealed in plastic bags and
autoradiographed with an intensifying screen at –80°C for several days.
3.4.7 PCR
Required reagents:
DNA polymerase 0.04-0.67 U/µl Taq DNA polymerase or Expand High Fidelity
polymerase mix (Roche Biochemicals) with the
supplied reaction buffer
Primers 0.2-1 µM Sense-/antisense primers (10-100 µM)
dNTP 0.2-0.25 mM dATP, dCTP, dGTP, dTTP (25 mM each)
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The polymerase chain reaction (PCR) allows in-vitro synthesis of large amounts of
DNA by primed, sequence-specific polymerization of nucleotide triphosphates
catalyzed by DNA polymerase (Mullis et al., 1986).
PCRs were generally performed in thick PCR tubes in 20-100 µl of reaction volume.
If performed on a Perkin Elmer 480 (PE 480), reactions were overlaid with two drops
or 30 µl mineral oil. On the MJ research PTC 200 thermocycler (Biozym), the
"calculated temperature" feature was used to decrease temperature hold times. The
nucleotide sequences of the utilized primersare given in 3.1.4. If not indicated
otherwise, the primer annealing temperature was 65°C.
Typical reaction parameters for analytical PCR:
Action \ Cycler PE 480 PTC 200
Initial Melting 95°C 2-5 min 93°C 30 s
 Melt 95°C 1 min 93°C 15 s
 Anneal 65°C 1 min 65°C 15 s20-35Cycles  Extend 72°C 1 min 72°C 45 s
Final Extension 72°C 10 min 72°C 5-7 min
Cool to 4°C 15°C
If PCRs were performed from bacterial colonies, on the PTC 200 cycler the initial
melting step was prolonged to 2 min. To avoid generating unspecific products during
the first heating phase on the PE 480, reactions were generally started by adding the
Taq polymerase after the melting the template and annealing the primers at the
beginning of the first extension step ("Hotstart"). For preparative and semi-
quantitative PCRs on the PTC 200, the DNA polymerase or DNA polymerase mix
was diluted 2:1 with TaqStart antibody (Clontech).
3.4.8 RT-PCR
Required additional reagents:
MMLV-RT Superscript II (200 U/µl) (RNase H- Moloney
Murine Leukemia Virus reverse transcriptase,
Gibco, Eggenstein, Germany) with supplied
buffer and DTT (0.1 M)
Oligo dT Oligo dT (100 µM) (Pharmacia)
H2ODEPC
In RT-PCR, the cDNA PCR template is produced from RNA by reverse transcription
with reverse transcriptase after priming with a poly dT oligonucleotide which is
complementary to the poly A tail common to most mRNAs. For higher yields, mutated
MMLV-RT devoid of the otherwise inherent 3'-5' RNase H activity was deployed.
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One to two micrograms of total RNA were denatured for 5 min at 70°C in 12 µl
H2ODEPC containing 100 pmol (1 µl) oligo dT (100 µM) and put on ice. After adding 4
µl MMLV-RT First Strand buffer, 1 µl dNTP (25 mM each) and 2 µl DTT (0.1 M), the
primer was annealed for 2 min at 42°C, 1 µl MMLV-RT added and the reaction
incubated for 1 h at 42°C. After inactivation of the enzyme for 10 min at 70°C, 0.5-1
µl of the cDNA were used as a template for PCR.
3.4.8.1 SMART-RACE
Rapid amplification of cDNA ends (RACE) allows to determine the sequence of
mRNA ends by adding known sequences to the cDNA ends during or prior to reverse
transcription. In conjunction with nested gene-specific primers and primers
complementary to the added terminal sequence portions, the mRNA section between
these primer pairs can be amplified by PCR, cloned and sequenced. To determine
the 5'-ends of particular transcripts, and thus the transcription start site, SMART-
RACE was performed according to the manufacturer's instructions. This RACE
variant takes advantage of the 3'-terminal nucleotide transferase activity of MMLV-RT
which adds 3-5 nucleotides of predominantly dC to the 3'-ends of the reverse
transcripts. A "SMART" oligonucleotide, containing a terminal stretch of dG residues
then can anneal to the 3' dC cDNA overhang and serve as additional template for the
reverse transcriptase which switches template and extends the cDNA, adding a copy
of the SMART oligo to its 3' end containing primer binding sites for subsequent
nested PCRs. After carrying out nested PCRs with gene-specific primers vs. SMART-
specific, the PCR products were cloned into the pCR TOPO 2.1 vector (see 3.6.4)
and sequenced with M13 primers.
3.4.9 Precipitation of DNA using PEG
Required reagents:
PEG-mix 26.2 g (26.2 %) PEG 8000
20 ml (0.67 M) NaOAc pH 5.2 (3 M)
660 µl (0.67 mM) MgCl2 (1 M)
add H2O to 250 ml
100% Ethanol
To precipitate DNA from small volumes, e.g. PCR reactions or endonuclease
digestion, one volume of PEG-mix was added to the DNA-containing solution,
vortexed and incubated for 10 min at RT. After centrifugation (10 min, 16000xg, RT),
the supernatant was discarded and the precipitated DNA (often only visible as a faint
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smear) was washed by carefully adding 200 µl 100% EtOH to the tube wall opposite
of the (often invisible) pellet, centrifugation (10 min, 16000xg, RT) and careful
removal of the supernatant. The pellet was dried and resuspended in H2O at half to
three-quarters of the initial volume.
3.4.10 PCR-based Site-Specific Mutagenesis
For site-specific mutagenesis of single sites in the MCP-4 promoter, two overlapping
fragments containing the desired mutation at their ends were generated by PCR
using sense/antisense mutant primers (PXS/PXAS=CpG1M1s/as, M2s/as), which
contained the mutation in the center of the oligonucleotide together with fragment-
specific (outer) primers (GS/GAS=MCP-4pPGL3s/MCP-4pAS) featuring NheI and
BglII restriction sites for directional cloning in two separate reactions. As template, an
MCP-4 promoter fragment ranging from –1121 bp to +8 bp previously cloned in
pGL3-Basic using MCP-4pS/AS was used. The PCR products were gel-extracted
together to give 20 µl of gel extract (GE) which served as template for a second PCR
employing the outer primers to assemble the two fragments at their overlapping
portion. The ensuing PCR product with the lowest cycle number as above, was PEG-
precipitated, endonuclease-digested to create sticky ends, gel-extracted, cloned
directionally into the BglII/NheI site of the pGL3-Basic reporter and sequenced. To
ensure incorporation of the mutation into the PCR product, the first round of PCRs
was performed with Taq polymerase which does not possess a 3'->5' proofreading
activity. For maximum accuracy, the second PCR was carried out using a DNA
polymerase mix (Expand High Fidelity, Roche) with proofreading activity.
PCR-Reactions: PCR 1 PCR 1' PCR 2
DNA template 1 µg 1 µg 20 µl GE PCR1+1'
10x Taq Buffer 10 µl 10 µl -
10x HiFi Buffer - - 10 µl
dNTP (10mM each) 2 µl 2 µl 2 µl
GS (10 pmol/µl) 5 µl - 5 µl
GAS (10 pmol/µl) - 5 µl 5 µl
PXS (10 pmol/µl) - 5 µl -
PXAS (10 pmol/µl) 5 µl - -
H20 to 98 µl to 98 µl to 98 µl
Taq+Start-Ab 2 µl 2 µl -
HiFi+Start-Ab - - 2 µl
To avoid producing amplification errors due to high cycle numbers, PCRs were
performed in quadruplicates for 6, 9, 12 and 15 cycles and the product generated by
the lowest number of cycles was used for the rest of the procedure. For each PCR,
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the 100 µl master mix was divided into four 25 µl aliquots, one of which was removed
after each of the above numbers of cycles and later placed back in the cycler for the
terminal elongation step. PCRs were performed on an MJ research PTC 200
thermocycler (Biozym) using the following program:
93°C, 30 s; (6/9/12/15)x(93°C, 15 s; 65°C, 15 s; 72°C, 45 s); 72°C, 5 min;
15°C, ∞.
3.4.11 Genome Walking
To obtain the sequence upstream of the Hep27 transcription start in DCs, genome
walking was performed using the GenomeWalker Kit (Clontech) according to the
manufacturer's instructions.
Genome walking enables cloning of genomic sequences adjacent to a known
genomic site. The method encompasses PCR amplification of genomic fragments
using a primer specific for the known site and a primer complementary to the
adapters that have been ligated to both ends of genomic fragments prepared by
restriction endonuclease-digestion of genomic DNA. Five genomic libraries prepared
with a different enzyme were screened with nested PCRs.
The five primary PCRs employing the outer AP1 (supplied) and Hep27GWouter
primers were performed on an MJ Research PTC-200 Thermal Cycler with a
modified cycling program:
7x(94°C, 5 s; 72°C, 3 min); 32x(94°C, 5 s; 67°C, 3 min); 67°C, 5 min.
The five nested PCR were carried out with the inner AP2 (supplied) and
Hep27GWinner primers as follows:
5x(94°C, 5 s; 72°C, 3min); 22x(94°C, 5 s; 67°C, 3 min); 67°C, 4 min.
The ensuing PCR products were visualised on a 1.5% agarose/TAE gel, PEG-
precipitated and sequenced from both ends using the inner AP2 and Hep27GWinner
primers.
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3.4.12 Preparation of Genomic DNA and Bisulfite Sequencing
Required reagents:
NaOH (3 M) 1.2 g (3 M) NaOH
add H2O to 10 ml, prepare fresh before use
Hydroquinone (0.4 M) 0.44 g (0.4 M) Hydroquinone
add H2O to 10 ml, prepare fresh before use
Bisulfite (3.8 M NaHSO3) 4.5 g (3.8 M) Na2S2O5 (Metabisulfite)
dissolve in 5 ml H2O, adjust pH to 5.0 with NaOH (3 M), add H2O to 10 ml
Ammonium acetate (10 M)
Genomic DNA from various cell types was prepared using the Blood and Cell Culture
DNA Midi Kit (Qiagen). Modification of DNA with sodium bisulfite, leading to
conversion of unmethylated cytosine residues to uracil while leaving 5-methylcytosine
residues intact (Frommer et al., 1992) was performed as follows.
5 µg genomic DNA in 50 µl TE were denatured with 5.5 µl NaOH (3 M) at 37°C for 15
min. After the addition of 540 µl sodium bisulfite (3.8 M) and 15 µl hydroquinone (0.4
M), samples were mixed, divided into 6 aliquots and covered with mineral oil.
Incubation was performed in a PCR cycler (95°C, 3 min, 55°C, 57 min, 5 cycles).
Samples were combined after treatment, DNA was recovered in 100 µl H2O using the
Wizard DNA Clean-Up System (Promega) and desulfonated by the addition of 11 µl
NaOH (3M) and subsequent incubation at 37°C for 15 min. The DNA was then
precipitated using 44 µl ammonium acetate (10 M) and 390 µl ice-cold 100% ethanol
and resuspended in 50 µl TE. 5 µl of DNA were amplified in individual nested PCR
reactions for both strands using the following primers: sense strand, first round: sS,
sAS; sense strand, second round: s2S, as2S; anti-sense strand, first round:, asAS;
anti-sense strand, second round: as2S, as2AS.
Outer PCR mixture (50 µl each)
5 µl (1x) PCR buffer (10x)
1 µl (0.2 mM) dNTP (10 mM each)
2 µl (0.4 µM) sense primer (10 µM)
2 µl (0.4 µM) antisense primer (10 µM)
1 µl (3.3 U) Taq DNA polymerase (5 U/µl):TaqStart Ab (Clontech) 2:1
34 µl H20USB
5 µl (0.5 µg) Bisulfite-treated genomic DNA as template
The nested PCRs were set up correspondingly with 0.5 µl outer PCR product as
template and additional H2O to give 50 µl/reaction.
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PCRs were performed on an MJ research PTC 200 thermocycler (Biozym) under the
following conditions:
93°C, 30 s; 35x(93°C, 15 s; 55°C, 15 s; 72°C, 70 s); 72°C, 5 min; 15°C.
Products from the nested PCR were PEG-precipitated (see 3.4.9) and sequenced
using the nested PCR primers to prime the sequencing reaction.
3.4.13 DNA Sequencing and Sequence Analysis
Sequencing was performed by dideoxy termination  (Sanger et al., 1977) using
fluorescent dye-labeled terminators (Dye Deoxy Terminator Cycle Sequencing Kit,
Applied Biosystems, Weiterstadt, Germany) according to the manufacturer's
instructions on an Applied Biosystems DNA sequencing system model 373A.
Database searches in GenBank were performed with BLAST v2.0 at the NCBI (URL:
http://www.ncbi.nlm.nih.gov/BLAST/), to identify putative transcription factor the
MatInspector software (Quandt et al., 1995) from Genomatix Software GmbH (URL:
http://genomatix.gsf.de/) was employed. DNA sequences were analyzed for known
repetitive elements using the RepeatMasker program (Smit and Green, 2001) (URL:
http://ftp.genome.washington.edu/cgi-bin/RepeatMasker).
3.5 RNA
3.5.1 RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-
Chloroform Extraction
Required solutions and materials:
Solution D 47.2 g (4 M) Guanidine thiocyanate (GTC)
2.5 ml (25 mM) Sodium citrate 1 M / HCl, pH7.0
1.67 ml (0.5 %) Sodium N-lauroylsarcosine solution (30%)
add H2ODEPC to 100 ml, store at 4°C for up to 3 months
add 7.2 µl/ml β-mercaptoethanol (fume hood) directly before use
2 M Acetate 16.4 g (2 M) NaOAc⋅3H2O
dissolve in 40 ml H2ODEPC, adjust to pH 4.0 mit 2 M HAc,
add H2ODEPC to 100 ml
Phenol unbuffered, saturated with H2ODEPC:
melt redistilled phenol in water bath and add
0.1% 8-Hydroxyquinoline
2x 40% H2ODEPC
shake well and let sit overnight (top water layer should be ¼ of the phenol
phase)
Materials and Methods
43
CHCl3/IAA (49:1) 2 ml 1 Vol Isoamyl alcohol
98 ml 49 Vol Chloroform
100% Isopropanol store at 4°C
80% Ethanol 80 ml (80 %) Ethanol
add H2ODEPC to 100 ml, chill on ice
Up to 1.5x107 cells were lysed per 1 ml of solution D, adherent cells directly in the
culture vessel followed by scraping with a sterile rubber policeman, suspension cells
after pelleting, discarding the supernatant and resuspending in the residual medium.
The lysate was transferred to sterile 14 ml centrifuge tubes (volumes below 850 µl
were processed in 2 ml micro centrifuge tubes), DNA sheared by passing 10 times
through a 20G (0.9 mm x 40 mm) needle fitted to a syringe and 0.1 volumes 2M
acetate were added to the lysate which at this point could be stored at -20°C. For
each 1 ml solution D used, 1 ml phenol and 0.2 ml CHCl3/IAA were added, and the
RNA extracted into the aqueous phase by vigorous shaking, phase separation on ice
for 15 min and centrifugation (20 min, 1000xg, 4°C). The upper aqueous phase was
carefully aspirated without disturbing the protein-containing interphase and combined
with an equal volume of cold 100% isopropanol in a fresh tube. Total RNA was
precipitated by mixing thoroughly, incubation at –20°C for at least 1 h and
centrifugation for 20 min at >10000xg and 4°C. The supernatant was discarded, the
RNA pellet dissolved in 0.3 ml per 1 ml lysate of solution D, transferred to a sterile
1.5 ml screw-cap micro centrifuge tube and precipitated a second time by adding an
equal volume of isopropanol, thorough mixing, incubation for > 1h at –20°C and
centrifuging for 20 min at >10000xg and 4°C. The supernatant was discarded and the
pellet was washed twice with 1 ml each of 80% EtOH (15 min, 10000xg, 4°C), air-
dried and dissolved in H2ODEPC.
RNA yield and purification efficiency was determined on a spectrophotometer (an
OD260 of 1 corresponds roughly to 40 µg/ml RNA, OD260/OD280 < 1.8-2.0 indicates
protein contamination, OD260/OD230 < 2 indicates GTC carry-over), RNA integrity was
assessed by running 0.5 µg of RNA on an agarose/formaldehyde gel (intact RNA has
28S:18S rRNA band intensity ration of 2:1, and the highest RNA density around 2
kb). Modified from Sambrook et al. (Sambrook et al., 1989).
Alternatively, for Northern blots, RNA was prepared using the RNeasy Mini Kit
(Qiagen) according to the manufacturer's instructions.
Materials and Methods
44
3.5.2 CsCl purification of RNA
Required solutions and materials:
Solution D β-mercaptoethanol added directly before use, see 3.5.1
CsCl solution 96 g (5.7M) CsCl
(d=1.69 g/ml) 2.0 ml (0.01 M) EDTA (0.5 M), pH7.0
 add H2O to 100 ml
add 100 µl (0.1 %) DEPC (fume hood), shake well, allow to sit
overnight at RT, autoclave
3 M Acetate 24.6 g (3 M) NaOAc, pH 5.2 with 3 M HAc,
dissolve in 40 ml H2ODEPC
add H2ODEPC to 100 ml
80% Ethanol
Polyallomer ultracentrifuge tubes Beckman, Munich, Germany
For the construction of cDNA representations, RNA purified by CsCl gradient
centrifugation proved to be superior to the RNA isolated by the standard acid phenol
extraction method.
Up to 100x106 cells were lysed in 6 ml solution D (1-1.5 Mio cells/ml). Suspension
cells were centrifuged (8 min, 300xg, 4°C), the supernatant discarded and the pellet
resuspended in residual medium before adding solution D. Adherent cells were lysed
directly in the tissue culture vessel in 2-3 ml solution D/160 cm2 after medium
removal and scraped with a sterile rubber policeman. Lysates were homogenized
and nuclear DNA sheared by passing the lysates 10 times through a 20G needle.
The samples were layered onto 5 ml CsCl solution in bottom-labeled ∅14 cm
ultracentrifuge tubes pre-rinsed with solution D and the tubes were filled to within 4-5
mm of the top and weight-matched within 10 mg with solution D. After centrifugation
for 18 h at 35000 rpm and 20°C in an SW40 Ti or SW 41 Ti swing bucket rotor with
the brake off, supernatants were carefully aspirated with a fresh Pasteur pipette from
the top to approximately 1 cm above the tube bottom and the remaining liquid was
poured off by inverting the tubes onto a fresh Kleenex wipe. The tube bottoms
containing the RNA pellets were cut off with a hot disposable scalpel ~1 cm above
the bottom and place on ice. The RNA pellets were dissolved by rinsing the tube
bottoms with four portions of 100 µl H2ODEPC which were transferred to RNAse-free
1.5 ml screw cap tubes. RNA was precipitated for at least 1 h at -20°C with 40 µl of 3
M acetate and 1 ml ice-cold 100% ethanol, centrifuged (30 min, 15000xg, 4°C),
washed once with 1 ml ice-cold 80% ethanol (15 min, 15000xg, 4°C), air-dried at RT
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and dissolved in 20-80 µl H2ODEPC. RNA was stored at –20°C. (modified from
Sambrook et al., 1989). RNA yield and integrity was assessed as described under
3.5.1.
3.5.3 Poly-A mRNA Isolation
Poly-A+ mRNA was isolated from CsCl-purified total RNA using oligo-dT-conjugated
polystyrene latex beads (Oligotex beads, Qiagen), following the supplied instructions.
3.5.4 Electrophoresis of RNA in Denaturing Formaldehyde Agarose Gels
Required buffers:
MOPS (20x) 42 g (0.4 M) MOPS/NaOH, pH 7.0
4.1 g (100 mM) NaOAc
3.7 g (20 mM) EDTA
add H2ODEPC to 500 ml, store in the dark
RNA loading buffer 10 ml (50%) Formamide, deionized
3.5 ml (2.2 M) Formaldehyde (37%)
1 ml (1x) MOPS (20x)
0.8 ml (0.04%) Bromophenol blue (1% in H2O)
0.2 g (1%) Ficoll 400, Pharmacia (dissolve in 2 ml H2O)
add H2ODEPC to 20 ml, store in 1 ml aliquots at –20°C
add 5 µl/ml EtBr (10 mg/ml) before use
The agarose was dissolved in MOPS/H2ODEPC by heating in a microwave oven,
cooled to 60°C, formaldehyde was added while stirring the solution under a fume
hood and the gel was cast, mounted in an electrophoresis tank and overlaid with 1x
MOPS as electrophoresis buffer. RNA samples were prepared by diluting with four
volumes RNA loading buffer (1:4), denaturing for 20 min at 65°C and brief incubation
on ice. Samples were centrifuged and loaded into the gel slots. Gels were run at 40-
60 V; for subsequent Northern blotting, gels were run overnight at 13-16 V.
3.5.5 Northern Blot – RNA Transfer
Required buffers:
SSC (20x) 88 g (0.3 M) Na3Citrate⋅2H2O/HCl, pH 7.0
175 g (3 M) NaCl
add H2O to 1 l, autoclave
Following separation on formaldehyde/agarose gels, the RNA was transferred to
nylon membranes by capillary elution.
A nylon membrane (Magna NT, MSI) was cut to gel size, wetted with H2O, and briefly
soaked in 20x SSC. The RNA gel was placed upside-down on two layers of 20x
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SSC-soaked Whatman 3MM filter papers on a glass plate, the ends of which were
reaching into a buffer reservoir placed below filled with 20X SSC. The membrane
was laid on top of the gel, avoiding to trap air bubbles. One corner of the membrane
was marked by cutting it of and plastic stripes were placed on the membrane borders
to avoid short-circuiting the capillary flow past the membrane to the two layers of 20x
SSC-soaked Whatman filters which were put on top of the membrane and the plastic
covers. A 6-8 cm stack of cellulose wadding was placed on top to draw the 20x SSC
through the gel and the membrane. The cellulose was weighed down with a glass
plate (more weight was not necessary and only led to decreased transfer efficiency
for higher molecular weight RNA).
After transfer overnight, completeness of the transfer was checked under UV
illumination, the gel lanes and 18S and 28S rRNA bands were marked with a soft
pencil and the RNA was fixed to the membrane by UV-crosslinking with 120 mJ/cm2
at 254 nm in a Stratalinker.
3.5.6 Radioactive Labeling of DNA
Plasmid-excised or PCR-generated DNA fragments were radioactively labeled by
second-strand synthesis with Klenow fragment either random-primed or primed with
an end-specific antisense primer to reduce background. For random priming, either
random hexamers (Boehringer Mannheim, Germany) and 50 µCi [α-32P]-dCTP  or
random decamers (Strip-EZ DNA Kit, Ambion, Huntingdon, UK) and 50 µCi [α-32P]-
dATP were used according to the supplied instructions and purified by gel filtration as
described below.
For antisense-primed labeling, 25 ng DNA fragment (200-1000 bp) were heat-
denatured in 10 µl H2O for 5 min at 95°C, chilled on ice or snap-frozen in liquid
nitrogen, and combined with a 3-10-fold molar excess of antisense primer, 2.5 µl 10x
Klenow buffer (InViTek, Berlin, Germany), 3 µl (0.5 pmol each) dA/G/TTP (133 µM
each) (Pharmacia), 5µl (50 µCi) [α-32P]-dCTP (3000 µCi/mmol)(Amersham) and 1 µl
(2 U) Klenow fragment in 25 µl reaction volume. In some experiments, instead of the
above nucleotides, modified dCTP and dTTP/dGTP from the Strip-EZ DNA Kit
(Ambion) were used together with 50 µCi [α-32P]-dATP to produce easily strippable
probes for multiple successive hybridizations of the same blot with different probes.
Reactions were incubated for 20-45 min at 37°C and put on ice.
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18S rRNA-specific oligonucleotide was 5'-end-labeled by phosphorylation with T4
polynucleotide kinase (PNK) and [γ-32P]-ATP using the 5'-end Labeling Kit from
Amersham according to the manufacturer's instructions.
Unincorporated nucleotides were removed by gel filtration on a TE-equilibrated G50
Sepharose NICK column (Pharmacia). The reaction volume of the labeling reaction
was brought to 50 µl with TE buffer, one microliter of the reaction was removed for
determining labeling efficiency and the remaining solution was applied to the column.
350 µl TE were added after the solution had entered the column, the flow-through
was discarded and the labeled probe was collected by eluting with 400 µl TE. To
determine the specific activity and the efficiency of the labeling reaction, 5 µl probe
solution and the 1 µl aliquot taken from the diluted labeling reaction were added to
water-filled scintillation tubes and the Cherenkov counts were measured in a β-
counter (TRI-CARB 1600 TR, Canberra-Packard, Frankfurt, Germany). Labeling
efficiencies were frequently between 10-30% of the radioactive input, ranging to up to
60% with random priming.
3.5.7 Northern Blot Hybridization
Required buffers:
Church buffer 250 ml (0.5 M) Phosphate buffer (1M), pH7.2
175 ml (7%) SDS (20%)
add H2O to 500 ml
Wash buffer 5 ml (0.1x) SSC (20x)
50 ml (1%) SDS (20%)
add H2O to 1 l
tRNA 25 mg/ml tRNA from Baker's Yeast
1 ml aliquots in H2O, heat-denature for 5 min in boiling water and put on ice
Herring Sperm DNA 10 mg/ml Sonicated, Promega, Mannheim, Germany
heat-denature for 5 min in boiling water and put on ice
Denhardt's reagent 0.5 g (1%) Ficoll 400, Pharmacia
0.5 g (1%) Polyvinylpyrrolidone
0.5 g (1%) BSA (Fraction V), Sigma
add H2O to 50 ml
Northern blot membranes were washed for 30 min at 65°C in wash solution and
prehybridized for at least 45 min in Church buffer at the temperature later used for
hybridization, i.e. 65°C for cDNA and 55°C for 18S rRNA oligonucleotide. To reduce
background, 150 µg/ml tRNA and 100 µg/ml Herring sperm DNA were added to the
pre-heated Church buffer. For Hep27 and MCP-4 cDNA hybridizations, the Church
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buffer contained additional 1x and 5x Denhardt's reagent, respectively. The
radioactive probe was melted for 10 min at 95°C and 0.5-5x106 cpm/ml were added
directly to the prehybridization solution. Blots were hybridized overnight, rinsed once
with wash buffer and washed with fresh wash buffer for 10-15 min each at increasing
temperatures, starting at RT and gradually increasing the temperature from 42°C to
up to 60°C in 5-6°C steps until the overall radioactivity of the blot was between 0.1-5
Bq/cm2 as measured with a Geiger counter. In most cases, the final washing
temperature was below 55°C. Blots were heat-sealed in plastic bags, fixed with
adhesive tape in an X ray cassette with intensifying screen and exposed to
autoradiography film at –80°C overnight to up to three weeks.
3.6 Molecular Cloning
3.6.1 Bacterial Culture
Required solutions:
LB medium 10 g (1%) NaCl
10 g (1%) Bacto Tryptone (Difco)
5 g (0.5%) Yeast extract
add H2O to 1 l, autoclave
LB-agar 1.5 g (1.5%) Agar
add LB medium to 100 ml, dissolve by boiling,
cool to 60°C and add antibiotic if required and pour into ∅10 cm Petri
dishes. Store inverted at 4°C in the dark.
Antibiotics 50 µg/ml Ampicillin (100 mg/ml)
or 30 µg/ml Kanamycin
80% Glycerol
X-gal 40 mg (40 mg/ml) X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactoside)
in 1 ml DMF, store in a brown bottle at –20°C in the dark
IPTG 238 mg (100 mM) IPTG (isopropyl-β-D-thiogalactopyranoside)
add H2O to 10 ml, filter-sterilize and store in 1ml aliquots at –20°C
E.Coli strains were streaked out on solid LB-agar with antibiotic, if necessary, were
grown overnight and single colonies were picked and grown in liquid cultures
overnight. For blue/white screening of insert-containing clones after transformation,
40 µl of X-gal (if TOP10F' cells were used, 40 µl of IPTG in addition to X-gal) were
dispersed on the pre-warmed LB plates, plates incubated at 37°C for an additional 30
min prior to use and the transformation spread out using a Drigalski spatula. Liquid
cultures were grown overnight at 37°C in LB medium with the necessary antibiotics.
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Bacteria were stored in 20% glycerol by adding 500 µl liquid culture to 200 µl of 80%
glycerol, mixing and freezing at –80°C.
3.6.2 Preparation of Chemically Competent E.Coli
Required buffers:
Ψ Broth 20 g (2%) Bacto Tryptone (Difco)
5 g (0.5%) Bacto Yeast Extract (Difco)
8,18 g (0.4%) MgSO4⋅7H2O
0.745 g (10 mM) KCl
adjust to pH 7.6 with KOH
add H2O to 1 l
TfBI 6.045 g (100 mM) RbCl2
4.5 g (50 mM) MnCl2
1.472 g (30 mM) KOAc
0.735 g (10 mM) CaCl2⋅2H2O
75 ml (15%) Glycerol
adjust to pH 5.8 with 0.2 M HOAc
add H2O to 500 ml, filter sterilize and store at 4°C
TfBII 1.047 g (10 mM) MOPS/NaOH, pH 7.0
0.605 g (10 mM) RbCl2
5.513 g (75 mM) CaCl2
75 ml (15%) Glycerol
add H2O to 500 ml, filter sterilize and store at 4°C
The desired bacterial strain was streaked out on LB agar, grown overnight and a
single bacterial colony was picked into 5 ml ψ Broth. Bacteria were grown at 37°C
with shaking to an OD550 of 0.3, and the 5 ml culture was used to inoculate 100 ml ψ
Broth prewarmed to 37°C. After growing to an OD550 of 0.48, the cells were chilled on
ice and pelleted at 1300xg and 4°C for 5-10 min. The pellet was loosened up by
vortexing and resuspended in 30 ml ice-cold TfBI. After incubation on ice for 0-5 min,
cells were collected by centrifugation (5 min, 4000xg, 4°C) and resuspended in 4 ml
ice-cold TfBII. The suspension was dispensed into 50 µl aliquots and frozen at –
80°C.
3.6.3 Transformation of Chemically Competent E.Coli
Required:
SOC medium 20 g (2%) Bacto Tryptone (Difco)
5 g (0.5%) Bacto Yeast Extract (Difco)
0.6 g (10 mM) NaCl
0.2 g (3 mM) KCl
add H2O to 1 l, autoclave and add to the cooled solution:
10 ml (10 mM) MgCl2 (1 M), sterile filtered
10 ml (10 mM) MgSO4 (1 M), sterile filtered
10 ml (20 mM) Glucose (2 M), sterile filtered
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Chemically competent E.Coli (50 µl) were thawed on ice, 1-25 ng of plasmid DNA in
2-5 µl volume were added and the suspension was mixed gently and incubated on
ice for 20 min. Cells were heat-shocked in a water bath at 42°C for 60 s, immediately
cooled on ice for 2 min and 250 µl SOC medium were added. To express the
resistance, bacteria were incubated for 1 h at 37°C with shaking and 50-150 µl of the
transformation were plated and incubated overnight at 37°C on LB-agar containing
the antibiotic necessary for selection of transformed cells.
3.6.4 Cloning
DNA fragments to be cloned were prepared by PCR from genomic DNA or cDNA.
For directional cloning, restriction sites were introduced by adding the appropriate
recognition sequences to the primer sequences, and, depending on the enzyme, an
extra arbitrary overhang to allow for efficient endonuclease digestion.
The fragments were either cloned as described below and excised from the cloning
vector after sub-cloning or PEG-precipitated and the precipitate as well as the cloning
vector were digested with the necessary endonucleases in 10-30 µl reactions at
37°C. To suppress self-annealing of the vector, the vector ends were
dephosphorylated by adding 1 µl (1 U) of calf intestinal phosphatase CIP to the
digestion reaction and incubating for an additional 30 min at 37°C. The cut fragment
and vector were gel-purified (see 3.4.4) , and combined in a 10 µl ligation reaction at
a 3-fold molar excess of insert to vector, using 25 –50 ng of vector. To control for self
ligation, an additional vector-only ligation reaction was included. Ligation was carried
out overnight at 16°C with 1 U T4 DNA ligase in ligase buffer and 2 µl of the reaction
were used to transform chemically competent E.Coli.
PCR products were alternatively cloned in TOP10F or TOP10F' cells using the
TOPO-TA Cloning Kit (Invitrogen) with the supplied pCR2.1 or pCRII vectors
according to the manufacturer's instructions.
Successful insertion of the fragment into the vector was checked either by performing
PCR directly from single colonies with vector-specific primers such as M13 fwd/rev,
or by preparing plasmid DNA from liquid cultures of insert-containing white colonies
after blue/white screening. To check for correct insertion and sequence integrity,
PCR products and plasmid constructs were sequenced using vector-specific primers.
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3.6.5 Plasmid DNA Preparation
Plasmids were isolated from liquid cultures of transformed bacteria using QIAGEN
Plasmid Kits (QIAGEN) according to the supplied instructions.
3.7 Protein Methods
3.7.1 Nuclear Extraction Procedure
Reagents (prepare fresh before use, keep on ice):
Buffer A (hypotonic) 100 µl (10 mM) HEPES (1 M)/KOH, pH 7.9 @4°C
15 µl (1.5 mM) MgCl2 (1 M)
100 µl (10 mM) KCl (2 M)
50 µl (0.5 mM) DTT (100 mM)
100 µl (1.0 mM) PMSF (100 mM)
10 µl (2 µg/ml) Aprotinin (2 µg/µl)
25 µl (2.5 µg/ml) Leupeptin (1 µg/µl)
10 µl (1 µg/ml) Pepstatin (1 µg/µl)
5 µl (10 µg/ml) E46 (20 µg/µl)
10 µl (20 µg/ml) Antipain (20 µg/µl)
40 µl (80 µg/ml) Chymostatin (20 µg/µl in DMSO)
100 µl (1 mM) Sodium o-vanadate (100 mM)
add H2O to 10ml
add protease and phosphatase inhibitors before use
Buffer B Buffer A
0.5 % NP-40
use lowest possible concentration to lyse cells
Buffer C 20 µl (20 mM) HEPES (1 M) pH 7.9 @4°C
1.5 µl (1.5 mM) MgCl2 (1 M)
84 µl (420 mM) NaCl (5 M)
310 µl (25 %) Glycerol (80 %)
 0.4 µl (0.2 mM) EDTA (0.5 M) pH 8.0
5 µl (0.5 mM) DTT (100 mM)
10 µl (1.0 mM) PMSF (100 mM)
1 µl (2 µg/ml) Aprotinin (2 µg/µl)
5 µl (5.0 µg/ml) Leupeptin (1 µg/µl)
1 µl (1 µg/ml) Pepstatin (1 µg/µl)
1 µl (20 µg/ml) E46 (20 µg/µl)
2.5 µl (50 µg/ml) Antipain (20 µg/µl)
8.0 µl (160 µg/ml) Chymostatin (20 µg/µl in DMSO)
5.0 µl (0.5 mg/ml) Pefabloc SC (100 µg/µl)
10.0 µl (1 mM) Sodium o-vanadate (100 mM)
add H2O to 1ml,
add protease and phosphatase inhibitors fresh before use
The employed nuclear extraction method was a modification of the method used by
Osborn et al. (Osborn et al., 1989): Cells are first suspended in a hypotonic buffer to
osmotically enlarge the cells and lyse them by adding the weak detergent NP-40,
which leaves the nuclei intact. Soluble nuclear proteins are subsequently extracted
by applying a hypertonic buffer and high centrifugal force to "press out" the nuclei.
Materials and Methods
52
Cells were harvested, centrifuged (8 min, 300xg, 4°), washed three times in ice-cold
PBS, resuspended at 10-20 Mio cells/ml in buffer A dispersed into eppendorf cups in
1 ml aliquots. After letting the cells swell for 3 min on ice, they were pelleted in a
cooled microcentrifuge (6 min, 400xg, -9°C) and resuspended in 150-200 µl buffer A
with a pipette. An equal volume of buffer B was added rapidly, the samples vortexed
immediately for 1 s at 1400 rpm and incubated for 5-15 min on ice. When most of the
nuclei had been released (as checked under a microscope), the nuclei were spun
down (6 min, 600xg, -9°C), and washed once with 300-500 µl of buffer A, if
necessary. After careful removal of the supernatant, depending on the size of the
nuclear pellet 30-60 µl of buffer C were swiftly added and the tube was flicked until
the nuclei were completely resuspended. The nuclei were incubated on ice for 8 min,
centrifuged at maximal speed (10 min, 16000xg, -9°C) and the supernatant,
representing the nuclear extract was aliquoted, snap frozen on dry ice and stored at
–80°C.
3.7.2 BCA Protein Assay
Required reagents:
Working reagent 50 Volumes Bicinchoninic acid (BCA) (Sigma)
1 Volume CuSO4⋅5 H2O in H2O (4% (w/v)) (Sigma)
prepare fresh, stable for at least 1 day
Protein standard BSA, 6 concentrations from 8 mg/ml to 0.125 mg/ml, sequential 1:2 dilutions
Duplicates of each protein sample were assayed in 96-well microtiter plates. Per well,
200 µl working reagent and 10 µl sample or protein standard were combined,
incubated for 30 min at 37°C, cooled to RT for 10 min and the absorbance was
measured at 540 nm on a plate reader. The protein concentration of each sample
was calculated using the parameters obtained from linear regression of the protein
standard values.
3.7.3 Electrophoretic Mobility Shift Assay
Required buffers and material:
10x Binding buffer 20 µl (200 mM) HEPES (1 M)/KOH, pH 7.9 at 4°C
(freshly prepared) 2 µl (20 mM) MgCl2 (1 M)
30 µl (600 mM) KCl (2 M)
10 µl (10 mM) DTT (100 mM)
2 µl (10 mM) EDTA pH 8.0 (500 mM)
36 µl H2O to give 100 µl
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10x Gel buffer 90.8 g (1.5 M) Tris/HCl pH 8.8
add H2O to 500 ml
10x electrophoresis 15.14 g (250 mM) Tris
buffer TGE (10x ) 72.07 g (1.92 M) Glycine
(pH 8.3) 2 ml (2 mM) EDTA pH 8.0 (500 mM)
add H2O to 500 ml
Nucleotide mix 1 µl each (1 mM each) dNTP-dXTP (100 mM) Pharmacia
97 µl H2O
dXTP(α-32P) 50 µCi (3000µCi/mmol) Amersham, Braunschweig, Germany
NICK column Sephadex G50 size exclusion column, Pharmacia, Freiburg, Germany
Poly (dI-dC) Poly(dI-dC) (1µg/µl)
5% Acetic acid
In the nucleus, gene expression is controlled by DNA-binding transcription factors
which bind to characteristic DNA motifs to initiate or repress transcription.
The electrophoretic mobility shift assay (EMSA) is a powerful tool for evaluating DNA-
protein interactions. It is based on the principle that when subjected to
electrophoresis in native polyacrylamide gels, free DNA has a different
electrophoretic mobility than a DNA-protein complex.
Double-stranded DNA probes were prepared by annealing 100 pmol complementary
single-stranded synthetic oligonucleotides each (sense/antisense, featuring 5'-
overhangs of 3-6 bp for labeling by fill-in with Klenow fragment) (1 µl of 100 µM
solution each) in 20 µl H2O. The mixture was heated for 10 min to 10-15°C above the
calculated melting point of the double-stranded DNA oligonucleotides, annealed with
high stringency for 45 min at 5°C below the melting point and then allowed to cool to
RT to give a 5 µM (5pmol/µl) solution of double-stranded oligonucleotide. The probe
was end-labeled with 32P using Klenow fragment by incubating 5 pmol (1 µl) of 5'
overhang-containing double-stranded oligonucleotide with radioactively labeled dXTP
complementary to one or more bases of the overhang in a reaction mixture as given
below for 45 min at 37°C.
Labeling Reaction (20 µl)
10 µl H2O
1 µl (5 pmol) double-stranded oligonucleotide (5
pmol/µl)
2 µl Klenow buffer (10x)
1 µl Nucleotide mix (1 mM each) without dXTP
5 µl (50 µCi) α-[32P]-dXTP (3000 µCi/mmol)
1 µl (2 U) Klenow fragment
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The reaction was diluted with 30 µl TE and the labeled probe was separated from
unincorporated oligonucleotides by passing over a NICK column. The column was
flushed with 350 and 400 µl of TE buffer and fractions of 3 drops were collected in
micro-reaction tubes. After the initial 350 µl portion had run through, the radioactive
probe typically eluted in the 2nd and 3rd fraction. The two fractions containing the
highest amount of radioactivity were combined and directly used for gel shifts or
stored at –20°C for up to two weeks.
The non-denaturing PAA gel was cast at least 2 h before the experiment as given
below, AA concentrations ranging from 5-9% to achieve maximal resolution. The
discontinuous buffer system with TGE as electrophoresis buffer and Tris buffer in the
gel served to produce focussed bands and to further enhance resolution.
15 ml PAA gel (9 % AA, other concentrations accordingly)
1.5 ml Gel buffer (10x)
4.5 ml (9%) Acrylamide (30%, )
9 ml H2O
75 µl Ammonium peroxodisulfate (10%), fresh
15 µl TEMED
Binding reactions were prepared by combining the following in 1.5 ml micro-reaction
tubes:
Binding reaction (10 µl)
1.5 µl (12%) Glycerol (80%)
1 µl (1x) 10x binding buffer
0.5 µl (0.05 µg/µl) Poly (dI-dC) (1µg/µl)
1 µl Nuclear extract (~5 µg/µl)
1 µl (25 fmol) Labeled probe (~25 fmol/µl)
H2O to 10 µl
To check specificity of nuclear factor binding, cold competitor, i.e. unlabeled probe,
was added (0.5 µl (2.5 nmol) double-stranded probe (5 pmol/µl)) prior to adding the
labeled probe in control binding reactions. Purity of the labeled probe preparation
was checked by omitting nuclear extract. After 15 min incubation at RT, samples
were loaded into the wells, and 5 µl of a 0.02% bromophenol blue solution were
loaded into a separate well to track the position of unbound probe. The gel was run
with 1x TGE as electrode buffer for 2½ h at 160 V, until the bromophenol blue marker
reached the bottom of the gel. The gel was removed, fixed in 5% HOAc for 10 min,
mounted onto Whatman 3MM filter paper and dried under vacuum for 1 h at 80°C.
Dried gels were autoradiographed overnight at RT without intensifying screen.
Materials and Methods
55
3.7.4 Immunoprecipitation
Required buffers and chemicals:
TBS (2×) 4.8 g (40 mM) Tris / HCl, pH 8.0
18 g (0.3 M) NaCl
0.74 g (2 mM) EDTA
50 mg (0.05%) NaN3
add H2O to 1000 ml
Protease inhibitors:
PMSF 1.74 g (100 mM) PMSF
dissolve in 100 ml Isopropanol
Aprotinin 10 mg/ml Aprotinin in H2O
store 50 µl aliquots at –20°C
Leupeptin 0.5 mg/ml Leupeptin in H2O
store 100 µl aliquots at –20°C
Wash buffer 5 ml (1x) TBS (2x)
100 µl (1 mM) PMSF
2 µl (2 µg/ml) Aprotinin
10 µl (0.5 µg/ml) Leupeptin
add H2O to 10 ml
PGS Protein G-Sepharose 4 Fast Flow; Amersham-Pharmacia, Freiburg,
Germany
Immunoprecipitation was performed with supernatants of 3x106 DCs or teflon bag-
cultured monocyte-derived macrophages after overnight culture in 6-well cell culture
plates in 2 ml medium. The supernatants were supplemented with PMSF (1mM),
aprotinin (2µg/ml) and leupeptin (0.5 mg/ml) and immunoprecipitation was performed
by adding 30 µg rabbit polyclonal anti-MCP-4 antibody (15 µg/ml) (Pepro Tech EC,
London, England) for 2 h at 4°C and precipitating with 30 µl Protein G Sepharose
(Pharmacia) for 1 h at 4°C on a rotating mixer. Immunoprecipitates were washed 3
times with 1 ml wash buffer (8 min, 730xg, 4°C), diluted with 1 volume 2x SDS
sample buffer, boiled for 5 min at 95°C and subjected to SDS-PAGE and subsequent
Western blotting.
3.7.5 Discontinuous SDS-PAGE
Acrylamide stock 146 g Acrylamide
solution AA (30 %) 4.0 g (%C=2.67 %) BIS
add H2O to 500 ml
Separating gel buffer 90.83 g (1.5 M) Tris / HCl, pH 8.8
add H2O to 500 ml
Stacking gel buffer 30 g (0.5 M) Tris / HCl, pH 6.8
add H2O to 500 ml
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SDS (10 %) 10 g (10 %) SDS
add H2O to 100 ml
Tris buffer TP (1.25 M)13 g (1.25 M) Tris / HCl, pH 6.8
add H2O to 100 ml.
Sample buffer (2x) 10 ml (20 %) Glycerol
5 ml (125 mM) TP (1.25 M)
2 g (4 %) SDS
5 ml (10 %) 2-Mercaptoethanol
10 mg (0.02 %) Bromophenol blue
add H2O to 50 ml
Ammonium persulfate 100 mg (10 %) Ammonium persulfate
AP (10 %) add H2O to 1 ml
(frisch hergestellt)
Isobutanol saturated with H2O
Laemmli buffer (5×) 10 g (40 mM) Tris
144g (0.95 M) Glycine
10 g (0.5 %) SDS
add H2O to 2000 ml
TEMED
Table 3.1 SDS-PAGE gel mixtures
Stock solutions Separating gel Stacking Gel
Final AA concentration 7.5 % 10 % 12 % 15 % 5 %
Stacking gel buffer 25 ml
Separating gel buffer 25 ml 25 ml 25 ml 25 ml
SDS (10 %) 1.0 ml 1.0 ml 1.0 ml 1.0 ml
AA (30 %) 25 ml 33 ml 40 ml 50 ml 16.65 ml
H2O add H2O to 100 ml
The separating gel was cast the day before electrophoresis according to Table 3.1
and overlaid with water-saturated isobutanol until polymerized. The isobutanol was
exchanged for separating gel buffer diluted 1:3 with water and the gel stored
overnight at 4°C. The following day, the stacking gel was cast on top of the
separating gel, polymerized for 1 h and the gel mounted in the electrophoresis tank,
which was filled with 1x Laemmli buffer. Meanwhile, the protein samples were mixed
with an equal volume 2x sample buffer, heated for 5 min to 95°C and loaded into the
wells . Gels were run with 25 mA per gel for 3-4 h.  (Shapiro et al., 1967; Laemmli,
1970).
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3.7.6 Western Blot
Required buffers and materials:
Buffer A 36.3 g (0.3 M) Tris (pH 10.4)
(Anode) 200 ml (20 %) Methanol
add H2O to 1000 ml
B 3.03 g (25 mM) Tris (pH 10.4)
200 ml (20 %) Methanol
add H2O to 1000 ml
Buffer C 5.20 g (4 mM) ε-amino-n-caproic acid pH 7.6
(Cathode) 200 ml (20 %) Methanol
add H2O to 1000 ml
Nitrocellulose membrane Protran, Schleicher und Schuell
PVDF membrane Immobilon P, Millipore
After separation by SDS-PAGE (3.7.5), proteins were blotted electrophoretically onto
nitrocellulose or PVDF membranes using a semi-dry technique  (Towbin et al., 1979).
The membrane was cut to gel size, moistened with buffer B (PVDF membrane was
first wet with methanol) and placed on top of three sheets each of Whatman 3MM
filter paper soaked with buffer A (bottom, on the anode) and buffer B, respectively.
The SDS-PAGE gel was removed from the glass plates, immersed in buffer B for 10-
20 s and placed on top of the membrane. Another three sheets of Whatman paper
soaked with buffer C were put on top of the gel, followed by the cathode. Protein
transfer was conducted for 45 min at 0.8 mA/cm2 gel surface area.
3.7.7 Immunostaining of Blotted Proteins
Buffers and reagents:
TTBS 1000 ml TBS (2x)
2 ml (0.1%) Tween-20
add H2O to 2000ml
BLOTTO 5 g (5%) Low fat dried milk, Nesté, Frankfurt, Germany
50 ml TBS (2x)
add H2O to 100 ml
STTBS required amount of (1-4%) Slimfast "Schoko Royale", Sun Nutritional,
Slough, England)
in 50 ml TTBS
Blots were blocked overnight at 4°C either with BLOTTO (for MCP-4 staining) or 4%
STTBS (for Hep27 immunostaining). Blots were washed three times for 10 min with
TTBS and incubated at RT with primary antibody: MCP-4 was stained for 1 h with
anti-MCP-4 (PeproTech) diluted 1:100 in BLOTTO, Hep27 was detected by staining
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with anti-Hep27 antibody diluted 1:2000 in STTBS for 2h. After washing with three
times for 10 min with TTBS, blots were developed using either HRP-conjugated goat
anti-rabbit antibody (DAKO) diluted 1:800 with 5% BLOTTO for 1 h at RT (MCP-4) or
HRP-conjugated goat anti-mouse antibody (DAKO) diluted 1:2000 with STTBS for 30
min at RT. Blots were washed three times for 10 min with TTBS and bound antibody
was visualized using ECL (Amersham-Pharmacia, Freiburg, Germany). To control for
equal protein loading of the Hep27 blots, gels run in parallel were stained with
Coomassie blue (BioRad, Munich, Germany) according to the manufacturer's
instructions. HepG2 whole-cell lysates were used as a positive control for Hep27
expression.
3.7.8 Flow Cytometry
Required buffers and reagents:
FACS buffer 5 ml (600 µg/ml) Immunoglobulins (60 mg/ml)
(Sandoglobin, Sandoz, Basel)
5 ml (0.1 %) Sodium azide (10 %)
in 500 ml PBS
Paraformaldehyde 1g (1 %) Paraformaldehyde
in 500 ml PBS, stir overnight at RT to clear solution
To characterize the phenotype of the different cell types, the cell surface expression
of a number of membrane proteins was assessed by flow cytometry. For
determination of surface expression, 1-5x105 cells per staining reaction were washed
twice for 5 min with 500 µl each of ice-cold FACS buffer and immunostained for 30
min at 4°C with a selection of fluorescein-isothiocyanate (FITC)- and phycoerythrin
(PE)-conjugated antibodies chosen from a panel of mouse anti-human antibodies to
CD1a, CD14, CD40, CD54, CD80, CD83, CD86, HLA-DR. Depending on the isotype,
fluorochrome-labeled purified IgM or polyclonal IgG from normal mouse serum were
used as isotype control. After two washing steps, cells were fixed in 500 µl 1%
paraformaldehyde/PBS and flow cytometric analysis of 10000 cells per antigen was
performed on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
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4 Results
4.1 Identification of genes with DC-specific expression by
Representational Difference Analysis
To identify genes relevant to dendritic cell (DC) differentiation and function, the gene
expression of monocyte-derived DCs versus monocytes and monocyte-derived
macrophages were compared by Representational Difference Analysis (RDA)
(Lisitsyn and Wigler, 1993). Originally described as a general method for finding the
difference between two complex genomes, the adaptation by Hubank and Schatz
(Hubank and Schatz, 1994) facilitates identification of differences in mRNA
expression, i.e. analysis of the difference between the polyA+ fractions of two
transcriptomes. In principle, RDA modifies and extends classical subtractive
hybridization (Lamar and Palmer, 1984) in which unique DNA (target) sequences
present in one DNA population (tester) but not a second (driver) DNA population are
enriched by depleting common sequences by mixed hybridization and removal of
heteroduplexes of sequences present in both tester and driver DNA.
In RDA, enrichment is accomplished by suppression of PCR amplification of common
sequences. Primer-ligated tester DNA is mixed and hybridized with an excess of
primer-less driver DNA. Tester-specific target DNA with no counterpart in the driver
population re-anneals and gives rise to double-stranded DNA with primer sequences
on both ends, which is amplified at an exponential rate in the subsequent PCR step.
Sequences common to both tester and driver population form mixed hybrids with the
primer sequence only on one end and thus are only amplified at a linear rate,
effectively resulting in enrichment of target sequences in the ensuing difference
product. After three rounds of hybridization and amplification, 105-107-fold enrichment
of target sequences can be achieved (Lisitsyn and Wigler, 1993). Figure 4.1 gives a
schematic overview of the RDA principle.
For the driver cDNA representations, mRNA from freshly isolated monocytes and
from monocytes after one and nine days culture towards a macrophage phenotype
was pooled. To generate the tester representation, mRNA from DCs derived from
monocytes of the same donor was used. RDA was performed as described under
Materials and Methods.
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Figure 4.1 Schematic diagram of RDA.
The filled bars represent cDNA strands, tester cDNA in black, driver cDNA in gray. Open bars show
the oligonucleotides which were ligated to the tester cDNA digest to facilitate suppressive amplification
and the complementary primers used for subtractive PCR. ssDNA: single-stranded DNA
In parallel, the superior antigen presentation capability of the DC preparation
compared to the original monocytes was confirmed by MLR. Figure 4.2 depicts the
produced driver and tester representations as well the resulting difference products
after each round of subtractive amplification.
Figure 4.2 RDA of DCs versus
monocytes and macrophages.
The driver and tester
representation as well as the
difference products (DP) after one,
two and three rounds of
hybridization and PCR
amplification were separated on a
1.3% Agarose gel containing EtBr.
The driver representation was
derived from pooled fresh
monocytes and monocytes
cultured with 2% human pooled
AB-serum for one or nine days.
The tester representation was
produced from nine day-old DCs
derived from monocytes of the
same donor.
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The third difference product was shotgun-cloned and the DC-specificity of the inserts
of 85 randomly picked clones was assessed by reverse dot blot analysis using the
tester and driver representations as probes. 11 clones were excluded from further
analysis because they were present in both representations (see Figure 4.3).
Figure 4.3 Reverse dot blot of cloned RDA fragments.
The inserts of randomly picked clones were PCR-amplified, denatured and blotted in duplicates onto
two separate Nylon membranes. The indicated radioactively labeled representation was hybridized to
each membrane. The arrow pairs indicate a β-actin fragment (left arrows) which served as a positive
control and a fragment of human cartilage glycoprotein 39 (HCgp39) (right arrows) which is expressed
late during macrophage differentiation and which was used to control for DC/macrophage phenotypes.
The remaining clones were sequenced and analyzed for homologies with known
sequences available in GenBank using BLAST. Each of the 61 inserts proved to be
derived from one out of six already known genes. Table 4.1 lists the number of
clones mapping to each gene. The chemokine DC-CK1 has previously been
described as a gene with specific expression in DCs (Adema et al., 1997) and thus
provided an internal positive control for the employed identification strategy.
Table 4.1 Overview of the DC-specific genes identified by RDA.
Gene Number of fragments
15-lipoxygenase 35
DC-CK1 13
MCP-4 10
Hep27 1
C1q c-chain 1
folate-binding protein 1
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4.2 Expression analyses by Northern blot hybridization
To analyze the expression kinetics of the identified genes during monocyte to
macrophage versus DC differentiation, Northern blots were hybridized with
radioactive probes for the respective genes (see Figure 4.4).
DC-CK1 was excluded from further analysis since its exclusive expression and
regulation in DCs had already been described (Adema et al., 1997). Monocytic
expression of 15-lipoxygenase in response to stimulation with IL-4 with or without
GM-CSF had been described before (Conrad et al., 1992) and could be confirmed to
be expressed in the DC context while being absent from macrophages. C1q
expression in humans had previously been ascribed to macrophages (Muller et al.,
1978) and interdigitating (Schwaeble et al., 1995) and follicular DCs (Parmentier et
al., 1991). Within the monocytic lineage, C1q C-chain expression could be shown to
be strongest in DCs while being expressed in a weaker fashion in macrophages.
Interestingly, its weak expression in one and seven day-old macrophages with a peak
on day four of culture mirrored the cell populations analyzed in the RDA assay which
did not include four day-old macrophages.
Expression of MCP-4 and Hep27 was up-regulated during DC differentiation and
restricted to DCs at an immature stage of differentiation. A maturation stimulus like
LPS led to down-regulation of the respective gene products. FR-β was weakly
expressed in freshly isolated monocytes but absent from macrophages. During DC
differentiation it became detectable after four days of culture and reached maximal
expression after more than seven days.
Figure 4.4 Northern blot analyses of the expression kinetics of the identified genes in
monocytes, macrophages and dendritic cells.
Northern blots were hybridized with probes for (A) 15-lipoxygenase (15LOX), (B) complement C1q, C-
chain (C1q C), (C) folate receptor β (FR-β), (D) monocyte chemotactic protein 4 (MCP-4) and (E)
Hep27. Freshly isolated monocytes (MO) were cultured in the presence of IL-4, GM-CSF (500 U/ml
each) and 10% FCS (DC) or 2% pooled human AB-serum (MAC). Cells were harvested and total RNA
was extracted after the indicated time periods (d1-11). Where indicated, 100 ng/ml LPS was added on
day 5 of culture (LPS) and DCs were matured for an additional two (d7) or four (d11) days. Blots were
sequentially probed with a gene-specific cDNA probe and an 18S rRNA-specific oligonucleotide as
loading control. Sequence variants of 15LOX and MCP-4 are indicated by arrows.
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4.3 MCP-4
Expression of the recently cloned CC-chemokine MCP-4 by DCs had not been
described before. To confirm and further analyze MCP-4 expression in DCs, Northern
blot analyses as well as Western blots were performed.
4.3.1 Analysis of MCP-4 expression during DC differentiation
MCP-4 mRNA was strongly induced during IL-4/GM-CSF-mediated differentiation of
immature DCs while its expression was undetectable in monocytes and
macrophages (Figure 4.4D). To assess the individual roles of IL-4 and GM-CSF in
MCP-4 induction, monocytes were incubated with either cytokine alone. As shown in
Figure 4.5, short term culture of freshly isolated monocytes readily induced robust
MCP-4 mRNA expression after only four hours. The induction occurred regardless of
whether human AB serum or FCS with or without GM-CSF was used and might be a
result of the adherence stimulus. The presence of IL-4 led to reduced MCP-4
induction at four hours which was partially overcome by the additional presence of
GM-CSF.
Figure 4.5 Northern blot analysis of the short time kinetics of MCP-4 expression by monocytes
in response to various stimuli.
Freshly isolated monocytes (MO 0 h) were incubated for four (4 h) or 16 hours (16 h) in RPMI1640
with 2% human pooled AB serum (AB), 10% FCS (FCS) alone or together with 500 U/ml GM-CSF
(GM), 500 U/ml IL-4 (IL-4) or both.
After 16 hours, the presumably adherence-induced initial MCP-4 expression
completely disappeared under serum-only conditions but was further enhanced in the
presence of GM-CSF. IL-4-induced MCP-4 expression was also stronger at 16 hours
and was enhanced by GM-CSF, reaching a similar level as the GM-CSF-
supplemented FCS culture. Interestingly, at 16 hours a shorter mRNA species could
be observed which was absent after four hours of culture.
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GM-CSF did not induce long-term MCP-4 expression (Figure 4.6A), while IL-4 alone
was able to induce MCP-4 mRNA in monocytes (Figure 4.6B). However, maximal
expression of MCP-4, which is associated with DC differentiation, required the
synergistic effect of both GM-CSF and IL-4.
Figure 4.6 GM-CSF acts synergistically on IL-4-induced MCP-4 mRNA expression in
monocytes.
Northern blots of total RNA of monocytes. A, Monocytes were cultured for seven days in 2%pooled
human AB-positive serum/RPMI (AB) or 10%FCS/RPMI supplemented with 500 U/ml IL-4, GM-CSF
or both. B, Monocytes were cultured in 10% FCS/RPMI with IL-4 (500 U/ml) with (+) or without (-) GM-
CSF (500 U/ml) for the stated time periods.
Induction of terminal DC differentiation by LPS or TNF after 5 days of culture led to a
decrease in MCP-4 expression, LPS exerting a more pronounced effect (see Figure
4.7). Activation of DCs by CD40 cross-linking with anti-CD40 antibody also caused
down-regulation of MCP-4 mRNA and exhibited a stronger effect on LPS-primed DCs
(data not shown).
Figure 4.7 Terminal maturation of DC induced by TNF or LPS leads to down-regulation of MCP-
4 mRNA.
On day 5 of culture, half of the medium was substituted for fresh medium (∅), or fresh medium
supplemented with 20 ng/ml TNF or 200 ng/ml LPS and culture was continued for the indicated time
periods. Blotting and hybridization was carried out as described before.
BA
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To investigate whether immature DCs also secrete MCP-4 protein,
immunoprecipitations from cell culture supernatants of monocytes, macrophages and
DCs were performed. As shown in Figure 4.8, immature DCs produce large amounts
of MCP-4 protein (≥3 ng/(106 DCsx24 h)) as visualized by immunoblotting of the
immunoprecipitates. Secretion of MCP-4 protein was reduced after terminal
maturation by LPS or CD40 cross-linking (data not shown) which correlates with
decreased mRNA expression in mature DCs. Supernatants of macrophages as well
as supernatants of monocytes (data not shown) contained no detectable amounts of
protein (detection limit: 1 ng/ml).
Figure 4.8 Immature DCs produce MCP-4 protein in large quantities.
Western blot of immunoprecipitates for MCP-4 from supernatants of macrophages (MAC) and DCs,
either untreated (DC) or stimulated with LPS (DC/LPS) as described in Figure 4.7. As control for the
immunoprecipitation, 10 ng rhMCP-4 were immunoprecipitated from 10% FCS/RPMI (MCP-4/IP). To
control for blotting and staining, 5 ng MCP-4 with 5 µg BSA as carrier protein were applied directly to
the gel (MCP-4).
4.3.2 Blood DC produce MCP-4 mRNA
Blood DC precursors represent an easily accessible sub-population of DCs and
differentiate into functional DC during overnight culture. As shown in Figure 4.9,
MCP-4 mRNA was detectable by RT-PCR in total RNA from blood DC precursors
either when freshly isolated or after overnight culture. In contrast, MCP-4 was not
detectable in freshly isolated blood monocytes by this technique. Overnight culture in
10% FCS transiently induced very low levels of MCP-4 mRNA in monocytes
(compare also with the data obtained by Northern blot analysis after 16 h of culture
with either 2% AB-serum or 10% FCS, shown in Figure 4.5). Blood DC preparations
Figure 4.9 Blood DC express MCP-4 mRNA.
RT-PCR for MCP-4 with total RNA from blood DC
precursors (BDC) directly after isolation (0h) and after
overnight culture (18h), monocytes (MO) after isolation
and after overnight culture (20h), as well as
macrophages (MAC) and DC. The amount of cDNA
used for PCR was normalized for β-actin. The reaction
products are shown after 33 cycles (MCP-4) and 18
cycles (β-actin).
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were 92-96% pure (lineage-negative (TCR, CD14, CD19, CD56)-, HLA-DR+, (CD123
v CD11c)+) as assessed by flow cytometry.
4.3.3 DCs utilize the same MCP-4 promoter as dermal fibroblasts
To characterize the regulation of MCP-4 expression in DCs, the 5’-end of DC-
expressed MCP-4 mRNA was determined by 5’-RACE followed by cloning and
sequencing of the ensuing PCR products. As shown in Figure 4.10, 5’-RACE with an
MCP-4-specific antisense primer yielded a homogenous amplification product of
approximately 800 bp length. Sequence analysis of several cloned products revealed
that transcription of MCP-4 is initiated at the same genomic site as in dermal
fibroblasts which have previously been reported to express MCP-4 mRNA.
4.3.4 Different regulatory pathways govern MCP-4 expression in DCs
and dermal fibroblasts
Normal human dermal fibroblast cells (NHDFC) have been reported to produce MCP-
4 mRNA after stimulation with IL-4, IFN-γ, or TNF. Comparison of DC with stimulated
NHDFC by Northern blot hybridization demonstrated that DC produce far greater
amounts of MCP-4 than dermal fibroblasts stimulated with either stimulus (seeFigure
4.11; data for TNF are not shown).
Whereas both IFN-γ and IL-4 induced MCP-4 mRNA in NHDFC, their effects adding
when combined, only IL-4 but not IFN-γ caused MCP-4 mRNA expression in
monocytes. On the contrary, IFN-γ counteracted the MCP-4-inducing effect of IL-4 in
these cells, suggesting different regulation pathways of MCP-4 in monocytes and
NHDFC. Western blot analyses of immunoprecipitates from supernatants of both cell
types confirmed these findings on the protein level.
Figure 4.10 5’-RACE PCR for MCP-4
with total RNA from DCs.
EtBr-stained 1.8% Agarose/TAE gel. A
primer located in exon 3 of the published
MCP-4 genomic sequence was utilized
(MCP-4 R5d).
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Figure 4.11 Comparison of MCP-4 mRNA expression in DC, stimulated NHDFC and monocytes
by Northern blot analysis.
A, Confluent NHDFC were left untreated (∅) or stimulated for 26 hours with IL-4 (500 U/ml), IFN-γ
(200 U/ml), or IL-4 and IFN-γ after 1 hour of preincubation with IFN-γ. DC were generated as
described above. B, In monocytes IFN-γ counteracts the induction of MCP-4 mRNA by IL-4. Freshly
isolated monocytes were cultured for 40 hours in RPMI1640 with 2% pooled AB-group human serum.
The stimulation pattern was as described in A. 10 µg of total RNA in each lane were probed
sequentially with an MCP-4 cDNA probe and an 18S rRNA-specific oligonucleotide as loading control.
4.3.5 CpG methylation analysis of the proximal MCP-4 promoter
Currently only limited data is available on the mechanisms regulating gene
expression in DCs. Due to the strong expression of MCP-4 in monocyte-derived DCs,
we examined the MCP-4 promoter as a possible prototype for DC-specific promoters.
As shown in Figure 4.12, the proximal MCP-4 promoter sequence contains a number
of CpG residues and putative binding sites for STAT factors, Ikaros 2, Oct-1, and NF-
AT as well as for the NF-κB family member c-Rel which has been implicated in DC
development. One major drawback in examining gene regulatory mechanisms in
monocytes and derived cells is the fact that they can not be transfected efficiently,
preventing promoter activity assays by transient transfection of reporter constructs.
Although there are a number of monocyte/macrophage cell lines which can substitute
for the primary cells in such assays, to date there are no human cell lines with DC
characteristics available which could fulfil a similar role for the DC system. Recent
reports by Koski et al. (Koski et al., 1999) showed that calcium ionophore-treated
myeloid cell lines like the promyelocytic HL-60 cell line display DC-like properties in
terms of antigen presentation and expression of typical surface markers and thus
might serve as a model for DCs. Indeed, Northern blot analysis of MCP-4 expression
of HL-60 cells showed up-regulation of MCP-4 mRNA in response to calcium
A B
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ionophore treatment (data not shown). However, transfection of the cells with a wide
array of methods was either unsuccessful (various lipid-based transfectants) or did
not produce reproducible results (electroporation).
-379                                            Oct-1        ____NF-AT_
-380 ACGTGAACAGAGTCCTTAGCACAGCACTCTTTCTCTACAGGAGTTAATTTTCATTGTTTTTCTCTTTCCTG
__                               __Ikaros 2              -251_Whn__
-309 TTGGAGAAAGTAAGAAGAAAACAGCTCCTTTATGGCTTCCCATGGTGAATGGCTGGGGCGCGTCTGTGTCC
                                                                     __
-238 CTTTCTCCTCTCTGGCTCCTTGTGGCCTGAACAGCCAGAAGGAAGCCATGCCATGCTGTTTCAGCCCTCAG
Ikaros 2        STAT   _
-167 CTTCCCTCTTGCATTTCCTAGAAAAGTCTTTGGTGCCCAGCTCCAGCTCAGCAGATTCAGGATCCCCCTTC
               -80 Whn                                           -30
-96 ATCATGACTTGGTCAACGCCCTGCTCAGGCCAAGGTCCTCTGAGAGTTCCAAGCTTCTCCACTCCCTATAA
    -20  __c-Rel___        
-25 AAGGCCGGCGGAACAGCCAGAGGAGCAGAGAGGCAAAGAAACATTGTGAAATCTCCAACTCTTAACCTTCA
+47 ACATG
Figure 4.12 Sequence of the human proximal MCP-4 promoter.
CpG motifs, TATA box and the start codon are in bold face, potential transcription factor binding sites
are overlined. The transcription start site is indicated by an arrow. The putative transcription factor
binding sites were identified with the MatInspector software (Quandt et al., 1995).
As an alternative approach to perform an initial characterization of the proximal
MCP-4 promoter, its CpG methylation status was assessed by genomic bisulfite
sequencing. In mammalian somatic cells, 60-90% cytosine residues in cytidine-
guanidine (CpG) sequences in genomic DNA are methylated at the 5’ position (Singal
and Ginder, 1999). Methylation of promoter regions of genes has been found to
correlate with repression of the respective genes, probably by histone deacetylation
and incorporation into heterochromatin (Razin, 1998). Cytosine methylation can be
determined by bisulfite-induced reductive deamination, effectively leading to its
conversion of cytosine to uracil. With 5’-methylated cytosine, the deamination step is
kinetically inhibited by the methyl group, leading to an estimated half-life of 34.6 hr
vs. 5.5 min of the unmethylated residue under the same conditions (Oakeley, 1999).
The procedure effectively leads to conversion of all unmethylated genomic cytosines
to uracil, i.e. thymidine  after the strand-specific PCR amplification step and only
previously methylated cytosines (in CpG motifs) are preserved in the sequence.
Consequently, sequencing of the PCR product provides information on the CpG
methylation status of the amplified genomic fragment before conversion.
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Applying bisulfite sequencing to the monocyte/macrophage/DC system, all CpGs of
the proximal promoter were found to be methylated in monocytes and macrophages,
while in DCs, the two CpGs adjacent to the transcription start site (one single and two
CpGs in tandem, located at -80 bp and -20 bp, respectively) become demethylated
during differentiation. In MCP-4 non-expressing T- and B-lymphocytes as well as HL-
60 with or without calcium ionophore treatment, THP-1 and U937 cells, the CpG
motifs of the MCP-4 promoter were found to be methylated (data not shown).
Figure 4.13 DC-specific demethylation of the MCP-4 promoter.
Sequencing pattern of the MCP-4 promoter at the -80 bp and the -20 bp CpG motifs after bisulfite
conversion of unmethylated cytosine residues to thymidine (after PCR). Methylated cytosines are
shown as mC.
The first intron of MCP-4 also contains a number of CpG motifs which were found to
remain methylated in curing monocyte to macrophage or DC differentiation.
The kinetics of CpG demethylation was assessed by bisulfite sequencing of DNA
extracted from IL-4 and GM-CSF-treated monocytes after 0, 1, 2 and 4 days. As
visible in Figure 4.14, demethylation of the –80 CpG was essentially completed after
24 h of culture, while maximal demethylation of the TATA-proximal CpGs at –20 bp
took until day 4 and was incomplete.
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4.3.6 Dendritic cell-specific demethylation of the MCP-4 promoter allows
binding of a nuclear factor
In order to characterize the effects of monocyte-derived DC-specific CpG
demethylation on nuclear protein binding to the MCP-4 promoter, electrophoretic
mobility shift assays with nuclear extracts from macrophages and DCs were
performed using probes that encompass either the single (-80bp) CpG motif
upstream of the TATA box or the TATA box and the two CpG (-20 bp) motifs
downstream (sequences are given in Table 4.2). While the latter oligonucleotide
bound nuclear proteins of DCs and macrophages either in the methylated or
unmethylated state (Figure 4.15A), the single (-80 bp) CpG motif-containing
oligonucleotide only complexed nuclear protein when unmethylated, again from both
cellular sources (Figure 4.15B). Competitor analysis revealed that unmethylated
probe was displaced exclusively by unmethylated oligonucleotide but not by its
methylated counterpart, indicating methylation-sensitive binding of an unknown factor
to the (-80 bp) CpG motif.
Figure 4.14 Kinetics of demethylation of the
MCP-4 promoter CpG motifs in DCs.
Bisulfite sequencing of the MCP-4 promoter in
monocytes cultured with 500 U/ml IL-4 and
GM-CSF each in 10% FCS/RPMI for the
indicated time periods. To circumvent
automatic normalization performed by the
sequencing software, raw data of the G (black)
and A (gray) sequencing reactions of the
antisense PCR product are shown,
corresponding to methylated and
demethylated cytosine residues of the
genomic DNA, respectively.
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Figure 4.15 Methylation-sensitive binding of a nuclear factor at the –80 bp but not the –20 bp
CpG motif.
A, Exclusive protein binding at the unmethylated –80 bp CpG motif which could only be competed for
by unmethylated competitor oligonucleotide. EMSA using radioactively labeled unmethylated (CpG1*)
or methylated (mCpG1*) oligonucleotide and nuclear extracts of monocyte-derived macrophage-
(MAC) or dendritic cell (DC). For competition analysis, unlabeled oligonucleotides were added at 100-
fold excess where indicated (+) above the respective lanes. B, Binding of nuclear proteins to the –20
bp CpG motifs is methylation-independent. EMSA using unmethylated (CpG2*) or methylated
(mCpG2*) oligonucleotide as in A. Specific bands are marked with arrows, non-specific bands are
marked with asterisks.
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Table 4.2 Sequences of oligonucleotides used in gel shift analysis and site-directed
mutagenesis.
Oligonucleotide Sequence Mutant construct
CpG1 (-80 bp) 5'-CATCATGACTTGGTCAACGCCCTGCTCA-3'
M1 5'-CATCATGACTTGGTCAAGCCCCTGCTCA-3' MCP-4pP1
M2 5'-CATCATGACTTGGTCAAGAGCCTGCTCA-3' MCP-4pP2
CpG2 (-20 bp) 5'-CTCCCTATAAAAGGCCGGCGGAACAGCCAG-3'
CpG motifs are underlined, introduced mutations are bold faced.
A query of the TRANSFAC database using the MatInspector tool (Quandt et al.,
1995) identified a putative core consensus binding site for the transcription factor
winged-helix nude (whn) at the CpG motif at -80 bp (see Figure 4.12). Reversing the
CpG (ACGC core to AGCC) or entirely eliminating the motif (ACGC to AGAG) almost
completely abolished the ability of the mutant oligonucleotides to compete with wild
type oligonucleotide for protein binding (Figure 4.16).
Figure 4.16 Mutation of the –80 bp CpG
motif mimics CpG methylation in EMSA.
Binding of nuclear extract protein from DCs to
labeled, unmethylated CpG1* oligonucleotide
(abbreviated as C*) was only competed for by
a 100-fold excess of unlabeled unmethylated
CpG1 (C) but not methylated (mC), or mutated
(M1, M2) CpG1 oligonucleotide. Specific
bands are marked with arrows, non-specific
bands are marked with asterisks.
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4.3.7 Nuclear factor binding at the -80 bp CpG is necessary for maximal
MCP-4 promoter activity in reporter assays in transiently
transfected THP-1 cells
To date, there are no human DC lines which could be used as model systems for the
analysis of gene regulation in DCs. However, EMSAs with nuclear extracts from the
monocytic cell line THP-1 using the -80 bp CpG-containing oligonucleotide as probe
displayed a protein binding pattern identical to that observed for monocyte-derived
DCs and monocyte-derived macrophages, indicating that the factor binding at the –
80 bp CpG motif is also present in these cells. (Figure 4.17).
To assess the effects exerted by inhibiting binding of the –80 CpG-binding factor on
MCP-4 promoter activity, luciferase reporter assays were performed in THP-1 cells.
As a first step, a luciferase reporter construct was prepared with the 5’-proximal
MCP-4 promoter, ranging from -380 bp to -1 bp upstream of the transcription start,
driving expression of firefly (Photinus pyralis) luciferase. Since the wild-type construct
(MCP-4pP*) showed significant reporter activity in these cells, two plasmids with a
mutated –80 bp CpG motif were constructed by site-directed mutagenesis employing
the oligonucleotides listed in Table 4.2. As shown in Figure 4.18, the ACGC to AGCC
Figure 4.17 The CpG methylation-sensitive
factor is also present in monocytic THP-1
cells.
Binding of nuclear extract protein from DCs to
labeled, unmethylated CpG1* oligonucleotide
(abbreviated as C*) was only competed for by
a 100-fold excess of unlabeled unmethylated
CpG1 (C) but not methylated (mC), or mutated
(M1, M2) CpG1 oligonucleotide. Specific
bands are marked with arrows, non-specific
bands are marked with asterisks.
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mutant (MCP-4pP1) exhibited 60% promoter activity compared to the wild type
promoter while the ACGC to AGAG mutant (MCP-4pP2) yielded only 47% of the wild
type promoter activity.
Figure 4.18 Mutation of the -80 bp CpG motif reduces the activity of the proximal MCP-4
promoter in THP-1 cells.
Mutations of the -80 CpG motif were introduced in a MCP-4 reporter construct by site-directed
mutagenesis using the oligonucleotides listed in Table 4.2. The mutations are indicated in the
schematic representations of the reporter constructs in bold face. Each construct was transiently
transfected in duplicates into the myeloid cell line THP-1 and luciferase activity was determined after
two days and normalized for total protein concentration of the samples. Luciferase activity is given
relative to wild type MCP-4 promoter (100%) and values are the means + S.D. obtained for four
independent experiments.
4.3.8 CpG demethylation of the MCP-4 promoter during monocyte to
dendritic cell differentiation is differentiation stage-dependent
Recent reports suggested that only activated DCs and macrophages represent stable
phenotypes and that non-activated macrophages can be converted to immature DCs
and vice versa by addition or withdrawal of IL-4 and GM-CSF, respectively (Palucka
et al., 1998). To test whether this conversion is reflected by the CpG methylation
status of the proximal MCP-4 promoter, seven day-old and immature DCs and
macrophages were cultured for an additional seven days in 2% AB serum without or
in 10% FCS with IL-4 and GM-CSF, respectively. MCP-4 mRNA expression was
assessed by Northern blot analysis and the CpG methylation status of the proximal
MCP-4 promoter was analyzed by bisulfite genomic sequencing. The conversion of
the macrophage/DC phenotypes was confirmed by flow cytometric analysis of CD14,
CD83 and HLA-DR expression (data not shown). As expected, differentiation of
monocytes into DCs was accompanied by demethylation of the CpG motifs at –80
and –20 bp, while no demethylation took place during macrophage (Figure 4.19).
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Figure 4.19 Analysis of MCP-4 mRNA expression and promoter CpG methylation after DC to
macrophage conversion and vice versa.
A, Northern blot hybridization with an MCP-4-specific cDNA probe. An arrow marks a shorter MCP-4
sequence variant. The lower inset shows the EtBr-stained gel before blotting, 28S and 18S bands are
indicated. B, genomic bisulfite sequencing. Freshly isolated monocytes (MO) were differentiated to
macrophages(MAC d7) (2% human pooled AB serum/RPMI in teflon bags) or DCs d7 (500 U/ml each
of IL-4 and GM-CSF/10% FCS/RPMI in cell culture flasks) for seven days. Half of each cell
preparation harvested and stained with antibodies against CD14, CD83 or HLA-DR or genomic DNA
or total RNA extracted. The other half was washed twice with PBS and DCs were re-seeded in 2%
human pooled AB serum/RPMI in teflon bags (DC d14-MAC d7), macrophages were re-seeded in
500 U/ml each of IL-4 and GM-CSF/10% FCS/RPMI in cell culture flasks (MAC d7-DC d14), for seven
additional days. Two arrows indicate two thymidine peaks of equal amplitude.
Intriguingly, exposure of macrophages to IL-4 and GM-CSF in 10% FCS/RPMI also
failed to induce demethylation. The lack of demethylation correlated with a reduced
induction of MCP-4 mRNA compared to DCs. In DCs, removal of cytokines for seven
days led to complete elimination of MCP-4 mRNA expression but did not alter CpG
methylation. (The observed peak at the –20 bp cytosine in the last sequence in
Figure 4.19 is probably an artifact of the automatic signal normalization algorithm of
the sequencer. Comparison with the raw data as well as the conversion of the
cytidine residues to thymidine which is apparent as a peak of similar amplitude as the
neighboring thymidine peak confirmed the demethylation of the shown CpG residue).
Similar results were obtained by using M-CSF as a DC de-differentiation agent
instead of cytokine withdrawal. Maturation of DCs with LPS or TNF yielded identical
results concerning CpG demethylation in both mature DC and mature DC after
cytokine withdrawal (data not shown).
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4.4 Hep27
Hep27 (HUGO nomenclature: dehydrogenase/reductase (SDR family) member 2,
DHRS2) is a member of the short-chain alcohol dehydrogenase family with an as yet
unidentified substrate and initially was cloned in HepG2 cells (Gabrielli et al., 1995).
4.4.1 Predominant expression of Hep27 in monocyte-derived dendritic
cells
Hep27 expression was further analyzed Northern blot hybridizations. As shown in
Figure 4.4E, Hep27 mRNA expression was up-regulated in monocyte-derived DCs
while freshly isolated monocytes or monocyte-derived macrophages at different time
points expressed only low to undetectable levels of Hep27 mRNA (see also). Up-
regulation of Hep27 mRNA expression was detectable after a minimum period of two
days of culture and required the presence of both GM-CSF and IL-4.
Figure 4.20 Both IL-4 and GM-CSF are necessary to induce Hep27 in monocytes.
Northern blots of total RNA of monocytes. A, Monocytes were cultured for seven days in 2%pooled
human AB-positive serum/RPMI or 10%FCS/RPMI supplemented with 500 U/ml IL-4, GM-CSF or
both. B, Monocytes were cultured in 10% FCS/RPMI with IL-4 (500 U/ml) with (+) or without (-) GM-
CSF (500 U/ml) for the stated time periods.
Maturation stimuli like LPS or TNF led to down-regulation of Hep27 expression in
monocyte-derived DCs Figure 4.4E and Figure 4.21).
Figure 4.21 Hep27 mRNA expression by DCs is down-regulated upon terminal maturation
induced by TNF or LPS.
On day 5 of culture, half of the medium was substituted for fresh medium (∅), or fresh medium
supplemented with 20 ng/ml TNF or 200 ng/ml LPS and culture was continued for the indicated time
periods. Blotting and hybridization was carried out as described before.
A B
Results
78
As shown in Figure 4.22, Hep27 protein could be detected in cytoplasmic extracts
from monocyte-derived DCs by Western blotting, using a Hep27-specific antibody
which was kindly provided by Dr. F. Gabrielli, University of Pisa, Italy.
Cytoplasmic extracts from monocyte-derived macrophages did not contain detectable
amounts of Hep27. A double band at 33 kDa was present in extracts from both
monocyte-derived macrophages and monocyte-derived DCs. Since in macrophages
no Hep27 mRNA could be detected, the signal might represent a cross reactivity of
the antibody and possibly corresponds to 11β-hydroxysteroid dehydrogenase type 1
which is 28% identical to Hep27 on the protein level and has been reported to be up-
regulated during monocyte to macrophage differentiation as well as in monocytes
after stimulation with IL-4 (Thieringer et al., 2001).
4.4.2 Tissue expression of Hep27 mRNA
To test whether Hep27 was expressed in cells other than monocyte-derived DCs and
HepG2 cells, RNA samples from various cell types including granulocytes, B- and T
lymphocyte-enriched elutriation fractions, HUVEC, dermal fibroblasts, the monocytic
cell line THP-1, the promyeloblastic HL-60 cell line and the colon carcinoma cell lines
HT-29 and CaCo-2 we analyzed for Hep27 mRNA by Northern blot hybridization.
As shown in Figure 4.23, apart from monocyte-derived DCs and HepG2 cells, only
HT-29 and CaCo-2 cells produced appreciable amounts of Hep27 mRNA. The single
transcript detected in monocyte-derived DCs was approximately 1.5 kb in length as
opposed to HepG2 cells, where a 1.9 kb transcript was prominent as the main
product and a shorter 1.3 kb sequence variant as well as a long transcript of about 4
kb length could be detected. Overexposure for 8 days revealed extremely weak
bands of 1.5 and 1.3 kb in monocytes, monocyte-derived macrophages, HUVEC,
Figure 4.22 Western blot of cytoplasmic
extracts from monocyte-derived macrophages
and monocyte-derived dendritic cells.
Cytoplasmic extracts from macrophages and DCs
were separated by SDS-PAGE, blotted on
nitrocellulose membrane, probed with a mouse
polyclonal anti-Hep27 serum and developed with
an HRP-conjugated goat anti-mouse antibody
and ECL. An unspecific band of 33 kDa is marked
with an asterisk.
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fibroblasts, THP-1 cells and HL-60, while in granulocytes or lymphocytes Hep27
mRNA was not detectable (data not shown).
Figure 4.23 Northern blot analysis of Hep27 mRNA expression in various cell types.
10 µg of total RNA were loaded for each lane. The probe used spanned exons III through VIII and was
labeled using an antisense primer (8as). The positions of the 28S (5025 bp) and 18S (1868bp) rRNA
bands are indicated. The bottom inset shows the EtBr-stained 18S rRNA bands after blotting.
Northern blot analysis of the tissues expression pattern of Hep27 mRNA revealed
that the 1.3 and 1.5 kb transcripts described above were present in all tissues (Figure
4.24).
Figure 4.24 Hep27 mRNA expression pattern in human tissues.
Hep27 probe was hybridized to commercially available tissue Northern blots (Clonetech, Heidelberg,
Germany) containing 2 µg polyA+ RNA per lane.
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Expression of the 1.3 kb and 1.5 kb transcripts was weakest in thymus and PBL,
followed by lung, brain, colon, small intestine and spleen. In heart and skeletal
muscle, the 1.3 and 1.5 kb variants exhibited stronger expression, accompanied by a
longer transcript of approximately 2.5 kb. A very similar transcript pattern was
detected in fetal liver. In liver and kidney, the two short variants were expressed the
strongest accompanied by expression of the 1.9 kb transcript observed in HepG2
cells. The latter was the main transcript in spleen and placenta. Additionally, a 4 kb
transcript was detectable in spleen, liver and placenta.
4.4.3 DC and HepG2 cells utilize different Hep27 promoters
The different transcript lengths of Hep27 in HepG2 cells and monocyte-derived DCs
suggested different splicing and/or promoter activity in both cell types. In order to
define the 5'-end and putative promoter sequences, 5'-RACE with primers for Hep27
was performed. Fig. 2A shows the resulting products of 860 bp from HepG2 and two
products of 680 and 550 bp length from monocyte-derived DCs. Shotgun cloning and
sequencing of 10 randomly picked clones for each cell type confirmed the previously
published main transcription start site of Hep27 in
HepG2 cells, which lies in an LTR (Gabrielli et al., 1995). In monocyte-derived DCs,
however, most of the resulting clones contained a new 5'-end lacking the LTR portion
which pointed to a new upstream exon and promoter employed by monocyte-derived
DCs.
To clone putative promoter sequences upstream of the newly identified Hep27 5'-
end, promoter walking with primers derived from the newly discovered 5'-mRNA
sequence of Hep27 was performed and the resulting PCR products were sequenced.
As shown in Figure 4.26, the genomic sequence 5' of the Hep27 transcription start in
DC contains a TATA box at -29 bp. Analysis of the sequence with the MatInspector
program (Quandt et al., 1995) identified a number of putative binding sites for
Figure 4.25 Monocyte-derived dendritic cells
utilize a different Hep27 promoter than HepG2
cells.
EtBr-stained products of 5-RACE for Hep27 in
HepG2 cells and monocyte-derived dendritic cells
separated on an agarose/TAE gel. Products lengths
(minus universal primer) in bp are noted in brackets.
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transcription factors including oct-1 and ets factors (core motifs at -131 bp and -101
bp, respectively), as well as an NF-AT/AP-1 module at around -210 bp.
DC
-350 TCTGTATTCCAAACCCTTTCTTTGAAAACTCCTACGTTCCCTCCACGAATTGAAGAGTGGAATTGCTTTC
                                                                  AP-1
-280 TACTCTTCCCCTGCTAGCATGGATAATAAAGACATCTTGCTCCCTCTTATCATAACTATTATTATTTTGA
_______NF-AT_
-210 CGTCTTTCCACAAGCAGCAAGCAGCTGGACTCTTTTGCTGGTTATGCTTGTTAAGTGGTATGTGCAGCAT
      oct-1                        ets        ets
-140 TCTGCAGAATATTACTCAGACAACAAGTCCTGCACTTCCCCTAGGTTTCCTCCCAAGTTGTGGGTGAGGC
                                         TATA box                   -1
-70 CTTTTCTGAAACCCTCCTCCAACCTTTCTGAATTCTGGGGCTATAAATTCCAGGAATCTTTGTGTTGTTC
   Exon I
+1 AGATAGAATCTGCAGTGCCT
HepG2
            CCAAT box               CCAAT box
-100 CTGTAAAATGGACCAATCAGCTCTCCATAAAATGGACCAATCAGCAGGATGTGGGTGTGGCCAGTTAAGG
 TATA-like motif            -1   Exon II
-30 GAATAAAAGCAGGCTGCCTGAGCCGGCAGCAGCAACCTGCTCT
Figure 4.26 Genomic sequences upstream of the transcription start sites of Hep27 in DCs and
HepG2 cells.
Sequences were determined by genome walking or sequence comparison using BLAST, respectively.
Putative transcription factor binding sites are overlined, CCAAT, TATA and core recognition motifs are
in boldface. Repetitive sequences are underlined, transcription start sites are marked by an arrow.
4.4.4 Genomic organization of Hep27
Comparison of the published Hep27 mRNA sequence (GenBank accession number
U31875) and the newly defined 5'-end in DCs with a recently published BAC clone
which contains the corresponding genomic sequence on chromosome 14q11.2
(accession number AL135999.2) yielded the intron/exon structure of Hep27 as
depicted in Figure 4.27.
Figure 4.27 Genomic organization of Hep27.
Schematic representation of the intron/exon structure of Hep27 as determined by BLAST. Exons are
depicted as filled boxes and numbered with roman numerals, introns are represented by the
connecting lines. Exon IIa is depicted as a hatched box. The drawing is up to scale.
Exon I represents the putatively DC-specific 5'-UTR. Together with the 350 bp
proximal alternative promoter it is located at the beginning of a short 723 bp island of
non-repetitive DNA following a repeat-only region of about 6 kb. Exon II lies in a
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repeat-rich region and separates into a 5'-UTR upstream of the internal splice
acceptor (exon IIa) and exon IIb downstream of the 3'-splice acceptor. Table 4.3 lists
the sizes of introns and exons as well as the nucleotide and amino acid sequences at
the exon/intron junctions. The genomic organization of Hep27 has been deposited in
GenBank (GenBank accession numbers AF244132 and AY036899).
Table 4.3 Positions of splice donor and acceptor sequences in the Hep27 gene.
Sequence at exon/intron junction
Exon Size
(bp)
Position 5’-splice donor Intron
(bp)
3’-splice acceptor Amino acid
interrupted
I 121     1-121 GCACAGCCAGGTAAGCCTGG- 6231 -CACCTTTAAGAGCTGTAACA untranslated
II 305 6353-6657 TCGCCAAGTGGTGAGTACCA- 2054 -TTTCCCCCAGGCCTGATTCA untranslated
III* 178 8712-8889 CCACCAGTGGGTGAGTGCTG- 174 -CTGCATTCAGGATCGGCTTT Ser-Gl/y-Ile
IV* 178 9064-9241 GGTGGCCAAGGTGAGGGGGC- 437 -CTCTCCGCAGGCCCTGGAGC Lys-/-Ala
V 102 9679-9780 CTGGGACAAGGTGAGAGGCC- 3256 -CTGATTTCAGATCCTAAGTG Lys-/-Ile
VI* 68 13037-13104 TGGAGAACAGGTATGGCAGG- 891 -CTTGTCTCAGGAGGGGTGCT Asn-Ar/g-Arg
VII 52 13996-14047 TCCAGTAGTGGTAAGTGCTT- 246 -CCCTTCCCAGGCGCTGGGTG Val-/-Ala
VIII 135 14294-14428 CAGCAAAGTGGTGAGGATTG- 283 -CTTTGCCCAGTTTCATGGGA Val-/-Phe
IX 56 14712-14767 AGCTGCAGAGGCAAGTGGGG- 259 -TTCCATCCAGGATTGGGGAG Gln-Ar/g-Ile
X 15027->15306
The main transcription starts site in HepG2 cells lies at 6249 bp. Start codon-containing exons are
marked with an asterisk, exon sequence portions are in boldface.
4.4.5 Exclusive utilization of the upstream Hep27 promoter by
monocyte-derived dendritic cells and alternative splicing
RT-PCR using sense primers derived from the first exon (1s) or exon IIa (a2s) and an
antisense primer specific for exon V (5as), VIII (8as) or X (10as) indicated that exon I
was exclusively transcribed in monocyte-derived DCs but not HepG2 cells,
confirming the 5'-RACE results (Figure 4.28). Additionally, none of the weakly Hep27-
expressing cell lines THP-1, HL-60, HT-29, CaCo-2 and HaCat were found to
express the first exon (data not shown). Instead, Hep27 transcripts in these cells
contained exon IIa which is spliced out in monocyte-derived DCs and is only present
in the mature transcript if transcription is initiated by the LTR promoter.
Figure 4.28 The upstream Hep27
promoter is not utilized in HepG2 cells.
Shown are the products of RT-PCR for
Hep27 using sense primers derived from
exon I (1s) or exon IIa (a2s) with 1 µg
total RNA from monocyte-derived
dendritic cells or HepG2 cells. The
antisense primer was derived from exon
X (10as).
Results
83
Cloning and sequencing of the products from both 5'-RACE and RT-PCR revealed at
least three different splice variants in monocyte-derived DCs, comprising exons I and
III through X, exons I, II and IV through X and exon I and VI through X. In HepG2
cells, the two predominant splice variants were sequenced, the first containing exons
II through X, the second comprising exons II and VI through X. Figure 4.29 shows the
predominant splice variants identified. Accordingly, the two bands of 955 bp and 370
bp observed for DCs in Figure 4.28 correspond to the first and third transcript
depicted schematically in Figure 4.29, the longest (1142 bp) and the main PCR
product (684 bp) from HepG2 cells accord with the full length transcript and the
shorter splice variant shown in Figure 4.29, respectively. Exons III, IV and VI contain
putative start codons. Consequently, the shorter splice variants code for the putative
catalytic triad Ser172, Tyr185, Lys189 (Benach-Andreu, 1999) which is located in
exons VII (Ser) and VIII (Tyr, Lys) but lack the putative coenzyme-binding region
which is encoded by exons III through V.
Figure 4.29 Hep27 mRNA splice variants in DCs and HepG2 cells.
Exons are represented by boxes. Spliced-out exons are empty, expressed exons are linked,
untranslated regions are gray, ORFs are black. Exon IIa is hatched. The numbers behind each mature
transcript represent the sums of the lengths of the included exons in bp. The orientation and
approximate positions of the exon-specific RT-PCR primers are indicated by arrows. The coenzyme-
binding domain- and catalytic domain-containing exons are underlaid in gray.
Results
84
4.4.6 Butyrate treatment activates the downstream Hep27 promoter
Sequence analysis of the promoter utilized in HepG2 cells with the RepeatMasker
program (Smit and Green, 2001) showed that Hep27 transcription is initiated at the
already defined transcription start site of a solitary LTR of endogenous retroviral
origin which is highly homologous to the LTR of the human endogenous provirus
ERV9 (La Mantia et al., 1992). Transposable elements are normally silenced in
somatic cells, possibly by methylation of CpG residues and concomitant chromatin
remodeling and translocation of the sequences to inactive heterochromatin (Yoder et
al., 1997; Razin, 1998; Razin, 1998). Silencing of retroviral sequences can be
overcome by histone deacetylase inhibitors like sodium butyrate or trichostatin A
which alleviate the chromatin-associated transcriptional repression (Barka, 1998;
Chen and Townes, 2000; Chen and Townes, 2000).
As shown in Figure 4.30, treatment with sodium butyrate induced Hep27 expression
in various cell lines. The Hep27 transcripts were of equal length as the main
transcript in HepG2 cells which pointed to transcription being initiated at the LTR.
Long-time exposure revealed that butyrate treatment also induced the other splice
variants found in HepG2 cells in all cell types examined.
Figure 4.30 Effect of butyrate treatment on Hep27 mRNA expression in different cell lines.
Northern blot analysis of Hep27 mRNA expression in monocyte-derived dendritic cells and the cell
lines HepG2, THP-1 HT-29 and CaCo-2. Culture conditions were 30 h and 48 h in the presence or
absence of 10 mM sodium butyrate (HepG2 and THP-1, respectively) or 22 h and 30 h in the
presence or absence of 5 mM sodium butyrate (HT-29 and CaCo-2, respectively). 10 µg of total RNA
were in each lane were hybridized with a random-primed probe encompassing exons II-VIII. The
bottom inset shows the EtBr-stained 18S rRNA bands immediately after blotting.
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Parallel RT-PCR experiments which were performed as described for Figure 4.28
confirmed that the Hep27 transcripts induced by sodium butyrate contained exon IIa
but not exon I, and thus had to be initiated at the LTR promoter as opposed to the
upstream promoter which seems to be utilized exclusively by DCs (Figure 4.31). In
separate experiments, butyrate-treatment also induced exon IIa-containing Hep27
transcripts in macrophages and DCs as assessed by RT-PCR (data not shown).
Figure 4.31 Sodium butyrate-treatment
activates the downstream Hep27
promoter.
RT-PCR for Hep27 was performed as
described for Figure 4.28 with 1 µg each
of the total RNA samples from butyrate-
treated THP-1, HT-29 and CaCo-2 cells
used in the Northern blot analysis shown
in Figure 4.30.
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5 Discussion
5.1 Identification of genes with DC-specific expression
The aim of this work was the identification of differentiation-associated genes with
specific expression in DCs. RDA was employed as a screening method to subtract
monocyte and macrophage-derived cDNA from DCs-derived cDNA. The resulting
fragments were cloned and checked for DC specificity by reverse dot blot. Clones
with exclusive expression in DCs were sequenced and the obtained sequences
compared to published sequences in GenBank. This approach yielded nine
differentially expressed fragments which mapped to six different genes. Three of the
genes had previously been described to either be expressed by DCs (DC-CK-1 and
complement C1q C-chain (Adema et al., 1997; Schwaeble et al., 1995)) or to be up-
regulated in monocytes by IL-4 (15-LOX) (Conrad et al., 1992). DC-specific
expression of the remaining genes, MCP-4, Hep27 and FR-β had not been described
before to be expressed by DCs. Further efforts focussed on the characterization of
MCP-4 and Hep27 expression and the analysis of their regulation during DC
differentiation.
5.2 MCP-4
Analysis of MCP-4 mRNA expression in monocytes, macrophages and DCs by
Northern blot analysis confirmed the initial RDA data and revealed that MCP-4
expression was restricted to immature DCs. Although MCP-4 expression could be
induced by adherence alone, this stimulus only led to short-term MCP-4 mRNA
expression, with mRNA levels becoming undetectable after 16 h. Long-term MCP-4
expression required the presence of IL-4 which delayed the onset of MCP-4 mRNA
expression. GM-CSF was found to further enhance IL-4-induced MCP-4 expression
but was not sufficient to induce MCP-4 by itself.
Maturation of DCs can be induced by a number of „danger“ signals (Gallucci and
Matzinger, 2001), TNF, LPS and CD40 ligation being most commonly used in vitro.
Culture of DCs with either TNF or LPS led to down-regulation of MCP-4 expression,
LPS exhibiting a more rapid effect than TNF.
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Assessment of MCP-4 protein in DC supernatants showed that DCs secrete large
amounts of MCP-4 into the supernatant, exceeding 3 ng/(24 h x 106 cells). The
decrease in transcription induced by DC maturation also led to diminished to non-
detectable protein levels in the supernatants.
Taken together, it could be shown that DCs express MCP-4 while in an immature
state and that MCP-4 is down-regulated during DC maturation.
MCP-4 is a member of the chemokine family of proteins which to date comprises
more than 50 members. Chemokines (derived from "chemotactic cytokines") elicit
chemotactic responses (directional migration) of responsive leukocytes along
chemokine gradients through interactions with a subset of seven transmembrane
domain, G protein-coupled receptors. Chemokines are small (~8-14 kDa), mostly
basic, structurally related proteins with four conserved cysteines close to the N-
terminus which form two essential disulfide bonds (Cys1-Cys3 and Cys2-Cys4). Their
tertiary structure is characterized by a typical chemokine fold containing a free amino
terminus followed by the first cysteine residue, three antiparallel β-sheets and a
carboxy-terminal α-helix. The chemokine fold seems to be critical to the activity of the
free amino-terminal domain (Crump et al., 1997), which contains the epitopes
responsible for the specific interactions with the cognate chemokine receptors after
the first contact of an exposed loop of the β-sheet between the second and third
cysteine residue with the receptor has occurred (Clark-Lewis et al., 1995).
Based on the arrangement and the presence of the two N-terminal cysteine residues,
chemokines have been divided into four subfamilies. The two large CC-(β-) and CXC-
(α-) families which include all but two of the known chemokines are characterized by
the two cysteine residues being either adjacent (CC) or separated by one amino acid
(CXC). The other two subfamilies only comprise one chemokine each, the
transmembrane protein fractalkine/neurotactin forming the CX3C- or γ-class, the
chemokine fold being attached to a transmembrane domain by a mucin-like stalk and
the two cysteine residues separated by three amino acids in between, and
lymphotactin, which only contains two instead of four cysteine residues, constituting
the C- or δ-class (Baggiolini, 1998).
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MCP-4 is a member of the MCP-subfamily of CC-chemokines which - in humans -
comprises MCP-1 through –4 and eotaxin. The majority of the genes encoding CXC-
and CC-chemokines are located in gene clusters on chromosomes 4q13 and
17q11.2-12, respectively, and share a common exon-intron structure (CXC, 4 exons;
CC, 3 exons) (Baggiolini et al., 1997). Accordingly, the MCP-4 gene contains three
exons which encode for a 98 aa residue precursor protein with a 23 aa residue
hydrophobic signal peptide that is cleaved to yield a 8 kDa, 75 aa mature MCP-4.
Two longer MCP-4 variants of 77 and 82 residues termed LA-MCP-4 and FNPQGLA-
MCP-4 have been described in the literature, the shorter of which was found to be
30-fold less potent than the main, 75 aa variant (Uguccioni et al., 1996).
Mature MCP-4 lacks potential N-glycosylation sites and, like the other human MCPs,
contains an N-terminal pyroglutamate proline motif. In its mature form, human MCP-4
shares 56-62% aa sequence identity with the other members of the MCP family,
being most homologous to MCP-1 (60%),-3 (60%) and eotaxin (62%).
MCP-4 acts through the promiscuous chemokine receptors CCR2B, CCR3, CCR9
(cloned as D6 and CCR10) and CCR11 (Garcia-Zepeda et al., 1996; Godiska et al.,
1997; Berkhout et al., 1997; Stellato et al., 1997; Nibbs et al., 1997; Ruffing et al.,
1998; Schweickart et al., 2000) and has been shown to be chemotactic for
monocytes, T lymphocytes, eosinophils, basophils and immature monocyte-derived
DCs (Uguccioni et al., 1996; Sozzani et al., 1997). MCP-4 mRNA is expressed
strongly at sites with exposure to exogenous antigens like lung, small intestine and
colon and displays consecutively weaker expression in other tissues such as heart,
thymus, placenta, uterus, skeletal muscle, pancreas, liver, kidney, prostate, testis
and peripheral blood leukocytes and is not expressed in brain and spleen (Godiska et
al., 1997; Stellato et al., 1997; Berkhout et al., 1997; Garcia-Zepeda et al., 1996).
Weak basal MCP-4 expression has been reported in airway endothelial cells and
submucosal airway mononuclear cells (Chakravorty et al., 2001). Elevated MCP-4
protein expression has been described in endothelial and epithelial cells in several
inflammatory settings comprising atherosclerosis (Berkhout et al., 1997), asthma
(Lamkhioued et al., 2000), acute renal inflammation (Chakravorty et al., 2001) and
basal epithelial cells in the crypts of inflamed tonsils as well as blood vessel-
contacting basal keratinocytes in psoriatic skin lesions (Vanbervliet et al., 2002).
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MCP-4 expression by cells of the mononuclear infiltrate in interstitium or submucosa
was always observed in CD68+ areas.
In vitro, MCP-4 mRNA has been detected in primary endothelial and epithelial cells
and cell lines (Garcia-Zepeda et al., 1996), dermal and lung fibroblasts (Petering et
al., 1998; Teran et al., 1999), the promonocytic U937 cell line and monocyte-derived
macrophages (Godiska et al., 1997).
During the course of this work, MCP-4 expression was also identified in monocyte-
derived DCs by SAGE but only confirmed by RT-PCR (Hashimoto et al., 1999). In the
work presented here, monocyte-derived DCs could be shown to produce large
amounts of MCP-4 mRNA as well as protein. MCP-4 mRNA was detectable as early
as one day after the onset of culture, expression reaching its maximum after two
days. While GM-CSF alone did not induce MCP-4 by itself, it had a synergistic effect
on IL-4-induced MCP-4 production.
Proinflammatory stimuli like TNF, LPS or CD40-ligation lead to terminal differentiation
of DCs, which was found to be accompanied by down-regulation of MCP-4 in
monocyte-derived DCs, indicating that MCP-4 production may be characteristic of
DCs at an immature stage in vivo.
Indeed, an in vivo DC subpopulation, mixed lineage-negative, CD11c- or CD123-
positive blood DCs (BDCs) tested weakly positive for MCP-4 mRNA in RT-PCR.
However, maturation did not alter MCP-4 expression in these cells which might be
explained by their pertinence to a DC subset different from interstitial DCs and the
monocyte-derived DC model (Dzionek et al., 2000). Further experiments will be
necessary to identify the source of MCP-4 in BDC preparations.
In contrast to the findings of Godiska et al. (Godiska et al., 1997), MCP-4 could not
be detected in monocyte-derived macrophages either by Northern blot hybridization
and PCR or in Western blots. However, monocytes were found to express
intermediate levels of MCP-4 mRNA when treated with LPS, while macrophages
were less responsive (data not shown), suggesting that the macrophage preparation
used in their experiments might have been activated by contaminating LPS.
Apart from epithelial cells and endothelium, subepithelial or subendothelial
expression of MCP-4 in inflamed tissues has largely been attributed to macrophages,
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either based on the morphology (Garcia-Zepeda et al., 1996; Lamkhioued et al.,
2000) or CD68-positivity of the infiltrated area (Berkhout et al., 1997; Ying et al.,
1999; Chakravorty et al., 2001). Since both macrophages and DCs have been
described to express CD68 in vivo (Betjes et al., 1991), the findings that in vitro-
derived immature DCs but not in vitro-derived macrophages produce copious
amounts of MCP-4, suggest that the mononuclear MCP-4-expressing cells in vivo
might be CD68+ immature DCs.
The recently published promoter sequence of MCP-4 contains several putative GAS,
IREγ and NF-κB consensus sites. These sites have been implied in the observed
MCP-4 induction by IFN-γ and TNF in dermal fibroblasts  (Hein et al., 1999). In
monocytes, however, IFN-γ did not induce MCP-4 message. On the contrary, IFN-γ
abolished the induction of MCP-4 mRNA in monocytes if added prior to stimulation
with IL-4. Analogous patterns of gene regulation in monocytes and DC have been
described for 15-lipoxygenase (Dickensheets and Donnelly, 1997) and the
chemokines DC-CK1/AMAC-1  (Adema et al., 1997; Kodelja et al., 1998) and MDC
(Bonecchi et al., 1998). This phenomenon has been suggested as a general
regulation pattern for IL-4-inducible genes in monocytes  (Levings and Schrader,
1999) and has been shown to be caused by suppression of IL-4-induced STAT6
tyrosine phosphorylation by interferons, probably through the induction of de novo
expression of the JAK/STAT inhibitory gene SOCS-1 (suppressor of cytokine
signaling) (Dickensheets et al., 1999).
Additionally, comparison of MCP-4 mRNA expression by DCs and fibroblasts
stimulated with various agents indicated that fibroblasts produce only negligible
amounts of MCP-4, probably making their contribution to the overall MCP-4
production in vivo insignificant.
The trafficking of DCs in the body is guided by gradients of specific chemokines
emanating from cells in the different tissues. Inflammation-induced chemokines
cause directional migration of DCs towards the chemokine source and thus sites of
inflammation and possible antigen uptake. Later on, chemokines are essential for DC
homing to secondary lymphatic organs where they effectively support the induction of
specific immune responses. DC-expressed chemokine receptors include CCR1,
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CCR2, and CCR5  (Sozzani et al., 1997), CCR3  (Delgado et al., 1998), and CXCR1,
CXCR2, and CXCR4  (Sozzani et al., 1997), some of which have been suggested to
mediate tissue-specific DC migration, such as CCR6 on Langerhans cells as the
targeting receptor for the epidermis (Charbonnier et al., 1999) or CCR7 as lymphoid
organ-homing receptor (Dieu et al., 1998).
DC function requires the interaction with other immune cells. Consequently, DCs
have been found to express a number of chemokines in a differentiation-associated
fashion, which direct effector cells like T lymphocytes to sites of antigen presentation
and activation. Examples of chemokines produced by DC are DC-CK1, which attracts
naive B and T lymphocytes  (Adema et al., 1997; Lindhout et al., 2001), the activated
and memory T cell-attracting chemokines TARC (Imai et al., 1999), MDC (Tang and
Cyster, 1999) and MIP-3β/ELC  (Ngo et al., 1998), as well as BLC (Vissers et al.,
2001), which acts on B cells and activated T and has been shown to be required for
the development of most lymph nodes and Peyer's patches in mice (Ansel et al.,
2000).
At this point, one can only speculate on the putative role of MCP-4 expression by
immature DCs. The receptors for MCP-4 are expressed mainly on monocytes,
eosinophils, T lymphocytes and DCs themselves. One hypothesis that might explain
the basal MCP-4 expression found in different tissues involves the fact that immature
DCs form tight networks in these tissues, e.g. airway epithelium (Holt et al., 1989),
extracting antigen from each other and surrounding cells (Harshyne et al., 2001) and
exhibit constitutive turnover (Fossum, 1989; Holt et al., 1994). Immature DCs express
receptors for MCP-4, namely CCR2, CCR3 and CCR5 (Delgado et al., 1998; Sallusto
et al., 1998) and have been reported to be attracted by MCP-4 (Sozzani et al., 1997).
Therefore, its expression by DCs as well as epithelial and endothelial cells (Berkhout
et al., 1997; Lamkhioued et al., 2000; Vanbervliet et al., 2002) might help to establish
and keep a network of MCP-4-expressing, antigen-exchanging immature DCs in
close association with the cells lining sites of possible antigen entry. Indeed, CD11c+
DC were shown to localize to MCP-4-expressing blood vessel-contacting inflamed
basal epithelial cells in tonsil crypts, which themselves are rich sources of MCP-4
(Vanbervliet et al., 2002). The turnover of DCs in these tissues requires their
maturation after a period of antigen sampling, including up-regulation of the homing
receptor CCR7 (Dieu et al., 1998) and concomitant down-regulation of MCP-4 and its
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receptors (Delgado et al., 1998; Sallusto et al., 1998). On the one hand this would
lead to their departure from the DC network in response to SLC, produced by
secondary lymphoid tissue endothelial cells and on the other hand keep them from
attracting the remaining, still immature DCs, leaving the network intact. The
described increased DC turnover in inflammation (Holt et al., 1994) and rapid
recruitment of MCP-4-expressing immature DCs to the tissues (McWilliam et al.,
1994) would account for the elevated MCP-4 expression associated with CCR3- and
CCR5-, CD68-positive infiltrates in inflamed tissues (Chakravorty et al., 2001) and
add to the observed attraction of CCR3+ cells such as eosinophils, monocytes and T
lymphocytes.
The hypothesis developed here is further complicated by the fact that in vivo,
chemokines mostly do not work as isolated reagents that bring about one unique
effect but rather act in concert, making it impossible to trace back a complex event
like e.g. antigen-induced eosinophil influx to one single cellular signal. Clearly, further
experiments are needed to elucidate the roles of MCP-4 expression in vivo.
Due to the high expression levels of MCP-4 and its exclusive presence in DCs, the
MCP-4 promoter was characterized as a model for a DC-specific promoter.
The sequence of the MCP-4 promoter contains several putative binding sites for
transcription factors, some of which have been implied in the regulation of DC-
specific genes. Currently, no human DC lines are available which would allow
analysis of MCP-4 promoter by transient reporter assays. However, the proximal
promoter also contains a number of CpG motifs. Methylation of CpG motifs in
mammals has been described as a repression mechanism active in X-chromosome
inactivation, genomic imprinting and silencing of mobile elements (Siegfried and
Cedar, 1997) and acts either directly via inhibition of binding of methylation-sensitive
transcription factors to their CpG-containing DNA recognition sequence or indirectly,
by recruiting methylcytosine-binding proteins which have been shown to both actively
repress transcription through interaction with RNA polymerase II and to recruit
histone deacetylases. These in turn deacetylate the surrounding histones which
eventually leads to inaccessibility of the promoter to transcription factors and
silencing of the gene  (Razin, 1998). Due to its repressive effects, CpG methylation
Discussion
94
has been implied in tissue-specific repression of genes with low CpG density (Razin
and Cedar, 1991), CpG demethylation taking place as a differentiation-associated
event that accompanies and enables gene activation.
Therefore, as an initial characterization, the methylation status of the MCP-4
promoter in monocytes, monocyte-derived macrophages and monocyte-derived DCs
was analyzed. Using bisulfite sequencing, two CpG motifs of the proximal MCP-4
promoter were found to be demethylated during monocyte to DC differentiation and
to remain methylated during monocytes to macrophage differentiation.
Two mechanisms of demethylation are discussed in the literature: passive
demethylation, which is coupled to DNA replication, originating from suppressed
maintenance methylation of the newly synthesized DNA strand, and active
demethylation, which can take place in the absence of DNA replication. Up to now,
active demethylation in vivo has only been demonstrated in early embryonic cells,
where the paternal genome undergoes genome-wide demethylation before the onset
of DNA replication (Mayer et al., 2000). Demethylation in somatic cells after the
embryonic phase so far has been assumed to be a passive event. Although there is
evidence that active, i.e. DNA replication-independent, demethylation might exist in
somatic cells (Lucarelli et al., 2001), somatic active DNA demethylation has not yet
been demonstrated conclusively.
Differentiation of human monocytes to DCs has been shown to proceed in the
absence of DNA replication (Cavanagh et al., 1998; Ardeshna et al., 2000),
effectively ruling out a DNA replication-based mechanism to explain the
demethylation observed for the MCP-4 promoter. Thus, this finding probably
represents the first report of active CpG demethylation in non-proliferating somatic
cells.
Demethylation of one of the CpG motifs of the MCP-4 promoter facilitated binding of
a nuclear factor that was present in both monocyte-derived macrophages and
monocyte-derived DCs. Binding was sequence-specific and alterations of the CpG
motif mimicked the effect of CpG methylation. In transient transfections of THP-1
cells, which express the CpG methylation-sensitive DNA-binding factor as well,
mutation of the CpG motif reduced promoter activity by approximately 50%,
indicating a possible role of this element in regulation of MCP-4 expression in DCs.
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A query of the TRANSFAC database showed that the respective CpG lies in a core
recognition motif of the murine winged-helix nude (whn) transcription factor, a
member of the forkhead family of transcription factors. Several facts like the highly
conserved core consensus binding sequence and the sensitivity of murine whn
binding to DNA methylation (Lee et al., 1999) point to human whn as the nuclear
protein in question. However, its exclusive expression in skin and thymic epithelial
cells makes it a less likely candidate. As a side note, in a recent paper by Thomassin
et al. (Thomassin et al., 2001), methylation-sensitive binding of a nuclear factor to an
oligonucleotide containing a sequence motif identical (ACGC) to the whn core
consensus binding site encompassing the –80 bp CpG of the human MCP-4
promoter is reported. The factor binds to a region within an enhancer of the rat liver-
specific Tat gene after rapid chromatin remodeling which is followed by targeted CpG
demethylation. Although the actual binding motif of the factor was not identified, it
can be inferred from the hyperreactivity of the guanosine residue complementary to
the second cytosine in the ACGC motif in the in vivo footprints that the factor binds to
or in the immediate neighborhood of this motif. Together with the sensitivity of the
binding to CpG methylation this suggests identity of the factor with the factor binding
to the corresponding site of the MCP-4 promoter. Since HeLa cells also express the
–80 bp CpG-binding factor, the protein itself is probably ubiquitously expressed.
Identification of the factor after purification from nuclear protein extracts by affinity
chromatography with the -80 CpG EMSA oligonucleotide will likely provide more
insight into its possible properties as a target of CpG-induced silencing and its
putative role in enhancing or enabling transcription.
Nearly 30 years after the predictions of Riggs (Riggs, 1975) and Holliday and Pugh
(Holliday and Pugh, 1975) that tissue-specific genes would be found to be methylated
within regulatory regions before the onset of transcription, and that programmed
demethylation would allow transcription in the appropriate cell type, the role of CpG
methylation in the tissue-specific regulation of gene expression is still controversial.
This is mainly due to the large body of correlative data of promoter demethylation
coinciding with up-regulation of tissue-specific genes which has accumulated since
then, without ever supplying evidence for demethylation as the actual cause for
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upregulation of gene expression (Walsh and Bestor, 1999). Similarly, in DNA
methyltransferase-deficient mice which exhibit genome-wide hypomethylation, DNA
methylation could be shown to play central roles in genomic imprinting (Li et al.,
1993) (hypomethylation leads to biallelic expression of imprinted genes), X
chromosome inactivation (Panning and Jaenisch, 1996) (hypomethylation leads to
ectopic Xist gene expression and X chromosome inactivation) and silencing of mobile
genomic elements (Walsh et al., 1998), but there has been no indication of ectopic
expression of tissue-specific genes in these mice.
Given the ambiguous data, Walsh and Bestor (Walsh and Bestor, 1999) have
suggested that the observed correlations between demethylation and transcription
might be due to demethylation being a consequence of transcriptional activation
rather than the cause. In agreement with their analysis, demethylation of the MCP-4
promoter in DCs occurs after the onset of MCP-4 transcription and is not necessary
to allow MCP-4 transcription, as can be seen in IL-4 and GM-CSF-treated
macrophages which transcribe MCP-4 mRNA from a completely methylated
promoter. Additionally, CpG demethylation alone is not sufficient to sustain MCP-4
expression in DCs after withdrawal of IL-4 and GM-CSF. However, since mutation of
the –80 bp CpG decreases the activity of the MCP-4 promoter in THP-1 cells, CpG
demethylation might be necessary to attain maximal MCP-4 expression in DCs which
approximately coincides with completion of demethylation after two days of culture. In
comparison, the weaker expression of MCP-4 mRNA in IL-4/GM-CSF-treated
macrophages might be caused by the methylated –80 bp CpG in the MCP-4
promoter of these cells presumably by preventing transcription factor binding to the
site. This would be in line with the recent finding that TH2 differentiation-associated
demethylation of the IL-4 locus is correlated with high-level IL-4 expression (Lee et
al., 2002). In order to verify the hypothesis that demethylation is necessary for
maximal MCP-4 transcription, identification of the CpG-binding factor will enable to
assess its role in realizing maximal MCP-4 promoter activity by analyzing its impact
on the activity of methylated vs. unmethylated MCP-4 reporter constructs in
cotransfection/ overexpression experiments.
A recent report (Palucka et al., 1998) suggested that in their immature states,
macrophages and DC retain plasticity in their differentiation potential, allowing them
to convert from the DC to the macrophage phenotype and vice versa. Although this
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might be true concerning the phenotypic aspects examined in this paper, the results
presented here indicate that for the demethylation events in the MCP-4 promoter
there is only a short time slot during which differentiation-coupled demethylation can
take place during DC development. After completion of this period, the methylation
status seems to become refractory to change and thus appears to conserve the
differentiation history of the MCP-4 gene in each particular cell and to define its
capacity to react to new stimulatory events, be it in macrophages or DCs. Hence the
different states of CpG methylation of the MCP-4 promoter in macrophages and DCs
seem to be characteristic of the distinct monocytic differentiation pathways.
5.3 Hep27
Hep27 was originally cloned from HepG2 cells where it is constitutively expressed
and is up-regulated following butyrate-treatment (Donadel et al., 1991; Gabrielli et al.,
1995). Hep27 protein has a molecular mass of approximately 27 kDa. Its amino acid
sequence classifies Hep27 as a member of the short chain dehydrogenase/reductase
(SDR) family of enzymes. The substrate for Hep27 has not yet been identified.
Northern blot analysis and RT-PCR confirmed that expression of Hep27 was
restricted to DCs and HepG2 cells. Hep27 mRNA was absent from other
hematopoietic cells such as granulocytes or lymphocytes as well as HUVEC, dermal
fibroblasts and two colon epithelial cell lines. During differentiation of monocyte-
derived DCs, Hep27 mRNA was detectable as early as two days after the onset of
culture. Hep27 expression was restricted to monocyte-derived DCs at an immature
state, since Hep27 was down-regulated by DC maturation stimuli like LPS or TNF.
Hep27 was initially described as a nuclear protein. However, using a polyclonal
antiserum in Western blots, Hep27 protein was detectable only in cytoplasmic DC
extracts but not in nuclear extracts nor the remaining nuclear envelopes. These
findings are in line with more recent immunohistochemical data which indicates that
Hep27 is mainly located in the cytosol and only a small fraction of the Hep27 protein
pool can be found in the nucleus (Pellegrini et al., 2002).
To understand the molecular basis for the highly selective expression of Hep27, the
transcription start site in DCs and HepG2 cells was identified by 5’-RACE and the
upstream genomic sequences were analyzed. The 5'-end of the HepG2-expressed
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transcript is related to the LTR consensus of the human endogenous ERV9 provirus,
pointing to a solitary ERV9-derived LTR driving Hep27 expression in these cells (La
Mantia et al., 1991). Alignment with the publicly available genomic sequence and
analysis of the upstream sequence confirmed this hypothesis and showed that the
start site of Hep27 transcription in HepG2 cells coincides with the previously
described ERV9 transcription start site (La Mantia et al., 1992). In DCs, 5'-RACE and
subsequent promoter walking revealed a different promoter to be active. In contrast
to the TATA-less retroviral HEP27 LTR promoter utilized by HepG2 cells, the DC-
specific promoter, which lies approximately 6.2 kb upstream, does not contain
repetitive sequences and features a regular TATA box 29 bp upstream of the
transcription start as well as a number of putative binding sites for several
transcription factors. Analysis of the surrounding genomic region with the
RepeatMasker program  (Smit and Green, 2001) showed that the alternative
promoter and the first exon lie in a repeat-less island which is positioned in a repeat-
rich stretch containing multiple remnants of retroviral integration.
Analyzing the Hep27 transcripts in HepG2 cells and monocyte-derived DCs a number
of splice variants were identified, which in conjunction with the different transcription
start sites were cell type-specific and could be distinguished by Northern blot analysis
based on their different lengths. The main transcripts in HepG2 cells and monocyte-
derived DCs were 1.9 kb and 1.5 kb in length, respectively.
In Northern blots of tissue mRNA, transcript variants similar to the ones observed for
the different cell types could be detected. The short variants found in monocyte-
derived DCs were present in almost all tissues, which is in agreement with the almost
ubiquitous presence of DCs in vivo. A longer Hep27 transcript corresponding to the
main transcript in HepG2 was strongly expressed in liver. It is also the main transcript
in placenta and spleen, as well as in kidney. The ERV9 LTR promoter has been
suggested to induce tissue-specific gene expression in erythroid cells (Long et al.,
1998). Hence the liver-specific expression of Hep27 might also be a trait of the LTR
promoter. On the other hand, using the histone deacetylase inhibitor sodium
butyrate, Hep27 transcription driven by the LTR promoter could be initiated in several
non-hepatocytic cell lines as well as monocyte-derived DCs. Butyrate-induced
histone hyperacetylation leads to an open chromatin conformation which in turn
makes the DNA more accessible to the transcription machinery. Using Trichostatin A,
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Plant et al. (Plant et al., 2001) recently described similar findings for ERV9 LTR-
initiated intergenic transcription in the human β-globin gene cluster which is normally
erythrocyte-specific. The authors suggest that in non-transcribing cell types the block
to transcription may lie at the level of chromatin structure rather than at the level of
LTR-specific transcription factors, i.e. the lack thereof. As butyrate concentrations of
portal vein blood can reach concentrations of up to 40 µM (Peters et al., 1992),
expression of the LTR-initiated Hep27 transcript in liver might be the result of LTR
activation caused by the high butyrate concentrations. In fetal liver, where butyrate
should not be present due to the absence of bacterial inhabitation of the fetal
intestine, only the short, presumably exon I-containing Hep27 fragment is expressed,
but not the longer, LTR-initiated transcript found in adult liver, pointing to a potential
role of bacterially produced butyrate in Hep27 induction in adult liver. However, this
reasoning does not account for the observation of the long transcript in spleen,
kidney and placenta, where butyrate concentrations are extremely low (Peters et al.,
1992). One possible explanation, at least for the placental expression, might be the
fact that placental DNA remains hypomethylated after blastocyst formation (Ehrlich et
al., 1982). Since CpG methylation has been suggested as one mechanism to
suppress expression of endogenous retroviral sequences (Yoder et al., 1997),
placental DNA hypomethylation might induce Hep27 expression from its LTR
promoter.
Expression of the Hep27 variant produced in immature monocyte-derived DCs is
most prominent in non-lymphoid tissues like liver, kidney, heart and skeletal muscle
where DCs are known to reside in an immature state (Hart , 1997). In spleen, where
mature DCs are also present (McIlroy et al., 2001), weaker expression of the shorter
Hep27 mRNA variant was observed. Clearly, immunohistochemical studies with
suitable antibodies or isolation and purification of DCs ex vivo followed by RT-PCR
are necessary to confirm that DCs are sources of Hep27 in vivo.
5.4 Complement C1q C-chain
In line with the previously identified sources of C1q (Schwaeble et al., 1995),
Northern blot analysis for C1q C-chain expression confirmed macrophages and DCs
as producers of C1q C-chain mRNA in vitro. Interestingly, macrophages, which are
commonly viewed as the main source of C1q, only transiently expressed readily
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detectable levels after four days of culture, i.e. at an intermediate stage of
differentiation, and exhibited weaker C1q C-chain expression on day one and seven.
Conversely, immature DCs produced far greater levels of C1q C-chain mRNA which
was down-regulated by the maturation stimuli LPS and TNF. Similar results have
been published recently for the mRNA expression of all three C1q subchains in a
spleen-derived murine DC cell line (Granucci et al., 2001). The data obtained for
macrophages contradict recently published results for C1q C-chain expression in
macrophages which show a continual increase of C-chain expression during
monocyte to macrophage differentiation (Kaul and Loos, 2001). The differing results
might arise from the different culture conditions (2% vs. 10% pooled human AB
serum).
Complement C1q C-chain is a subcomponent of the C1q component of C1, the first
component of the classical complement activation pathway. Together with the A- and
B-chains, the C1q C-chain forms triple helices between their N-terminal collagen-like
sequences. Six of these collagen-like “stalks” then self-assemble symmetrically to
form the fibril-like central core of the umbrella-shaped C1q hexamer with the globular
heads at their C-termini projecting on radial arms. Association of C1q with a
C1r2C1s2 tetramer of the serine esterases C1r and C1s yields C1. Upon binding of
antigen-bound to the globular heads, a conformational change activates C1r which in
turn cleaves C1s. The activated C1s then hydrolyzes other complement components,
thus initiating a protease cascade which leads to opsonization of antigen-bearing
cells, release of chemotactic and pro-inflammatory degradation products
(anaphylatoxins) and eventually to osmotic lysis of antigen-bearing cells through
assembly of the Membrane Attack Complex.
Apart from its activating role in the classical complement pathway, C1q has been
shown to bind to a variety of cell types as well as apoptotic cells (Korb and Ahearn,
1997; Navratil et al., 2001) and to interact with a number of cognate cell surface
receptors (reviewed in  (Eggleton et al., 2000) ). The elicited effects depend on the
triggered receptor and range from activation of respiratory burst in neutrophils and
macrophages and inhibition of proliferation of activated T lymphocytes (Chen et al.,
1994) to enhancement of phagocytosis (Guan et al., 1994), the initiation of
macropinocytosis and uptake of apoptotic cells (Navratil et al., 2001). The latter has
recently been shown to proceed through binding of apoptotic cell-bound C1q to
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calreticulin on the macrophage cell surface, which in turn is bound by CD91 (Ogden
et al., 2001).
In a recent report, Steinberger et al. (Steinberger et al., 2002) showed one of the
previously identified receptors for C1q, the phagocytosis-enhancing C1qRp
(Nepomuceno et al., 1997) to be identical to CD93 which had previously been shown
to be expressed by monocytes, granulocytes and endothelial cells (Menetrier-Caux et
al., 1998) as well as immature DCs (Pickl et al., 1996). Additionally, they found CD93
expression to be down-regulated upon DC maturation. (This is in contrast to another
report on C1qRp (Fonseca et al., 2001) which described C1qRp to be absent from
both immature as well as mature DC.)
Functionally, the expression of C1q as well as its phagocytosis-enhancing receptors
by DCs might contribute to the avid endocytic activity of immature DCs. Their
maturation-induced down-regulation consequently would add to the general shut-
down of endocytosis in maturing DCs. Additionally, the described antiproliferative
effect of C1q on activated T cells (Chen et al., 1994) might contribute to the tolerizing
effect of immature DCs. Interesting questions to answer in further experiments
therefore would be whether C1q is able to induce endocytosis levels in mature DCs
comparable to immature DCs and whether addition of C1q to MLCs with mature DCs
vs. immature DCs as stimulators alters the T cell proliferation rate.
5.5 15-Lipoxygenase
In agreement with previously published data showing induction of the lipid-
peroxidating 15-lipoxygenase type 1 (EC 1.13.11.33) (15-LOX) in monocytes by IL-4
in the presence or absence of GM-CSF (Conrad et al., 1992), 15-LOX was found to
be strongly expressed in immature DCs and to be absent from macrophages and
freshly isolated monocytes. DC maturation with LPS or TNF led to down-regulation of
15-LOX.
15-LOX has been implicated in a number of cellular processes, ranging from
metabolic and structural changes to cell signaling and transcriptional control. 15-LOX
is a non-heme iron-containing fatty acid-peroxidating enzyme and catalyses the
stereospecific oxygenation of arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid)
and linoleic acid (9Z,12Z-octadecadienoic acid) to yield mainly 15-HPETE (15S-
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hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid) (as well as minor amounts of 12-
HPETE (12S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid)) and 13-HPODE
(13S-hydroperoxy-9Z,11E-octadecadienoic acid), respectively. The products are then
rapidly reduced to the stable hydroxylated forms.
Unlike the other known lipoxygenases, 15-LOX is able to oxygenate its substrates
either as free acid or esterified to lipid components or cholesterol in lipoproteins or
biological membranes.
Since 15-LOX co-localizes with oxidized low density lipoprotein (oxLDL) in
macrophage-rich regions of atheroscerotic lesions (Yla-Herttuala et al., 1990) and
has been shown to oxidize LDL to pro-atherogenic oxLDL in vitro, the enzyme has
been implicated in the oxidation of LDL in vivo, a key event in the initiation of
atherosclerosis. Due to contradicting evidence for a pro-atherogenic effect of 15-LOX
in mice vs. anti-atherogenic effects in 15-LOX in rabbits, by gene knockout and 15-
LOX overexpression, respectively, its actual role in atherogenesis is still a point of
discussion (Funk and Cyrus, 2001).
In the functional context of DCs, several recent findings point to a possible
involvement of 15-LOX in endocytic uptake of apoptotic cells, cross-presentation and
the tolerogenic effects of immature DCs: Membrane translocation and activation of
15-LOX in eosinophils has been shown to be calcium-dependent (Brinckmann et al.,
1998). In a recent report, 15-LOX was shown to translocate to the cell membrane
and to enhance actin-polymerization in IL-4-treated murine macrophages
phagocytosing apoptotic cells, which could be inhibited using the specific 15-LOX
inhibitor PD146176 (Miller et al., 2001). Since phagocytosis of apoptotic cells by DCs
has been shown to be calcium-dependent (Rubartelli et al., 1997), 15-LOX might play
a role in enhancing DC phagocytosis.
DCs have been shown to cross-present exogenous antigen to MHC class I-restricted
CD8+ T cells (Albert et al., 1998b), owing to their unique ability to transport
endocytosed antigen to the cytosol (Rodriguez et al., 1999). DCs are avidly
macropinocytic at an immature stage and macropinocytotic vesicles have been
suggested to have a fatty acid composition similar to the ruffled membrane rafts they
may be derived from (Nichols and Lippincott-Schwartz, 2001), containing elevated
levels of arachidonic acid (Pike et al., 2002). Since the membrane lipid-peroxidating
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properties of 15-LOX have been shown to promote degradation of organelle
membranes in reticulocytes (van Leyen et al., 1998) and 15-LOX is expressed in
immature DCs, 15-LOX might be involved in mediating permeabilization of
macropinocytic vesicles and in generating the observed strong capacity of DCs to
cross-present exogenous antigen. Additionally, the 15-LOX product 13-HODE is a
potent ligand for the nuclear receptor PPAR-γ (Nagy et al., 1998). Activation of
PPAR-γ by binding of 13-HODE produced by IL-4-activated monocytes has recently
been shown to suppress production of the key autocrine growth factor IL-2 by T
lymphocytes (Yang et al., 2002). Since the IL-4-induced expression of 15-LOX is
downregulated by danger signals such as LPS or TNF, the production of 13-HODE
by DCs or IL-4-activated monocytes might provide another feedback loop to prevent
aberrant T cell activation and inflammation.
15-LOX has also been demonstrated recently in stem cell-derived DCs derived in the
presence of IL-4, but as a caveat it has to be pointed out that although all the findings
and conclusions for 15-LOX cited above do apply to DCs generated from monocytes
in vitro, until now 15-LOX expression in DCs has not yet been demonstrated in vivo.
5.6 Folate Receptor β
Similar to most other genes identified in this study, folate receptor β (FR-β) or type 2
folate binding protein, was identified in immature DCs and its expression was
downregulated upon maturation.
FR-β was originally cloned from placenta by Ratnam et al. (Ratnam et al., 1989).
Expression of FR-β has previously been demonstrated in spleen, thymus and
neutrophils (Ross et al., 1994; Ross et al., 1999)as well as in synovial macrophages
in rheumatoid arthritis (Nakashima-Matsushita et al., 1999). Like the closely related
FR-α, FR-β is a GPI-anchored membrane molecule and mediates uptake of folates
by endocytosis. In contrast to FR-α, which binds the physiologically relevant 6S
diastereomers of the reduced folates such as 5-methyltetrahydrofolate and 5-
formyltetrahydrofolate, the FR-β has been reported to greatly favour binding of the
unphysiologic 6R forms over the 6S diastereomers (Wang et al., 1992).
Folic acid plays an important role as a carrier of one-carbon groups in several
intracellular metabolic pathways. It is especially important for purine and thymidylate
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synthesis, both of which are required for DNA synthesis. One could hypothesize that
upregulation of FR-β on DCs might lead to depletion of folic acid around immature
DCs which would halt proliferation of activated T cells in the vicinity of the non-
activated DCs, similar to the inhibitory effect of tryptophane depletion by DC-
produced indoleamine 2,3-dioxygenase (Hwu et al., 2000). A proinflammatory signal
would then relieve the metabolic T cell proliferation block by induction of DC
maturation and downregulation of FR-β and thus validate the T cell-activating
stimulus.
Further work is necessary to determine the relevance of these findings by assessing
whether DCs express FR-β in vivo as well as to elucidate the function of FR-β
expression in non-malignant adult cells.
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6 Summary
During the course of this work, the genes DC-CK1, 15-LOX, MCP-4, Hep27,
complement C1q C-chain and FR-β could be identified as being transcribed in
monocyte-derived DCs but not in monocyte-derived macrophages or the precursor
monocytes. Expression of all genes except DC-CK1 was restricted to immature DCs
and was down-regulated upon DC maturation initiated by TNF or LPS.
MCP-4 expression in response to various stimuli could be shown to be different in
DCs, macrophages, differentiating monocytes and human dermal fibroblasts on the
mRNA level, immature DCs expressing the highest levels of MCP-4 mRNA as well as
protein. Additionally, weak MCP-4 expression was observed in sorted blood DCs by
RT-PCR.
DC specificity of expression of the SDR family member Hep27 (HUGO nomenclature:
DHRS2) was confirmed in Western blots from cytosolic extracts from DCs and
macrophages. Additionally, Hep27 mRNA could not be detected in a number of
hematopoietic cells. Low level Hep27 mRNA expression could be demonstrated in all
tissues examined; high level expression was found in heart and skeletal muscle, liver,
kidney and placenta as well as spleen and fetal liver.
Several splice variants of Hep27 were identified and analyzed in DCs and HepG2
cells, which differ in their 5'-ends and overall length and seem to reflect the mature
transcripts of distinct length detected in tissue Northern blots.
Its high-level expression in immature DCs made MCP-4 an interesting target for
analysis of the mechanisms underlying its induction in DCs. Owing to the lack of DC
cell line models suitable for classical reporter analysis to define a minimal promoter,
the CpG methylation status of the MCP-4 promoter in monocytes, monocyte-derived
macrophages and monocyte-derived DCs was analyzed by bisulfite sequencing.
Exclusive CpG demethylation of two CpG sites at –80 bp and –20 bp, respectively,
was detected in DCs.
Using electrophoretic mobility shift assays (EMSAs), binding of a nuclear factor to the
demethylated but not the methylated or mutated –80 bp CpG motif could be
demonstrated in macrophages, DCs, the monocytic cell line THP-1 and the human
cervix carcinoma cell line HeLa.
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Mutation of the –80 bp CpG abolished binding of the nuclear factor in EMSAs similar
to CpG methylation and decreased activity of the proximal MCP-4 promoter by 50%
in transient transfections of reporter constructs in THP-1 cells.
De-differentiation of immature DCs to macrophage-like cells and vice versa revealed
the differentiation pathway dependency of the observed demethylation reaction,
which apparently only takes place during the initial monocyte-DC transition and can
not be induced at a later time point.
To elucidate the reasons for the DC-restricted Hep27 expression, the genomic
structure of Hep27 was characterized. An alternative promoter could be defined,
which is used exclusively in DCs, making it an interesting model for further analysis
of DC-specific gene regulation.
References
107
7 References
Adema,G.J., Hartgers,F., Verstraten,R., de Vries,E., Marland,G., Menon,S., Foster,J., Xu,Y.,
Nooyen,P., McClanahan,T., Bacon,K.B. and Figdor,C.G. (1997). A dendritic-cell-derived C-C
chemokine that preferentially attracts naive T cells. Nature 387, 713-717.
Aderem,A. and Underhill,D.M. (1999). Mechanisms of phagocytosis in macrophages. Annu. Rev.
Immunol. 17, 593-623.
Albert,M.L., Pearce,S.F., Francisco,L.M., Sauter,B., Roy,P., Silverstein,R.L. and Bhardwaj,N. (1998a).
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present
antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359-1368.
Albert,M.L., Sauter,B. and Bhardwaj,N. (1998b). Dendritic cells acquire antigen from apoptotic cells
and induce class I- restricted CTLs.  Nature 392, 86-89.
Andreesen,R., Picht,J. and Lohr,G.W. (1983). Primary cultures of human blood-born macrophages
grown on hydrophobic teflon membranes. J Immunol Methods 56, 295-304.
Ansel,K.M., Ngo,V.N., Hyman,P.L., Luther,S.A., Forster,R., Sedgwick,J.D., Browning,J.L., Lipp,M. and
Cyster,J.G. (2000). A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature
406, 309-314.
Ardeshna,K.M., Pizzey,A.R., Thomas,N.S., Orr,S., Linch,D.C. and Devereux,S. (2000). Monocyte-
derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J.
Haematol.  108, 817-824.
Baggiolini,M. (1998). Chemokines and leukocyte traffic. Nature 392, 565-568.
Baggiolini,M., Dewald,B. and Moser,B. (1997). Human chemokines: an update. Annu. Rev. Immunol.
15, 675-705.
Bain,B., Vas,M.R. and Lowenstein,L. (1964). The development of large immature mononuclear cells in
mixed leukocyte cultures. Blood 23, 108-116.
Barka,T. (1998). Effect of sodium butyrate on the expression of genes transduced by retroviral
vectors. J. Cell Biochem. 69, 201-210.
Benach-Andreu, J. X-ray Structure Analysis of Short-Chain Dehydrogenases/Reductases.  1999.
Karolinska Institute, Center for Structural Biochemistry.
Ref Type: Thesis/Dissertation
Bennett,S.R., Carbone,F.R., Karamalis,F., Flavell,R.A., Miller,J.F. and Heath,W.R. (1998). Help for
cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480.
Berkhout,T.A., Sarau,H.M., Moores,K., White,J.R., Elshourbagy,N., Appelbaum,E., Reape,R.J.,
Brawner,M., Makwana,J., Foley,J.J., Schmidt,D.B., Imburgia,C., McNulty,D., Matthews,J.,
O'Donnell,K., O'Shannessy,D., Scott,M., Groot,P.E. and Macphee,C. (1997). Cloning, in vitro
expression, and functional characterization of a novel human CC chemokine of the monocyte
chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor
2B. J Biol Chem 272, 16404-16413.
Betjes,M.G., Haks,M.C., Tuk,C.W. and Beelen,R.H. (1991). Monoclonal antibody EBM11 (anti-CD68)
discriminates between dendritic cells and macrophages after short-term culture. Immunobiology 183,
79-87.
Bonecchi,R., Sozzani,S., Stine,J.T., Luini,W., D'Amico,G., Allavena,P., Chantry,D. and Mantovani,A.
(1998). Divergent effects of interleukin-4 and interferon-gamma on macrophage- derived chemokine
production: an amplification circuit of polarized T helper 2 responses. Blood 92, 2668-2671.
Borkowski,T.A., Letterio,J.J., Farr,A.G. and Udey,M.C. (1996). A role for endogenous transforming
growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice
is devoid of epidermal Langerhans cells. J. Exp. Med. 184, 2417-2422.
Brinckmann,R., Schnurr,K., Heydeck,D., Rosenbach,T., Kolde,G. and Kuhn,H. (1998). Membrane
translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the
oxygenase activity of the enzyme. Blood 91, 64-74.
Caux,C., Dezutter-Dambuyant,C., Schmitt,D. and Banchereau,J. (1992). GM-CSF and TNF-alpha
cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261.
References
108
Cavanagh,L.L., Saal,R.J., Grimmett,K.L. and Thomas,R. (1998). Proliferation in monocyte-derived
dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. Blood 92 , 1598-
1607.
Cella,M., Engering,A., Pinet,V., Pieters,J. and Lanzavecchia,A. (1997). Inflammatory stimuli induce
accumulation of MHC class II complexes on dendritic cells [see comments]. Nature 388, 782-787.
Cella,M., Salio,M., Sakakibara,Y., Langen,H., Julkunen,I. and Lanzavecchia,A. (1999). Maturation,
activation, and protection of dendritic cells induced by double-stranded RNA [In Process Citation]. J
Exp Med 189, 821-829.
Chakravorty,S.J., Howie,A.J., Girdlestone,J., Gentle,D. and Savage,C.O. (2001). Potential role for
monocyte chemotactic protein-4 (MCP-4) in monocyte/macrophage recruitment in acute renal
inflammation. J. Pathol. 194, 239-246.
Charbonnier,A.S., Kohrgruber,N., Kriehuber,E., Stingl,G., Rot,A. and Maurer,D. (1999). Macrophage
inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal langerhans cells. J.
Exp. Med. 190, 1755-1768.
Chen,A., Gaddipati,S., Hong,Y., Volkman,D.J., Peerschke,E.I. and Ghebrehiwet,B. (1994). Human T
cells express specific binding sites for C1q. Role in T cell activation and proliferation. J. Immunol. 153,
1430-1440.
Chen,W.Y. and Townes,T.M. (2000). Molecular mechanism for silencing virally transduced genes
involves histone deacetylation and chromatin condensation. Proc. Natl. Acad. Sci. U. S. A 97, 377-
382.
Chu,A., Eisinger,M., Lee,J.S., Takezaki,S., Kung,P.C. and Edelson,R.L. (1982). Immunoelectron
microscopic identification of Langerhans cells using a new antigenic marker. J. Invest Dermatol. 78,
177-180.
Clark-Lewis,I., Kim,K.S., Rajarathnam,K., Gong,J.H., Dewald,B., Moser,B., Baggiolini,M. and
Sykes,B.D. (1995). Structure-activity relationships of chemokines. J. Leukoc. Biol. 57, 703-711.
Conrad,D.J., Kuhn,H., Mulkins,M., Highland,E. and Sigal,E. (1992). Specific inflammatory cytokines
regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl. Acad. Sci. U. S. A 89, 217-
221.
Crump,M.P., Gong,J.H., Loetscher,P., Rajarathnam,K., Amara,A., Arenzana-Seisdedos,F.,
Virelizier,J.L., Baggiolini,M., Sykes,B.D. and Clark-Lewis,I. (1997). Solution structure and basis for
functional activity of stromal cell- derived factor-1; dissociation of CXCR4 activation from binding and
inhibition of HIV-1. EMBO J. 16, 6996-7007.
de Saint-Vis,B., Vincent,J., Vandenabeele,S., Vanbervliet,B., Pin,J.J., Ait-Yahia,S., Patel,S.,
Mattei,M.G., Banchereau,J., Zurawski,S., Davoust,J., Caux,C. and Lebecque,S. (1998). A novel
lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently
expressed in MHC class II compartment. Immunity 9, 325-336.
Delgado,E., Finkel,V., Baggiolini,M., Mackay,C.R., Steinman,R.M. and Granelli-Piperno,A. (1998).
Mature dendritic cells respond to SDF-1, but not to several beta- chemokines. Immunobiology 198,
490-500.
Dhodapkar,M.V., Steinman,R.M., Krasovsky,J., Munz,C. and Bhardwaj,N. (2001). Antigen-specific
inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med.
193, 233-238.
Dickensheets,H.L. and Donnelly,R.P. (1997). IFN-gamma and IL-10 inhibit induction of IL-1 receptor
type I and type II gene expression by IL-4 and IL-13 in human monocytes. J. Immunol. 159, 6226-
6233.
Dickensheets,H.L., Venkataraman,C., Schindler,U. and Donnelly,R.P. (1999). Interferons inhibit
activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc.
Natl. Acad. Sci. U. S. A 96, 10800-10805.
Dieu,M.C., Vanbervliet,B., Vicari,A., Bridon,J.M., Oldham,E., Ait-Yahia,S., Briere,F., Zlotnik,A.,
Lebecque,S. and Caux,C. (1998). Selective recruitment of immature and mature dendritic cells by
distinct chemokines expressed in different anatomic sites. J Exp Med 188, 373-386.
Donadel,G., Garzelli,C., Frank,R. and Gabrielli,F. (1991). Identification of a novel nuclear protein
synthesized in growth- arrested human hepatoblastoma HepG2 cells. Eur. J. Biochem. 195, 723-729.
References
109
Dubois,B., Massacrier,C., Vanbervliet,B., Fayette,J., Briere,F., Banchereau,J. and Caux,C. (1998).
Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J Immunol 161,
2223-2231.
Dubois,B., Vanbervliet,B., Fayette,J., Massacrier,C., Van Kooten,C., Briere,F., Banchereau,J. and
Caux,C. (1997). Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes
[see comments]. J Exp Med 185, 941-951.
Dzionek,A., Fuchs,A., Schmidt,P., Cremer,S., Zysk,M., Miltenyi,S., Buck,D.W. and Schmitz,J. (2000).
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human
peripheral blood. J. Immunol. 165, 6037-6046.
Eggleton,P., Tenner,A.J. and Reid,K.B. (2000). C1q receptors. Clin. Exp. Immunol. 120, 406-412.
Ehrlich,M., Gama-Sosa,M.A., Huang,L.H., Midgett,R.M., Kuo,K.C., McCune,R.A. and Gehrke,C.
(1982). Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of
cells. Nucleic Acids Res. 10, 2709-2721.
Fayette,J., Dubois,B., Vandenabeele,S., Bridon,J.M., Vanbervliet,B., Durand,I., Banchereau,J.,
Caux,C. and Briere,F. (1997). Human dendritic cells skew isotype switching of CD40-activated naive B
cells towards IgA1 and IgA2. J Exp Med 185, 1909-1918.
Fonseca,M.I., Carpenter,P.M., Park,M., Palmarini,G., Nelson,E.L. and Tenner,A.J. (2001). C1qR(P), a
myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue. J.
Leukoc. Biol. 70, 793-800.
Fossum,S. (1989). Dendritic leukocytes: features of their in vivo physiology. Res. Immunol. 140, 883-
891.
Fritsche,J., Moser,M., Faust,S., Peuker,A., Buttner,R., Andreesen,R. and Kreutz,M. (2000). Molecular
cloning and characterization of a human metalloprotease disintegrin--a novel marker for dendritic cell
differentiation. Blood 96, 732-739.
Frommer,M., McDonald,L.E., Millar,D.S., Collis,C.M., Watt,F., Grigg,G.W., Molloy,P.L. and Paul,C.L.
(1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in
individual DNA strands. Proc Natl Acad Sci U S A 89, 1827-1831.
Funk,C.D. and Cyrus,T. (2001). 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis.
Trends Cardiovasc. Med. 11, 116-124.
Gabrielli,F., Donadel,G., Bensi,G., Heguy,A. and Melli,M. (1995). A nuclear protein, synthesized in
growth-arrested human hepatoblastoma cells, is a novel member of the short-chain alcohol
dehydrogenase family. Eur. J. Biochem. 232, 473-477.
Gallucci,S. and Matzinger,P. (2001). Danger signals: SOS to the immune system. Curr. Opin.
Immunol. 13, 114-119.
Garcia-Zepeda,E.A., Combadiere,C., Rothenberg,M.E., Sarafi,M.N., Lavigne,F., Hamid,Q.,
Murphy,P.M. and Luster,A.D. (1996). Human monocyte chemoattractant protein (MCP)-4 is a novel
CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and
nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J Immunol
157, 5613-5626.
Geijtenbeek,T.B., Torensma,R., van Vliet,S.J., van Duijnhoven,G.C., Adema,G.J., van Kooyk,Y. and
Figdor,C.G. (2000). Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that
supports primary immune responses. Cell 100, 575-585.
Geissmann,F., Launay,P., Pasquier,B., Lepelletier,Y., Leborgne,M., Lehuen,A., Brousse,N. and
Monteiro,R.C. (2001). A subset of human dendritic cells expresses IgA Fc receptor (CD89), which
mediates internalization and activation upon cross-linking by IgA complexes. J. Immunol. 166, 346-
352.
Gerloni,M., Lo,D. and Zanetti,M. (1998). DNA immunization in relB-deficient mice discloses a role for
dendritic cells in IgM-->IgG1 switch in vivo. Eur. J. Immunol. 28, 516-524.
Gilliet,M. and Liu,Y.J. (2002). Generation of human CD8 T regulatory cells by CD40 ligand-activated
plasmacytoid dendritic cells. J. Exp. Med. 195, 695-704.
Godiska,R., Chantry,D., Raport,C.J., Schweickart,V.L., Trong,H.L. and Gray,P.W. (1997). Monocyte
chemotactic protein-4: tissue-specific expression and signaling through CC chemokine receptor-2. J
Leukoc Biol 61, 353-360.
References
110
Granucci,F., Vizzardelli,C., Pavelka,N., Feau,S., Persico,M., Virzi,E., Rescigno,M., Moro,G. and
Ricciardi-Castagnoli,P. (2001). Inducible IL-2 production by dendritic cells revealed by global gene
expression analysis. Nat. Immunol. 2, 882-888.
Graw,R.G., Jr., Herzig,G.P., Eisel,R.J. and Perry,S. (1971). Leukocyte and platelet collection from
normal donors with the continuous flow blood cell separator. Transfusion 11, 94-101.
Grouard,G., Rissoan,M.C., Filgueira,L., Durand,I., Banchereau,J. and Liu,Y.J. (1997). The enigmatic
plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med.
185, 1101-1111.
Guan,E., Robinson,S.L., Goodman,E.B. and Tenner,A.J. (1994). Cell-surface protein identified on
phagocytic cells modulates the C1q- mediated enhancement of phagocytosis. J. Immunol. 152, 4005-
4016.
Guermonprez,P., Valladeau,J., Zitvogel,L., Thery,C. and Amigorena,S. (2002). Antigen presentation
and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667.
Harshyne,L.A., Watkins,S.C., Gambotto,A. and Barratt-Boyes,S.M. (2001). Dendritic cells acquire
antigens from live cells for cross-presentation to CTL. J. Immunol. 166, 3717-3723.
Hart ,D.N. (1997). Dendritic cells: unique leukocyte populations which control the pimary immune
response. Blood 90, 3245-3287.
Hashimoto,S., Suzuki,T., Dong,H.Y., Nagai,S., Yamazaki,N. and Matsushima,K. (1999). Serial
analysis of gene expression in human monocyte-derived dendritic cells. Blood 94, 845-852.
Hein,H., Schluter,C., Kulke,R., Christophers,E., Schroder,J.M. and Bartels,J. (1999). Genomic
organization, sequence analysis and transcriptional regulation of the human MCP-4 chemokine gene
(SCYA13) in dermal fibroblasts: a comparison to other eosinophilic beta-chemokines. Biochem
Biophys Res Commun 255, 470-476.
Holliday,R. and Pugh,J.E. (1975). DNA modification mechanisms and gene activity during
development. Science 187, 226-232.
Holt,P.G., Haining,S., Nelson,D.J. and Sedgwick,J.D. (1994). Origin and steady-state turnover of class
II MHC-bearing dendritic cells in the epithelium of the conducting airways. J Immunol 153, 256-261.
Holt,P.G., Schon-Hegrad,M.A., Phillips,M.J. and McMenamin,P.G. (1989). Ia-positive dendritic cells
form a tightly meshed network within the human airway epithelium. Clin. Exp. Allergy 19, 597-601.
Huang,F.P., Platt,N., Wykes,M., Major,J.R., Powell,T.J., Jenkins,C.D. and MacPherson,G.G. (2000). A
discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of
mesenteric lymph nodes. J. Exp. Med. 191, 435-444.
Hubank,M. and Schatz,D.G. (1994). Identifying differences in mRNA expression by representational
difference analysis of cDNA. Nucleic Acids Res 22, 5640-5648.
Hwu,P., Du,M.X., Lapointe,R., Do,M., Taylor,M.W. and Young,H.A. (2000). Indoleamine 2,3-
dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J.
Immunol. 164, 3596-3599.
Imai,T., Nagira,M., Takagi,S., Kakizaki,M., Nishimura,M., Wang,J., Gray,P.W., Matsushima,K. and
Yoshie,O. (1999). Selective recruitment of CCR4-bearing Th2 cells toward antigen- presenting cells by
the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine.
Int Immunol 11, 81-88.
Ingulli,E., Mondino,A., Khoruts,A. and Jenkins,M.K. (1997). In vivo detection of dendritic cell antigen
presentation to CD4(+) T cells. J. Exp. Med. 185, 2133-2141.
Johnson,W.D., Jr., Mei,B. and Cohn,Z.A. (1977). The separation, long-term cultivation, and maturation
of the human monocyte. J. Exp. Med. 146, 1613-1626.
Jonuleit,H., Schmitt,E., Steinbrink,K. and Enk,A.H. (2001). Dendritic cells as a tool to induce anergic
and regulatory T cells. Trends Immunol. 22, 394-400.
Kadowaki,N., Antonenko,S., Ho,S., Rissoan,M.C., Soumelis,V., Porcelli,S.A., Lanier,L.L. and Liu,Y.J.
(2001). Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of
dendritic cells. J. Exp. Med. 193, 1221-1226.
Kamath,A.T., Pooley,J., O'Keeffe,M.A., Vremec,D., Zhan,Y., Lew,A.M., D'Amico,A., Wu,L., Tough,D.F.
and Shortman,K. (2000). The development, maturation, and turnover rate of mouse spleen dendritic
cell populations. J. Immunol. 165, 6762-6770.
References
111
Kaul,M. and Loos,M. (2001). Expression of membrane C1q in human monocyte-derived macrophages
is developmentally regulated and enhanced by interferon-gamma. FEBS Lett. 500, 91-98.
Kitamura,H., Iwakabe,K., Yahata,T., Nishimura,S., Ohta,A., Ohmi,Y., Sato,M., Takeda,K.,
Okumura,K., Van Kaer,L., Kawano,T., Taniguchi,M. and Nishimura,T. (1999). The natural killer T
(NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing
interleukin (IL)- 12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp.
Med. 189, 1121-1128.
Kodelja,V., Muller,C., Politz,O., Hakij,N., Orfanos,C.E. and Goerdt,S. (1998). Alternative macrophage
activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory
protein-1 alpha with a Th2-associated expression pattern. J Immunol 160, 1411-1418.
Korb,L.C. and Ahearn,J.M. (1997). C1q binds directly and specifically to surface blebs of apoptotic
human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J.
Immunol. 158, 4525-4528.
Koski,G.K., Schwartz,G.N., Weng,D.E., Gress,R.E., Engels,F.H., Tsokos,M., Czerniecki,B.J. and
Cohen,P.A. (1999). Calcium ionophore-treated myeloid cells acquire many dendritic cell
characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic
agents. Blood 94, 1359-1371.
Kurts,C., Cannarile,M., Klebba,I. and Brocker,T. (2001). Dendritic cells are sufficient to cross-present
self-antigens to CD8 T cells in vivo. J. Immunol. 166, 1439-1442.
La Mantia,G., Maglione,D., Pengue,G., Di Cristofano,A., Simeone,A., Lanfrancone,L. and Lania,L.
(1991). Identification and characterization of novel human endogenous retroviral sequences
prefentially expressed in undifferentiated embryonal carcinoma cells. Nucleic Acids Res. 19, 1513-
1520.
La Mantia,G., Majello,B., Di Cristofano,A., Strazzullo,M., Minchiotti,G. and Lania,L. (1992).
Identification of regulatory elements within the minimal promoter region of the human endogenous
ERV9 proviruses: accurate transcription initiation is controlled by an Inr-like element. Nucleic Acids
Res. 20, 4129-4136.
Laemmli,U.K. (1970). Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227, 680-685.
Lamar,E.E. and Palmer,E. (1984). Y-encoded, species-specific DNA in mice: evidence that the Y
chromosome exists in two polymorphic forms in inbred strains. Cell 37, 171-177.
Lamkhioued,B., Garcia-Zepeda,E.A., Abi-Younes,S., Nakamura,H., Jedrzkiewicz,S., Wagner,L.,
Renzi,P.M., Allakhverdi,Z., Lilly,C., Hamid,Q. and Luster,A.D. (2000). Monocyte chemoattractant
protein (MCP)-4 expression in the airways of patients with asthma. Induction in epithelial cells and
mononuclear cells by proinflammatory cytokines. Am. J. Respir. Crit Care Med. 162, 723-732.
Lee,D., Prowse,D.M. and Brissette,J.L. (1999). Association between mouse nude gene expression
and the initiation of epithelial terminal differentiation. Dev. Biol. 208, 362-374.
Lee,D.U., Agarwal,S. and Rao,A. (2002). Th2 Lineage Commitment and Efficient IL-4 Production
Involves Extended Demethylation of the IL-4 Gene. Immunity. 16, 649-660.
Levings,M.K. and Schrader,J.W. (1999). IL-4 inhibits the production of TNF-alpha and IL-12 by
STAT6-dependent and -independent mechanisms. J Immunol 162, 5224-5229.
Li,E., Beard,C., Forster,A.C., Bestor,T.H. and Jaenisch,R. (1993). DNA methylation, genomic
imprinting, and mammalian development. Cold Spring Harb. Symp. Quant. Biol. 58, 297-305.
Lindhout,E., Vissers,J.L., Hartgers,F.C., Huijbens,R.J., Scharenborg,N.M., Figdor,C.G. and
Adema,G.J. (2001). The dendritic cell-specific CC-chemokine DC-CK1 is expressed by germinal
center dendritic cells and attracts CD38-negative mantle zone B lymphocytes. J. Immunol. 166, 3284-
3289.
Lisitsyn,N. and Wigler,M. (1993). Cloning the differences between two complex genomes. Science
259, 946-951.
Liu,Y.J., Kanzler,H., Soumelis,V. and Gilliet,M. (2001). Dendritic cell lineage, plasticity and cross-
regulation. Nat. Immunol. 2, 585-589.
Long,Q., Bengra,C., Li,C., Kutlar,F. and Tuan,D. (1998). A long terminal repeat of the human
endogenous retrovirus ERV-9 is located in the 5' boundary area of the human beta-globin locus
control region. Genomics 54, 542-555.
References
112
Lucarelli,M., Fuso,A., Strom,R. and Scarpa,S. (2001). The dynamics of myogenin site-specific
demethylation is strongly correlated with its expression and with muscle differentiation. J. Biol. Chem.
276, 7500-7506.
Macatonia,S.E., Hosken,N.A., Litton,M., Vieira,P., Hsieh,C.S., Culpepper,J.A., Wysocka,M.,
Trinchieri,G., Murphy,K.M. and O'Garra,A. (1995). Dendritic cells produce IL-12 and direct the
development of Th1 cells from naive CD4+ T cells. J. Immunol. 154, 5071-5079.
Manz,M.G., Traver,D., Miyamoto,T., Weissman,I.L. and Akashi,K. (2001). Dendritic cell potentials of
early lymphoid and myeloid progenitors. Blood 97, 3333-3341.
Mayer,W., Niveleau,A., Walter,J., Fundele,R. and Haaf,T. (2000). Demethylation of the zygotic
paternal genome. Nature 403, 501-502.
McIlroy,D., Troadec,C., Grassi,F., Samri,A., Barrou,B., Autran,B., Debre,P., Feuillard,J. and
Hosmalin,A. (2001). Investigation of human spleen dendritic cell phenotype and distribution reveals
evidence of in vivo activation in a subset of organ donors. Blood 97, 3470-3477.
McWilliam,A.S., Nelson,D., Thomas,J.A. and Holt,P.G. (1994). Rapid dendritic cell recruitment is a
hallmark of the acute inflammatory response at mucosal surfaces. J Exp Med 179, 1331-1336.
Meierhoff,G., Krause,S.W. and Andreesen,R. (1998). Comparative analysis of dendritic cells derived
from blood monocytes or CD34+ hematopoietic progenitor cells. Immunobiology 198, 501-513.
Menetrier-Caux,C., Montmain,G., Dieu,M.C., Bain,C., Favrot,M.C., Caux,C. and Blay,J.Y. (1998).
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of
interleukin-6 and macrophage colony- stimulating factor. Blood 92, 4778-4791.
Micallef,M.J., Ohtsuki,T., Kohno,K., Tanabe,F., Ushio,S., Namba,M., Tanimoto,T., Torigoe,K., Fujii,M.,
Ikeda,M., Fukuda,S. and Kurimoto,M. (1996). Interferon-gamma-inducing factor enhances T helper 1
cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma
production. Eur. J. Immunol. 26, 1647-1651.
Miller,Y.I., Chang,M.K., Funk,C.D., Feramisco,J.R. and Witztum,J.L. (2001). 12/15-lipoxygenase
translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic
cells. J. Biol. Chem. 276, 19431-19439.
Mosialos,G., Birkenbach,M., Ayehunie,S., Matsumura,F., Pinkus,G.S., Kieff,E. and Langhoff,E. (1996).
Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein.
Am J Pathol. 148, 593-600.
Muller,W., Hanauske-Abel,H. and Loos,M. (1978). Biosynthesis of the first component of complement
by human and guinea pig peritoneal macrophages: evidence for an independent production of the C1
subunits. J. Immunol. 121, 1578-1584.
Mullis,K., Faloona,F., Scharf,S., Saiki,R., Horn,G. and Erlich,H. (1986). Specific enzymatic
amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb. Symp. Quant. Biol. 51
Pt 1, 263-273.
Nagy,L., Tontonoz,P., Alvarez,J.G., Chen,H. and Evans,R.M. (1998). Oxidized LDL regulates
macrophage gene expression through ligand activation of PPARgamma. Cell 93, 229-240.
Nakashima-Matsushita,N., Homma,T., Yu,S., Matsuda,T., Sunahara,N., Nakamura,T., Tsukano,M.,
Ratnam,M. and Matsuyama,T. (1999). Selective expression of folate receptor beta and its possible
role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis
Rheum. 42, 1609-1616.
Navratil,J.S., Watkins,S.C., Wisnieski,J.J. and Ahearn,J.M. (2001). The globular heads of C1q
specifically recognize surface blebs of apoptotic vascular endothelial cells. J. Immunol. 166, 3231-
3239.
Nepomuceno,R.R., Henschen-Edman,A.H., Burgess,W.H. and Tenner,A.J. (1997). cDNA cloning and
primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced
phagocytosis in vitro. Immunity. 6, 119-129.
Ngo,V.N., Tang,H.L. and Cyster,J.G. (1998). Epstein-Barr virus-induced molecule 1 ligand chemokine
is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B
cells. J Exp Med 188, 181-191.
Nibbs,R.J., Wylie,S.M., Yang,J., Landau,N.R. and Graham,G.J. (1997). Cloning and characterization
of a novel promiscuous human beta- chemokine receptor D6. J. Biol. Chem. 272, 32078-32083.
Nichols,B.J. and Lippincott-Schwartz,J. (2001). Endocytosis without clathrin coats. Trends Cell Biol.
11, 406-412.
References
113
Oakeley,E.J. (1999). DNA methylation analysis: a review of current methodologies. Pharmacol. Ther.
84, 389-400.
Ogden,C.A., deCathelineau,A., Hoffmann,P.R., Bratton,D., Ghebrehiwet,B., Fadok,V.A. and
Henson,P.M. (2001). C1q and mannose binding lectin engagement of cell surface calreticulin and
CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 194, 781-795.
Ohshima,Y., Yang,L.P., Uchiyama,T., Tanaka,Y., Baum,P., Sergerie,M., Hermann,P. and
Delespesse,G. (1998). OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and
promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood
92, 3338-3345.
Osborn,L., Kunkel,S. and Nabel,G.J. (1989). Tumor necrosis factor alpha and interleukin 1 stimulate
the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl
Acad Sci U S A 86, 2336-2340.
Palucka,K.A., Taquet,N., Sanchez-Chapuis,F. and Gluckman,J.C. (1998). Dendritic cells as the
terminal stage of monocyte differentiation. J. Immunol. 160, 4587-4595.
Panning,B. and Jaenisch,R. (1996). DNA hypomethylation can activate Xist expression and silence X-
linked genes. Genes Dev. 10, 1991-2002.
Parmentier,H.K., van der Linden,J.A., Krijnen,J., van Wichen,D.F., Rademakers,L.H., Bloem,A.C. and
Schuurman,H.J. (1991). Human follicular dendritic cells: isolation and characteristics in situ and in
suspension. Scand. J. Immunol. 33, 441-452.
Pavli,P., Hume,D.A., Van De Pol,E. and Doe,W.F. (1993). Dendritic cells, the major antigen-
presenting cells of the human colonic lamina propria. Immunology 78, 132-141.
Pellegrini,S., Censini,S., Guidotti,S., Iacopetti,P., Rocchi,M., Bianchi,M., Covacci,A. and Gabrielli,F.
(2002). A human short-chain dehydrogenase/reductase gene: structure, chromosomal localization,
tissue expression and subcellular localization of its product. Biochim. Biophys. Acta 1574, 215-222.
Petering,H., Hochstetter,R., Kimmig,D., Smolarski,R., Kapp,A. and Elsner,J. (1998). Detection of
MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol
160, 555-558.
Peters,J.H., Xu,H., Ruppert,J., Ostermeier,D., Friedrichs,D. and Gieseler,R.K. (1993). Signals
required for differentiating dendritic cells from human monocytes in vitro. Adv. Exp. Med. Biol. 329,
275-280.
Peters,S.G., Pomare,E.W. and Fisher,C.A. (1992). Portal and peripheral blood short chain fatty acid
concentrations after caecal lactulose instillation at surgery. Gut 33, 1249-1252.
Pickl,W.F., Majdic,O., Kohl,P., Stockl,J., Riedl,E., Scheinecker,C., Bello-Fernandez,C. and Knapp,W.
(1996). Molecular and functional characteristics of dendritic cells generated from highly purified
CD14+ peripheral blood monocytes. J. Immunol. 157, 3850-3859.
Pierre,P. and Mellman,I. (1998). Developmental regulation of invariant chain proteolysis controls MHC
class II trafficking in mouse dendritic cells. Cell 93, 1135-1145.
Pike,L.J., Han,X., Chung,K.N. and Gross,R.W. (2002). Lipid rafts are enriched in arachidonic acid and
plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative
electrospray ionization/mass spectrometric analysis. Biochemistry 41, 2075-2088.
Plant,K.E., Routledge,S.J. and Proudfoot,N.J. (2001). Intergenic transcription in the human beta-
globin gene cluster. Mol. Cell Biol. 21, 6507-6514.
Quandt,K., Frech,K., Karas,H., Wingender,E. and Werner,T. (1995). MatInd and MatInspector: new
fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic
Acids Res. 23, 4878-4884.
Randolph,G.J., Beaulieu,S., Lebecque,S., Steinman,R.M. and Muller,W.A. (1998). Differentiation of
monocytes into dendritic cells in a model of transendothelial trafficking [see comments]. Science 282,
480-483.
Randolph,G.J., Inaba,K., Robbiani,D.F., Steinman,R.M. and Muller,W.A. (1999). Differentiation of
phagocytic monocytes into lymph node dendritic cells in vivo. Immunity. 11, 753-761.
Ratnam,M., Marquardt,H., Duhring,J.L. and Freisheim,J.H. (1989). Homologous membrane folate
binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry 28, 8249-8254.
Razin,A. (1998). CpG methylation, chromatin structure and gene silencing-a three-way connection.
EMBO J 17, 4905-4908.
References
114
Razin,A. and Cedar,H. (1991). DNA methylation and gene expression. Microbiol. Rev. 55, 451-458.
Ridge,J.P., Di Rosa,F. and Matzinger,P. (1998). A conditioned dendritic cell can be a temporal bridge
between a CD4+ T- helper and a T-killer cell. Nature 393, 474-478.
Riggs,A.D. (1975). X inactivation, differentiation, and DNA methylation. Cytogenet. Cell Genet. 14, 9-
25.
Rissoan,M.C., Soumelis,V., Kadowaki,N., Grouard,G., Briere,F., de Waal,M.R. and Liu,Y.J. (1999).
Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186.
Rodriguez,A., Regnault,A., Kleijmeer,M., Ricciardi-Castagnoli,P. and Amigorena,S. (1999). Selective
transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat.
Cell Biol. 1, 362-368.
Roncarolo,M.G., Levings,M.K. and Traversari,C. (2001). Differentiation of T regulatory cells by
immature dendritic cells. J. Exp. Med. 193, F5-F9.
Ronchese,F. and Hausmann,B. (1993). B lymphocytes in vivo fail to prime naive T cells but can
stimulate antigen-experienced T lymphocytes. J. Exp. Med. 177, 679-690.
Ross,J.F., Chaudhuri,P.K. and Ratnam,M. (1994). Differential regulation of folate receptor isoforms in
normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.
Cancer 73, 2432-2443.
Ross,J.F., Wang,H., Behm,F.G., Mathew,P., Wu,M., Booth,R. and Ratnam,M. (1999). Folate receptor
type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer
85, 348-357.
Rubartelli,A., Poggi,A. and Zocchi,M.R. (1997). The selective engulfment of apoptotic bodies by
dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular
calcium. Eur. J. Immunol. 27, 1893-1900.
Ruffing,N., Sullivan,N., Sharmeen,L., Sodroski,J. and Wu,L. (1998). CCR5 has an expanded ligand-
binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 189,
160-168.
Saeki,H., Moore,A.M., Brown,M.J. and Hwang,S.T. (1999). Cutting edge: secondary lymphoid-tissue
chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of
mature dendritic cells from the skin to regional lymph nodes. J Immunol 162, 2472-2475.
Sallusto,F., Cella,M., Danieli,C. and Lanzavecchia,A. (1995). Dendritic cells use macropinocytosis and
the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II
compartment: downregulation by cytokines and bacterial products [see comments]. J Exp Med 182,
389-400.
Sallusto,F. and Lanzavecchia,A. (1994). Efficient presentation of soluble antigen by cultured human
dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4
and downregulated by tumor necrosis factor alpha. J Exp Med 179, 1109-1118.
Sallusto,F., Schaerli,P., Loetscher,P., Schaniel,C., Lenig,D., Mackay,C.R., Qin,S. and
Lanzavecchia,A. (1998). Rapid and coordinated switch in chemokine receptor expression during
dendritic cell maturation. Eur J Immunol 28, 2760-2769.
Sambrook, J, Fritsch, E. F., and Maniatis, T (1989). "Molecular Cloning, a laboratory manual.," Cold
Spring Harbor Laboratory Press.
Sanderson,R.J., Shepperdson,R.T., Vatter,A.E. and Talmage,D.W. (1977). Isolation and enumeration
of peripheral blood monocytes. J. Immunol. 118, 1409-1414.
Sanger,F., Nicklen,S. and Coulson,A.R. (1977). DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. U. S. A 74, 5463-5467.
Sareneva,T., Matikainen,S., Kurimoto,M. and Julkunen,I. (1998). Influenza A virus-induced IFN-
alpha/beta and IL-18 synergistically enhance IFN-gamma gene expression in human T cells. J.
Immunol. 160, 6032-6038.
Sauter,B., Albert,M.L., Francisco,L., Larsson,M., Somersan,S. and Bhardwaj,N. (2000).
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic
cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191 , 423-434.
Schoenberger,S.P., Toes,R.E., van der Voort,E.I., Offringa,R. and Melief,C.J. (1998). T-cell help for
cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483.
References
115
Schon-Hegrad,M.A., Oliver,J., McMenamin,P.G. and Holt,P.G. (1991). Studies on the density,
distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen
(Ia)- bearing dendritic cells (DC) in the conducting airways. J Exp Med 173, 1345-1356.
Schuurhuis,D.H., Ioan-Facsinay,A., Nagelkerken,B., van Schip,J.J., Sedlik,C., Melief,C.J.,
Verbeek,J.S. and Ossendorp,F. (2002). Antigen-antibody immune complexes empower dendritic cells
to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168, 2240-2246.
Schwaeble,W., Schafer,M.K., Petry,F., Fink,T., Knebel,D., Weihe,E. and Loos,M. (1995). Follicular
dendritic cells, interdigitating cells, and cells of the monocyte-macrophage lineage are the C1q-
producing sources in the spleen. Identification of specific cell types by in situ hybridization and
immunohistochemical analysis. J. Immunol. 155, 4971-4978.
Schweickart,V.L., Epp,A., Raport,C.J. and Gray,P.W. (2000). CCR11 is a functional receptor for the
monocyte chemoattractant protein family of chemokines. J. Biol. Chem. 275, 9550-9556.
Shapiro,A.L., Vinuela,E. and Maizel,J.V., Jr. (1967). Molecular weight estimation of polypeptide chains
by electrophoresis in SDS-polyacrylamide gels. Biochem. Biophys. Res. Commun. 28, 815-820.
Shortman,K. and Liu,Y.J. (2002). Mouse and human dendritic cell subtypes. Nature Rev. Immunol. 2,
151-161.
Siegal,F.P., Kadowaki,N., Shodell,M., Fitzgerald-Bocarsly,P.A., Shah,K., Ho,S., Antonenko,S. and
Liu,Y.J. (1999). The nature of the principal type 1 interferon-producing cells in human blood. Science
284, 1835-1837.
Siegfried,Z. and Cedar,H. (1997). DNA methylation: a molecular lock. Curr. Biol. 7, R305-R307.
Singal,R. and Ginder,G.D. (1999). DNA methylation. Blood 93, 4059-4070.
Singh-Jasuja,H., Scherer,H.U., Hilf,N., Arnold-Schild,D., Rammensee,H.G., Toes,R.E. and Schild,H.
(2000). The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its
receptor. Eur. J. Immunol. 30, 2211-2215.
Smit, A. F. A. and Green, P. unpublished data;  URL: http://repeatmasker.genome.washington.edu.
2001.
Ref Type: Computer Program
Sornasse,T., Flamand,V., De Becker,G., Bazin,H., Tielemans,F., Thielemans,K., Urbain,J., Leo,O.
and Moser,M. (1992). Antigen-pulsed dendritic cells can efficiently induce an antibody response in
vivo. J. Exp. Med. 175, 15-21.
Sozzani,S., Luini,W., Borsatti,A., Polentarutti,N., Zhou,D., Piemonti,L., D'Amico,G., Power,C.A.,
Wells,T.N., Gobbi,M., Allavena,P. and Mantovani,A. (1997). Receptor expression and responsiveness
of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 159, 1993-2000.
St Louis,D.C., Woodcock,J.B., Fransozo,G., Blair,P.J., Carlson,L.M., Murillo,M., Wells,M.R.,
Williams,A.J., Smoot,D.S., Kaushal,S., Grimes,J.L., Harlan,D.M., Chute,J.P., June,C.H., Siebenlist,U.
and Lee,K.P. (1999). Evidence for distinct intracellular signaling pathways in CD34+ progenitor to
dendritic cell differentiation from a human cell line model. J. Immunol. 162, 3237-3248.
Steinberger,P., Szekeres,A., Wille,S., Stockl,J., Selenko,N., Prager,E., Staffler,G., Madic,O.,
Stockinger,H. and Knapp,W. (2002). Identification of human CD93 as the phagocytic C1q receptor
(C1qRp) by expression cloning. J. Leukoc. Biol. 71, 133-140.
Steinman,R.M. (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9,
271-296.
Steinman,R.M. and Cohn,Z.A. (1973). Identification of a novel cell type in peripheral lymphoid organs
of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142-1162.
Steinman,R.M., Turley,S., Mellman,I. and Inaba,K. (2000). The induction of tolerance by dendritic cells
that have captured apoptotic cells. J. Exp. Med. 191, 411-416.
Stellato,C., Collins,P., Ponath,P.D., Soler,D., Newman,W., La Rosa,G., Li,H., White,J.,
Schwiebert,L.M., Bickel,C., Liu,M., Bochner,B.S., Williams,T. and Schleimer,R.P. (1997). Production
of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-
C chemokines. J Clin Invest 99, 926-936.
Strunk,D., Egger,C., Leitner,G., Hanau,D. and Stingl,G. (1997). A skin homing molecule defines the
langerhans cell progenitor in human peripheral blood. J. Exp. Med. 185, 1131-1136.
Takahashi,K., Yamaguchi,H., Ishizeki,J., Nakajima,T. and Nakazato,Y. (1981). Immunohistochemical
and immunoelectron microscopic localization of S- 100 protein in the interdigitating reticulum cells of
the human lymph node. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 37, 125-135.
References
116
Tang,H.L. and Cyster,J.G. (1999). Chemokine Up-regulation and activated T cell attraction by
maturing dendritic cells. Science 284, 819-822.
Teran,L.M., Mochizuki,M., Bartels,J., Valencia,E.L., Nakajima,T., Hirai,K. and Schroder,J.M. (1999).
Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by
human lung fibroblasts. Am J Respir. Cell Mol Biol 20, 777-786.
Thieringer,R., Le Grand,C.B., Carbin,L., Cai,T.Q., Wong,B., Wright,S.D. and Hermanowski-Vosatka,A.
(2001). 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon
differentiation to macrophages.  J. Immunol. 167, 30-35.
Thomassin,H., Flavin,M., Espinas,M.L. and Grange,T. (2001). Glucocorticoid-induced DNA
demethylation and gene memory during development. EMBO J. 20, 1974-1983.
Towbin,H., Staehelin,T. and Gordon,J. (1979). Electrophoretic transfer of proteins from polyacrylamide
gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A 76,
4350-4354.
Trinchieri,G. (1995). Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that
bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13, 251-276.
Tseng,S.Y., Otsuji,M., Gorski,K., Huang,X., Slansky,J.E., Pai,S.I., Shalabi,A., Shin,T., Pardoll,D.M.
and Tsuchiya,H. (2001). B7-DC, a new dendritic cell molecule with potent costimulatory properties for
T cells. J. Exp. Med. 193, 839-846.
Uguccioni,M., Loetscher,P., Forssmann,U., Dewald,B., Li,H., Lima,S.H., Li,Y., Kreider,B., Garotta,G.,
Thelen,M. and Baggiolini,M. (1996). Monocyte chemotactic protein 4 (MCP-4), a novel structural and
functional analogue of MCP-3 and eotaxin. J Exp Med 183, 2379-2384.
Urban,B.C., Willcox,N. and Roberts,D.J. (2001). A role for CD36 in the regulation of dendritic cell
function. Proc. Natl. Acad. Sci. U. S. A 98, 8750-8755.
Valladeau,J., Duvert-Frances,V., Pin,J.J., Dezutter-Dambuyant,C., Vincent,C., Massacrier,C.,
Vincent,J., Yoneda,K., Banchereau,J., Caux,C., Davoust,J. and Saeland,S. (1999). The monoclonal
antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly
internalized from the cell surface. Eur. J. Immunol. 29, 2695-2704.
Van den Eynde,B.J. and Morel,S. (2001). Differential processing of class-I-restricted epitopes by the
standard proteasome and the immunoproteasome. Curr. Opin. Immunol. 13, 147-153.
van Leyen,K., Duvoisin,R.M., Engelhardt,H. and Wiedmann,M. (1998). A function for lipoxygenase in
programmed organelle degradation. Nature 395, 392-395.
Vanbervliet,B., Homey,B., Durand,I., Massacrier,C., Ait-Yahia,S., de Bouteiller,O., Vicari,A. and
Caux,C. (2002). Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell
recruitment: possible role at inflamed epithelial surfaces. Eur. J. Immunol. 32, 231-242.
Villadangos,J.A., Cardoso,M., Steptoe,R.J., van Berkel,D., Pooley,J., Carbone,F.R. and Shortman,K.
(2001). MHC class II expression is regulated in dendritic cells independently of invariant chain
degradation. Immunity. 14, 739-749.
Vissers,J.L., Hartgers,F.C., Lindhout,E., Figdor,C.G. and Adema,G.J. (2001). BLC (CXCL13) is
expressed by different dendritic cell subsets in vitro and in vivo. Eur. J. Immunol. 31, 1544-1549.
Walsh,C.P. and Bestor,T.H. (1999). Cytosine methylation and mammalian development. Genes Dev.
13, 26-34.
Walsh,C.P., Chaillet,J.R. and Bestor,T.H. (1998). Transcription of IAP endogenous retroviruses is
constrained by cytosine methylation. Nat. Genet. 20, 116-117.
Wang,X., Shen,F., Freisheim,J.H., Gentry,L.E. and Ratnam,M. (1992). Differential stereospecificities
and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol.
44, 1898-1901.
Wu,L., Vandenabeele,S. and Georgopoulos,K. (2001). Derivation of dendritic cells from myeloid and
lymphoid precursors. Int. Rev. Immunol. 20, 117-135.
Wykes,M., Pombo,A., Jenkins,C. and MacPherson,G.G. (1998). Dendritic cells interact directly with
naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent
response. J. Immunol. 161, 1313-1319.
Yang,X.Y., Wang,L.H., Mihalic,K., Xiao,W., Chen,T., Li,P., Wahl,L.M. and Farrar,W.L. (2002).
Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome
proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands.
J. Biol. Chem. 277, 3973-3978.
References
117
Ying,S., Meng,Q., Zeibecoglou,K., Robinson,D.S., Macfarlane,A., Humbert,M. and Kay,A.B. (1999).
Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-
3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic
and nonatopic (Intrinsic) asthmatics. J. Immunol. 163, 6321-6329.
Yla-Herttuala,S., Rosenfeld,M.E., Parthasarathy,S., Glass,C.K., Sigal,E., Witztum,J.L. and
Steinberg,D. (1990). Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized
low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. U. S.
A 87, 6959-6963.
Yoder,J.A., Walsh,C.P. and Bestor,T.H. (1997). Cytosine methylation and the ecology of intragenomic
parasites. Trends Genet.  13, 335-340.
Zhou,L.J., Schwarting,R., Smith,H.M. and Tedder,T.F. (1992). A novel cell-surface molecule
expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a
new member of the Ig superfamily. J Immunol 149, 735-742.
Zhou,L.J. and Tedder,T.F. (1996). CD14+ blood monocytes can differentiate into functionally mature
CD83+ dendritic cells. Proc Natl Acad Sci U S A 93, 2588-2592.

I would like to thank Prof. Dr. Reinhard Andreesen for taking me back as a Ph.D.
student, his interest in my work and his continuous support during all those years.
I also wish to thank Prof. Dr. Buschauer for always going the extra mile for external
Ph.D. students and for supervising and reviewing my thesis.
To PD Dr. Stefan Krause, I am very grateful to him for designing the project, for his
enthusiasm and his guidance and all his support even in hard times.
I thank Dr. Harald Wagner for his early efforts.
I also would like to especially thank Dr. Michael Rehli for always being there for me,
for our many discussions, for endless support and his faith in me and for pointing my
nose in the right direction when I most desperately needed it.
I would like to thank everybody in the lab for the good atmosphere and fruitful
discussions, for the occasional chats on arbitrary topics over a coffee, splendid
breakfasts once in a while, a sporadic treat of cake and holiday-induced chocolate
overloads and last but not least, the fun we all had together:
Ute Ackermann, Achim Ehrnsperger, Dr. Jana Fritsche, Dr. Eva Gottfried, Viola Hähnel,
Silvia Kirchner, Dr. Marina Kreutz, Sabine Langmann, Dr. Krishna Mondal, Alexandra
Müller, Sabine Pape, Alice Peuker, Dr. Ute Schulz, Lucia Schwarzfischer-Pfeilschifter
and Sabine Sulzbacher.
Additionally, I would like to express special thanks to:
Dr. Christoph Ammon for sharing his experience with EMSA, for keeping up the good
spirit and for the never ending offer to help printing out *The Thesis* (think rumbling
thunder here!) ;-)
Lucia Schwarzfischer-Pfeilschifter, who introduced me to RDA, as well as to most of
the other molecular biological techniques used in the lab.
Prof. Dr. Franco Gabrielli, for providing me with anti-Hep27 antibody and for fruitful
and fun e-mail discussions on Hep27 biology.
Dr. Abdo Konur for all the time and discussions he invested in the 
immunohistochemical detection of MCP-4 and for recommending Slimfast!
Dr. Guido Meierhoff for introducing me to MLCs.
Sandra Vogl for her diligent help with chemotaxis assays and RNA isolation.
Silvia Haffner for taking the gummi-bears in exchange for HUVECs.
Monika Laumer and PD Dr. Stefan Krause for performing the multi-color FACS
analyses for BDC purity determination.
Dr. Carola Seitz from the Pathology Department for getting me going with fluorescence
microscopy.
Dr. Stefan Faust for teaching me how to sort blood DCs with MACS.
Last but not least, I wish to thank my mother, Ingrid Heinz, for her love and support
during all these years, enabling me to study and giving me the time to grow up, and
my aunt Dr. Rosalinde Fuggersberger who turned me on to science a long time ago.
(Parafilm did the trick.)
Finally, I have to thank my daughter Emily for ensuring that my home life was never
boring.
